Note: Descriptions are shown in the official language in which they were submitted.
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
G-PROTEIN 'COUPLED RECEPTORS
TECHNICAL FIELD
This invention relates to nucleic acid and amino acid sequences of G-protein
coupled
receptors and to the use of these sequences in the diagnosis, treatment, and
prevention of cell
proliferative, neurological, cardiovascular, gastrointestinal,
autoimmune/inflammatory, and metabolic
disorders, and viral infections, and in the assessment of the effects of
exogenous compounds on the
expression of nucleic acid and amino acid sequences of G-protein coupled
receptors.
BACKGROUND OF THE INVENTION
Signal transduction is the general process by which cells respond to
extracellular signals.
Signal transduction across the plasma membrane begins with the binding of a
signal molecule, e.g., a
hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The
receptor, thus
o
activated, triggers an intracellular biochemical cascade that ends with the
activation of an intracellular
target molecule, such as a transcription factor. This process of signal
transduction regulates all types
of cell functions including cell proliferation, differentiation, and gene
transcription. The G-protein
coupled receptors (GPCRs), encoded by one of the largest families of genes yet
identified, play a
central role in the transduction of extracellular signals across the plasma
membrane. GPCRs have a
proven history of being successful therapeutic targets.
GPCRs are integral membrane proteins characterized by the presence of seven
hydrophobic
transmembrane domains which together form a bundle of antiparallel alpha (a)
helices. GPCRs range
in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) Eur.
J. Biochem. 196:1-10;
Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of
a GPCR is
extracellular, is of variable length, and is often glycosylated. The carboxy-
terminus is cytoplasmic
and generally phosphorylated. Extracellular loops alternate with intracellular
loops and link the
transmembrane domains. Cysteine disulfide bridges linking the second and third
extracellular loops
may interact with agonists and antagonists. The most conserved domains of
GPCRs are the
transmembrane domains and the first two cytoplasmic loops. The transmembrane
domains account,
in part, for structural and functional features of the receptor. In most
cases, the bundle of a helices
~ forms a ligand-binding pocket. The extracellular N-terminal segment, or one
or more of the three
extracellular loops, may also participate in ligand binding. Ligand binding
activates the receptor by
inducing a conformational change in intracellular portions of the receptor. In
turn, the large, third
intracellular loop of the activated receptor interacts with a heterotrimeric
guanine nucleotide binding
(G) protein complex which 'mediates further intracellular signaling
activities, including the activation
of second messengers such as cyclic AMP (cAMP), phospholipase C, and inositol
triphosphate, and
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
d ~. ,~ ..~,.,- ,,
the interaction of the activated GPCR with ion channel proteins. (See, e.g.,
Watson, S. and S.
Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press,
San Diego CA, pp. 2-
6; Bolander, F.F. (1994) Molecular Endocrinolo~y, Academic Press, San Diego
CA, pp. 162-176;
Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190.)
GPCRs include receptors for sensory signal mediators (e.g., light and
olfactory stimulatory
molecules); adenosine, y-aminobutyric acid (GABA), hepatocyte growth factor,
melanocortins,
neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive
intestinal polypeptide
family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and
norepinephrine, histamine,
glutamate (metabotropic effect), acetylcholine (muscarinic effect), and
serotonin); chemokines; lipid
mediators of inflammation (e.g., prostaglandins and prostanoids, platelet
activating factor, and
leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin,
CSa anaphylatoxin,
endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone
(GnRH),
neurokinin, and thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs
which act as receptors
for stimuli that have yet to be identified are known as orphan receptors.
The diversity of the GPCR family is further increased by alternative splicing.
Many GPCR
genes contain introns, and there are currently over 30 such receptors for
which splice variants have
been identified. The largest number of variations are at the protein C-
terminus. N-terminal and
cytoplasmic loop variants are also frequent, while variants in the
extracellular loops or
transmembrane domains are less common. Some receptors have more than one site
at which variance
can occur. The splicing variants appear to be functionally distinct, based
upon observed differences
in distribution, signaling, coupling, regulation, and ligand binding profiles
(Kilpatrick, G.J. et al.
(1999) Trends Pharmacol. Sci. 20:294-301).
GPCRs can be divided into three major subfamilies: the rhodopsin-like,
secretin-like, and
metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies
share similar
functions and the characteristic seven transmembrane structure, but have
divergent amino acid
sequences. The largest family consists of the rhodopsin-like GPCRs, which
transmit diverse
extracellular signals including hormones, neurotransmitters, and light.
Rhodopsin is a photosensitive
GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded
in membranous
stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to
a photon of light by
triggering a decrease in cGMP levels which leads to the closure of plasma
membrane sodium
channels. In this manner, a visual signal is converted to a neural impulse.
Other rhodopsin-like
GPCRs are directly involved in responding to neurotransmitters. These GPCRs
include the receptors
for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors),
adenosine, galanin, and
glutamate (N-methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and
S. Arkinstall
(1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA,
pp. 7-9, 19-22,
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl.
Acad. Sci. USA
91:9780-9783.)
The galanin receptors mediate the activity of the neuroendocrine peptide
galanin, which
inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and
stimulates prolactin and
growth hormone release. Galanin receptors are involved in feeding disorders,
pain, depression, and
Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other
nervous system
rhodopsin-like GPCRs include a growing family of receptors for
lysophosphatidic acid and other
lysophospholipids, which appear to have roles in development and
neuropathology (Chum J. et al.
(1999) Cell Biochem. Biophys. 30:213-242).
The largest subfamily of GPCRs, the olfactory receptors, are also members of
the rhodopsin-
like GPCR family. These receptors function by transducing odorant signals.
Numerous distinct
olfactory receptors are required to distinguish different odors. Each
olfactory sensory neuron
expresses only one type of olfactory receptor, and distinct spatial zones of
neurons expressing distinct
receptors are found in nasal passages. For example, the RAlc receptor which
was isolated from a rat
brain library, has been shown to be limited in expression to very distinct
regions of the brain and a
defined zone of the olfactory epithelium (Raming, K. et al. (1998) Receptors
Channels 6:141-151).
However, the expression of olfactory-like receptors is not confined to
olfactory tissues. For example,
three rat genes encoding olfactory-like receptors having typical GPCR
characteristics showed
expression patterns not only in taste and olfactory tissue, but also in male
reproductive tissue
(Thomas, M.B. et al. (1996) Gene 178:1-5).
Members of the secretin-like GPCR subfamily have as their ligands peptide
hormones such as
secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid
hormone, and
vasoactive intestinal peptide. For example, the secretin receptor responds to
secretin, a peptide
hormone that stimulates the secretion of enzymes and ions in the pancreas and
small intestine
(Watson, supra, pp. 278-283). Secretin receptors are about 450 amino acids in
length and are found
in the plasma membrane of gastrointestinal cells. Binding of secretin to its
receptor stimulates the
production of cAMP.
Examples of secretin-like GPCRs implicated in inflammation and the immune
response
include the EGF module-containing, mucin-like hormone receptor (Emrl) and CD97
receptor
proteins. These GPCRs are members of the recently characterized EGF-TM7
receptors subfamily.
These seven transmembrane hormone receptors exist as heterodimers in vivo and
contain between
three and seven potential calcium-binding EGF-like motifs. CD97 is
predominantly expressed in
leukocytes and is markedly upregulated on activated B and T cells (McKnight,
A.J. and S. Gordon
(1998) J. Leukoc. Biol. 63:271-280).
The third GPCR subfamily is the metabotropic glutamate receptor family.
Glutamate is the
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
major excitatory neurotransmitter in the central nervous system. The
metabotropic glutamate
receptors modulate the activity of intracellular effectors, and are involved
in long-term potentiation
(Watson, supra, p.130). The Ca2+-sensing receptor, which senses changes in the
extracellular
concentration of calcium ions, has a large extracellular domain including
clusters of acidic amino
acids which may be involved in calcium binding. The metabotropic glutamate
receptor family also
includes pheromone receptors, the GABAB receptors, and the taste receptors.
Other subfamilies of GPCRs include two groups of chemoreceptor genes found in
the
nematodes Caenorhabditis elegans and Caenorhabditis bri~~sae, which are
distantly related to the
mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and
STE3, involved in
the response to mating.factors on the cell membrane, have their own seven-
transmembrane signature,
as do the CAMP receptors from the slime mold Dictyostelium discoideum, which
are thought to
regulate the aggregation of individual cells and control the expression of
numerous developmentally-
regulated genes.
GPCR mutations, which may cause loss of function or constitutive activation,
have been
associated with numerous human diseases (Coughlin, su ra . For instance,
retinitis pigmentosa may
arise from mutations in the rhodopsin gene. Furthermore, somatic activating
mutations in the
thyrotropin receptor have been reported to cause hyperfunctioning thyroid
adenomas, suggesting that
certain GPCRs susceptible to constitutive activation may behave as
protooncogenes (Parma, J. et al.
(1993) Nature 365:649-651). GPCR receptors for the following ligands also
contain mutations
associated with human disease: luteinizing hormone (precocious puberty);
vasopressin VZ (X-linked
nephrogenic diabetes); glucagon (diabetes and hypertension); calcium
(hyperparathyroidism,
hypocalcuria, hypercalcemia); parathyroid hormone (short limbed dwarfism); (33-
adrenoceptor
(obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing
hormone (dwarfism);
and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998)
Br. J. Pharmocol.
125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437).
GPCRs are also
involved in depression, schizophrenia, sleeplessness, hypertension, anxiety,
stress, renal failure, and
several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med.
76:464-468).
In addition, within the past 20 years several hundred new drugs have been
recognized that are
directed towards activating or inhibiting GPCRs. The therapeutic targets of
these drugs span a wide
range of diseases and disorders, including cardiovascular, gastrointestinal,
and central nervous system
disorders as well as cancer, osteoporosis and endometriosis (Wilson, supra;
Stadel, supra). For
example, the dopamine agonist L-dopa is used to treat Parkinson's disease,
while a dopamine
antagonist is used to treat schizophrenia and the early stages of Huntington's
disease. Agonists and
antagonists of adrenoceptors have been used for the treatment of asthma, high
blood pressure, other
cardiovascular disorders, and anxiety; muscarinic agonists are used in the
treatment of glaucoma and
4
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
.-,.m;. ", .
tachycardia; serotonin 5HT1D antagonists are used against migraine; and
histamine Hl antagonists
are used against allergic and anaphylactic reactions, hay fever, itching, and
motion sickness (Horn,
supra).
Recent research suggests potential future therapeutic uses for GPCRs in the
treatment of
metabolic disorders including diabetes, obesity, and osteoporosis. For
example, mutant V2
vasopressin receptors causing nephrogenic diabetes could be functionally
rescued in vitro by co-
expression of a C-terminal V2 receptor peptide spanning the region containing
the mutations. This
result suggests a possible novel strategy for disease treatment (Schoneberg,
T. et al. (1996) EMBO J.
15:1283-1291). Mutations in melanocortin-4 receptor (MC4R) are implicated in
human weight
regulation and obesity. As with the vasapressin V2 receptor mutants, these
MC4R mutants are
defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie
(1999) J. Biol. Chem.
274:35816-35822), and thus might be treated with a similar strategy. The type
1 receptor for
parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation
of calcium
homeostasis in the bloodstream. Study of PTH/receptor interactions may enable
the development of
novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et
al. (1999) Am. J.
Physiol. 277:F665-F675).
The chemokine receptor group of GPCRs have potential therapeutic utility in
inflammation
and infectious disease. (For review, see Locati, M. and P.M. Murphy ( 1999)
Annu. Rev. Med.
50:425-440.) Chemokines are small polypeptides that act as intracellular
signals in the regulation of
leukocyte trafficking, hematopoiesis, and angiogenesis. Targeted disruption of
various chemokine
receptors in mice indicates that these receptors play roles in pathologic
inflammation and in
autoimmune disorders such as multiple sclerosis. Chemokine receptors are also
exploited by
infectious agents, including herpesviruses and the human immunodeficiency
virus (HIV-1) to
facilitate infection. A truncated version of chemokine receptor CCRS, which
acts as a coreceptor for
infection of T-cells by HIV-1, results in resistance to AIDS, suggesting that
CCRS antagonists could
be useful in preventing the development of AIDS.
The discovery of new G-protein coupled receptors and the polynucleotides
encoding them
satisfies a need in the art by providing new compositions which are useful in
the diagnosis,
prevention, and treatment of cell proliferative, neurological, cardiovascular,
gastrointestinal,
autoimmune/inflammatory, and metabolic disorders, and viral infections, and in
the assessment of the
effects of exogenous compounds on the expression of nucleic acid and amino
acid sequences of G-
protein coupled receptors.
SUMMARY OF THE INVENTION
The invention features purified polypeptides, G-protein coupled receptors,
referred to
5
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
collectively as "GCREC" and individually as "GCREC-l," "GCREC-2," "GCREC-3,"
"GCREC-4,"
"GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11,"
"GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," "GCREC-17," "GCREC-
18," "GCREC-19," "GCREC-20," "GCREC-21," "GCREC-22," and "GCREC-23." In one
aspect,
the invention provides an isolated polypeptide selected from the group
consisting of a) a polypeptide
comprising an amino acid sequence selected from the group consisting of SEQ ID
NO:1-23, b) a
naturally occurring polypeptide comprising an amino acid sequence at least 90%
identical to an
amino acid sequence selected from the group consisting of SEQ ID NO:1-23, c) a
biologically active
fragment of a polypeptide having an amino acid sequence selected from the
group consisting of SEQ
ID NO:l-23, and d) an immunogenic fragment of a polypeptide having an amino
acid sequence
selected from the group consisting of SEQ ID NO:1-23. In one alternative, the
invention provides an
isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-23.
The invention further provides an isolated polynucleotide encoding a
polypeptide selected
from the group consisting of a) a polypeptide comprising an amino acid
sequence selected from the
group consisting of SEQ ID NO:1-23, b) a naturally occurring polypeptide
comprising an amino acid
sequence at least 90% identical to an amino acid sequence selected from the
group consisting of SEQ
ID NO:l-23, c) a biologically active fragment of a polypeptide having an amino
acid sequence
selected from the group consisting of SEQ ID NO:1-23, and d) an immunogenic
fragment of a
polypeptide having an amino acid sequence selected from the group consisting
of SEQ ID NO:1-23.
In one alternative, the polynucleotide encodes a polypeptide selected from the
group consisting of
SEQ ID NO:l-23. In another alternative, the polynucleotide is selected from
the group consisting of
SEQ ID N0:24-46.
Additionally, the invention provides a recombinant polynucleotide comprising a
promoter
sequence operably linked to a polynucleotide encoding a polypeptide selected
from the group
consisting of a) a polypeptide comprising an amino acid sequence selected from
the group consisting
of SEQ ID NO:l-23, b) a naturally occurring polypeptide comprising an amino
acid sequence at least
90% identical to an amino acid sequence selected from the group consisting of
SEQ ID NO: l-23, c) a
biologically active fragment of a polypeptide having an amino acid sequence
selected from the group
consisting of SEQ ID NO:1-23, and d) an immunogenic fragment of a polypeptide
having an amino
acid sequence selected from the group consisting of SEQ ID NO:1-23. In one
alternative, the
invention provides a cell transformed with the recombinant polynucleotide. In
another alternative, the
invention provides a transgenic organism comprising the recombinant
polynucleotide.
The invention also provides a method for producing a polypeptide selected from
the group
consisting of a) a polypeptide comprising an amino acid sequence selected from
the group consisting
of SEQ ID NO:l-23, b) a naturally occurring polypeptide comprising an amino
acid sequence at least
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
y~~: ,..
90% identical to an amino acid sequence selected from the group consisting of
SEQ m NO:1-23, c) a
biologically active fragment of a polypeptide having an amino acid sequence
selected from the group
consisting of SEQ m NO:1-23, and d) an immunogenic fragment of a polypeptide
having an amino
acid sequence selected from the group consisting of SEQ ID NO:l-23. The method
comprises a)
culturing a cell under conditions suitable for expression of the polypeptide,
wherein said cell is
transformed with a recombinant polynucleotide comprising a promoter sequence
operably linked to a
polynucleotide encoding the polypeptide, and b) recovering the polypeptide so
expressed.
Additionally, the invention provides an isolated antibody which specifically
binds to a
polypeptide selected from the group consisting of a) a polypeptide comprising
an amino acid
sequence selected from the group consisting of SEQ ID NO:1-23, b) a naturally
occurring polypeptide
comprising an amino acid sequence at least 90% identical to an amino acid
sequence selected from
the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a
polypeptide having an
amino acid sequence selected from the group consisting of SEQ )D NO:1-23, and
d) an immunogenic
fragment of a polypeptide having an amino acid sequence selected from the
group consisting of SEQ
ID NO:1-23.
The invention further provides an isolated polynucleotide selected from the
group consisting
of a) a polynucleotide comprising a polynucleotide sequence selected from the
group consisting of
SEQ m N0:24-46, b) a naturally occurring polynucleotide comprising a
polynucleotide sequence at
least 90% identical to a polynucleotide sequence selected from the group
consisting of SEQ ID
N0:24-46, c) a polynucleotide complementary to the polynucleotide of a), d) a
polynucleotide
complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
In one alternative, the
polynucleotide comprises at least 60 contiguous nucleotides.
Additionally, the invention provides a method for detecting a target
polynucleotide in a
sample, said target polynucleotide having a sequence of a polynucleotide
selected from the group
consisting of a) a polynucleotide comprising a polynucleotide sequence
selected from the group
consisting of SEQ ID N0:24-46, b) a naturally occurring polynucleotide
comprising a polynucleotide
sequence at least 90% identical to a polynucleotide sequence selected from the
group consisting of
SEQ m N0:24-46, c) a polynucleotide complementary to the polynucleotide of a),
d) a
polynucleotide complementary to the polynucleotide of b), and e) an RNA
equivalent of a)-d). The
method comprises a) hybridizing the sample with a probe comprising at least 20
contiguous
nucleotides comprising a sequence complementary to said target polynucleotide
in the sample, and
which probe specifically hybridizes to said target polynucleotide, under
conditions whereby a
hybridization complex is formed between said probe and said target
polynucleotide or fragments
thereof, and b) detecting the presence or absence of said hybridization
complex, and optionally, if
present, the amount thereof. In one alternative, the probe comprises at least
60 contiguous
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
nucleotides.
The invention further provides a method for detecting a target polynucleotide
in a sample,
said target polynucleotide having a sequence of a polynucleotide selected from
the group consisting
of a) a polynucleotide comprising a polynucleotide sequence selected from the
group consisting of
SEQ ID N0:24-46, b) a naturally occurring polynucleotide comprising a
polynucleotide sequence at
least 90% identical to a polynucleotide sequence selected from the group
consisting of SEQ ID
N0:24-46, c) a polynucleotide complementary to the polynucleotide of a), d) a
polynucleotide
complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
The method
comprises a) amplifying said target polynucleotide or fragment thereof using
polymerase chain
reaction amplification, and b) detecting the presence or absence of said
amplified target
polynucleotide or fragment thereof, and, optionally, if present, the amount
thereof.
The invention further provides a composition comprising an effective amount of
a
polypeptide selected from the group consisting of a) a polypeptide comprising
an amino acid
sequence selected from the group consisting of SEQ ID NO:1-23, b) a naturally
occurring polypeptide
comprising an amino acid sequence at least 90% identical to an amino acid
sequence selected from
the group consisting of SEQ ID NO:1-23, c) a biologically active fragment of a
polypeptide having an
amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and
d) an immunogenic
fragment of a polypeptide having an amino acid sequence selected from the
group consisting of SEQ
ID NO:1-23, and a pharmaceutically acceptable excipient. In one embodiment,
the composition
comprises an amino acid sequence selected from the group consisting of SEQ ID
NO:1-2.3. The .
invention additionally provides a method of treating a disease or condition
associated with decreased
expression of functional GCREC, comprising administering to a patient in need
of such treatment the
composition.
The invention also provides a method for screening a compound for
effectiveness as an
agonist of a polypeptide selected from the group consisting of a) a
polypeptide comprising an amino
acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a
naturally occurring
polypeptide comprising an amino acid sequence at least 90% identical to an
amino acid sequence
selected from the group consisting of SEQ ID NO:1-23, c) a biologically active
fragment of a
polypeptide having an amino acid sequence selected from the group consisting
of SEQ ID NO:1-23,
and d) an immunogenic fragment of a polypeptide having an amino acid sequence
selected from the
group consisting of SEQ ID NO:1-23. The method comprises a) exposing a sample
comprising the
polypeptide to a compound, and b) detecting agonist activity in the sample. In
one alternative, the
invention provides a composition comprising an agonist compound identified by
the method and a
pharmaceutically acceptable excipient. In another alternative, the invention
provides a method of
treating a disease or condition associated with decreased expression of
functional GCREC,
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
comprising administering to a patient in need of such treatment the
composition. -
Additionally, the invention provides a method for screening a compound for
effectiveness as
an antagonist of a polypeptide selected from the group consisting of a) a
polypeptide comprising an
amino acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a
naturally occurring
polypeptide comprising an amino acid sequence at least 90% identical to an
amino acid sequence
selected from the group consisting of SEQ ID NO:l-23, c) a biologically active
fragment of a
polypeptide having an amino acid sequence selected from the group consisting
of SEQ ID NO: l-23,
and d) an immunogenic fragment of a polypeptide having an amino acid sequence
selected from the
group consisting of SEQ ID NO: l-23. The method comprises a) exposing a sample
comprising the
polypeptide to a compound, and b) detecting antagonist activity in the sample.
In one alternative, the
invention provides a composition comprising an antagonist compound identified
by the method and a
pharmaceutically acceptable excipient. In another alternative, the invention
provides a method of
treating a disease or condition associated with overexpression of functional
GCREC, comprising
administering to a patient in need of such treatment the composition.
The invention further provides a method of screening for a compound that
specifically binds
to a polypeptide selected from the group consisting of a) a polypeptide
comprising an amino acid
sequence selected from the group consisting of SEQ ID NO:l-23, b) a naturally
occurring polypeptide
comprising an amino acid sequence at least 90% identical to an amino acid
sequence selected from
the group consisting of SEQ ID NO: l-23, c) a biologically active fragment of
a polypeptide having an
amino acid sequence selected from the group consisting of SEQ ID NO:1-23, and
d) an immunogenic
fragment of a polypeptide having an amino acid sequence selected from the
group consisting of SEQ
ID NO:1-23. The method comprises a) combining the polypeptide with at least
one test compound
under suitable conditions, and b) detecting binding of the polypeptide to the
test compound, thereby
identifying a compound that specifically binds to the polypeptide.
The invention further provides a method of screening for a compound that
modulates the
activity of a polypeptide selected from the group consisting of a) a
polypeptide comprising an amino
acid sequence selected from the group consisting of SEQ ID NO:1-23, b) a
naturally occurring
polypeptide comprising an amino, acid sequence at least 90% identical to an
amino acid sequence
selected from the group consisting of SEQ ID NO:1-23, c) a biologically active
fragment of a
polypeptide having an amino acid sequence selected from the group consisting
of SEQ ID NO:1-23,
and d) an immunogenic fragment of a polypeptide having an amino acid sequence
selected from the
group consisting of SEQ ID NO:1-23. The method comprises a) combining the
polypeptide with at
least one test compound under conditions permissive for the activity of the
polypeptide, b) assessing
the activity of the polypeptide in the presence of the test compound, and c)
comparing the activity of
the polypeptide in the presence of the test compound with the activity of the
polypeptide in the
9
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
absence of the test compound, wherein a change in the activity of the
polypeptide in the presence of
the test compound is indicative of a compound that modulates the activity of
the polypeptide.
The invention further provides a method for screening a compound for
effectiveness in
altering expression of a target polynucleotide, wherein said target
polynucleotide comprises a
sequence selected from the group consisting of SEQ ID N0:24-46, the method
comprising a)
exposing a sample comprising the target polynucleotide to a compound, and b)
detecting altered
expression of the target polynucleotide.
The invention further provides a method for assessing toxicity of a test
compound, said
method comprising a) treating a biological sample containing nucleic acids
with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe
comprising at Ieast 20
contiguous nucleotides of a polynucleotide selected from the group consisting
of i) a polynucleotide
comprising a polynucleotide sequence selected from the group consisting of SEQ
ID N0:24-46, ii) a
naturally occurring polynucleotide comprising a polynucleotide sequence at
least 90% identical to a
polynucleotide sequence selected from the group consisting of SEQ ID N0:24-46,
iii) a
polynucleotide having a sequence complementary to i), iv) a polynucleotide
complementary to the
polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization
occurs under conditions
whereby a specific hybridization complex is formed between said probe and a
target polynucleotide
in the biological sample, said target polynucleotide selected from the group
consisting of i) a
polynucleotide comprising a polynucleotide sequence selected from the group
consisting of SEQ ID
N0:24-46, ii) a naturally occurring polynucleotide comprising a polynucleotide
sequence at least
90% identical to a polynucleotide sequence selected from the group consisting
of SEQ ID N0:24-46,
iii) a polynucleotide complementary to the polynucleotide of i), iv) a
polynucleotide complementary
to the polynucleotide of ii), and v) an RNA equivalent of i)-iv).
Alternatively, the target
polynucleotide comprises a fragment of a polynucleotide sequence selected from
the group consisting
of i)-v) above; c) quantifying the amount of hybridization complex; and d)
comparing the amount of
hybridization complex in the treated biological sample with the amount of
hybridization complex in
an untreated biological sample, wherein a difference in the amount of
hybridization complex in the
treated biological sample is indicative of toxicity of the test compound.
BRIEF DESCRIPTION OF THE TABLES
Table 1 summarizes the nomenclature for the full length polynucleotide and
polypeptide
sequences of the present invention.
Table 2 shows the GenBank identification number and annotation of the nearest
GenBank
homolog for polypeptides of the invention. The probability score for the match
between each
polypeptide and its GenBank homolog is also shown.
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Table 3 shows structural features of polypeptide sequences of the invention,
including
predicted motifs and domains, along with the methods, algorithms, and
searchable databases used for
analysis of the polypeptides.
Table 4 lists the cDNA and/or genomic DNA fragments which were used to
assemble
polynucleotide sequences of the invention, along with selected fragments of
the polynucleotide
sequences.
Table 5 shows the representative cDNA library for polynucleotides of the
invention.
Table 6 provides an appendix which describes the tissues and vectors used for
construction of
the cDNA libraries shown in Table 5.
Table 7 shows the tools, programs, and algorithms used to analyze the
polynucleotides and
polypeptides of the invention, along with applicable descriptions, references,
and threshold
parameters.
Table 8 shows tissue-specific expression of polynucleotides of the invention.
DESCRIPTION OF THE INVENTION
Before the present proteins, nucleotide sequences, and methods are described,
it is understood
that this invention is not limited to the particular machines, materials and
methods described, as these
may vary. It is also to be understood that the terminology used herein is for
the purpose of describing
particular embodiments only, and is not intended to limit the scope of the
present invention which
. will be limited only by.the appended claims.
It must be noted that as used herein and in the appended claims, the singular
forms "a," "an,"
and "the" include plural reference unless the context clearly dictates
otherwise. Thus, for example, a
reference to "a host cell" includes a plurality of such host cells, and a
reference to "an antibody" is a
reference to one or more antibodies and equivalents thereof known to those
skilled in the art, and so
forth.
Unless defined otherwise, all technical and scientific terms used herein have
the same
meanings as commonly understood by one of ordinary skill in the art to which
this invention belongs.
Although any machines, materials, and methods similar or equivalent to those
described herein can be
used to practice or test the present invention, the preferred machines,
materials and methods are now
described. All publications mentioned herein are cited for the purpose of
describing and disclosing
the cell lines, protocols, reagents and vectors which are reported in the
publications and which might
be used in connection with the invention. Nothing herein is to be construed as
an admission that the
invention is not entitled to antedate such disclosure by virtue of prior
invention.
DEFINITIONS
"GCREC" refers to the amino acid sequences of substantially purified GCREC
obtained from
11
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
any species, particularly a mammalian species, including bovine, ovine,
porcine, murine, equine, and
human, and from any source, whether natural, synthetic, semi-synthetic, or
recombinant.
The term "agonist" refers to a molecule which intensifies or mimics the
biological activity of
GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small
molecules, or any other
compound or composition which modulates the activity of GCREC either by
directly interacting with
GCREC or by acting on components of the biological pathway in which GCREC
participates.
An "allelic variant" is an alternative form of the gene encoding GCREC.
Allelic variants may
result from at least one mutation in the nucleic acid sequence and may result
in altered mRNAs or in
polypeptides whose structure or function may or may not be altered. A gene may
have none, one, or
many allelic variants of its naturally occurring form. Common mutational
changes which give rise to
allelic variants are generally ascribed to natural deletions, additions, or
substitutions of nucleotides.
Each of these types of changes may occur alone, or in combination with the
others, one or more times
in a given sequence.
"Altered" nucleic acid sequences encoding GCREC include those sequences with
deletions,
insertions, or substitutions of different nucleotides, resulting in a
polypeptide the same as GCREC or
a polypeptide with at least one functional characteristic of GCREC. Included
within this definition
are polymorphisms which may or may not be readily detectable using a
particular oligonucleotide
probe of the polynucleotide encoding GCREC, and improper or unexpected
hybridization to allelic
variants, with a locus other than the normal chromosomal locus for the
polynucleotide sequence
encoding GCREC. The encoded protein may also be "altered," and may contain
deletions, insertions,
or substitutions of amino acid residues which produce a silent change and
result in a functionally
equivalent GCREC. Deliberate amino acid substitutions may be made on the basis
of similarity in
polarity, charge, solubility, hydrophobicity, hydrophilicity, andlor the
amphipathic nature of the
residues, as long as the biological or immunological activity of GCREC is
retained. For example,
negatively charged amino acids may include aspartic acid and glutamic acid,
and positively charged
amino acids may include lysine and arginine. Amino acids with uncharged polar
side chains having
similar hydrophilicity values may include: asparagine and glutamine; and
serine and threonine.
Amino acids with uncharged side chains having similar hydrophilicity values
may include: leucine,
isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
The terms "amino acid" and "amino acid sequence" refer to an oligopeptide,
peptide,
polypeptide, or protein sequence, or a fragment of any of these, and to
naturally occurring or synthetic
molecules. Where "amino acid sequence" is recited to refer to a sequence of a
naturally occurring
protein molecule, "amino acid sequence" and like terms are not meant to limit
the amino acid
sequence to the complete native amino acid sequence associated with the
recited protein molecule.
"Amplification" relates to the production of additional copies of a nucleic
acid sequence.
12
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Amplification is generally carried out using polymerase chain reaction (PCR)
technologies well
known in the art.
The term "antagonist" refers to a molecule which inhibits or attenuates the
biological activity
of GCREC. Antagonists may include proteins such as antibodies, nucleic acids,
carbohydrates, small
molecules, or any other compound or composition which modulates the activity
of GCREC either by
directly interacting with GCREC or by acting on components of the biological
pathway in which
GCREC participates.
The term "antibody" refers to intact immunoglobulin molecules as well as to
fragments
thereof, such as Fab, F(ab')z, and Fv fragments, which are capable of binding
an epitopic determinant.
Antibodies that bind GCREC polypeptides can be prepared using intact
polypeptides or using
fragments containing small peptides of interest as the immunizing antigen. The
polypeptide or
oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit)
can be derived from the
translation of RNA, or synthesized chemically, and can be conjugated to a
carrier protein if desired.
Commonly used carriers that are chemically coupled to peptides include bovine
serum albumin,
thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is
then used to immunize
the animal.
The term "antigenic determinant" refers to that region of a molecule (i.e..,
an epitope) that
makes contact With a particular antibody. When a protein or a fragment of a
protein is used to
immunize a host animal, numerous regions of the protein may induce the
production of antibodies
which bind specifically to antigenic determinants (particular regions or three-
dimensional structures
on the protein). An antigenic determinant may compete with the intact antigen
(i.e., the immunogen
used to elicit the immune response) for binding to an antibody.
The term "antisense" refers to any composition capable of base-pairing with
the "sense"
(coding) strand of a specific nucleic acid sequence. Antisense compositions
may include DNA;
RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone
linkages such as
phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides
having modified
sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or
oligonucleotides having
modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-
deoxyguanosine. Antisense
molecules may be produced by any method including chemical synthesis or
transcription. Once
introduced into a cell, the complementary antisense molecule base-pairs with a
naturally occurring
nucleic acid sequence produced by the cell to form duplexes which block either
transcription or
translation. The designation "negative" or "minus" can refer to the antisense
strand, and the
designation "positive" or "plus" can refer to the sense strand of a reference
DNA molecule.
The term "biologically active" refers to a protein having structural,
regulatory, or biochemical
functions of a naturally occurring molecule. Likewise, "immunologically
active" or "immunogenic"
13
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
refers to the capability of the natural, recombinant, or synthetic GCREC, or
of any oligopeptide
thereof, to induce a specific immune response in appropriate animals or cells
and to bind with specific
antibodies.
"Complementary" describes the relationship between two single-stranded nucleic
acid
sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its
complement,
3'-TCA-5'.
A "composition comprising a given polynucleotide sequence" and a "composition
comprising
a given amino acid sequence" refer broadly to any composition containing the
given polynucleotide
or amino acid sequence. The composition may comprise a dry formulation or an
aqueous solution.
Compositions comprising polynucleotide sequences encoding GCREC or fragments
of GCREC may
be employed as hybridization probes. The probes may be stored in freeze-dried
form and may be
associated with a stabilizing agent such as a carbohydrate. In hybridizations,
the probe may be
deployed in an aqueous solution containing salts (e.g., NaCI), detergents
(e.g., sodium dodecyl
sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk,
salmon sperm DNA, etc.).
"Consensus sequence" refers to a nucleic acid sequence which has been
subjected to repeated
DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit
(Applied
Biosystems, Foster City CA) in the 5' and%or the 3' direction, and
resequenced, or which has been
assembled from one or more overlapping cDNA, EST, or genomic DNA fragments
using a computer
program for fragment assembly, such as the GELVIEW fragment assembly system
(GCG, Madison
Wn or Phrap (University of Washington, Seattle WA). Some sequences have been
both extended and
assembled to produce the consensus sequence.
"Conservative amino acid substitutions" are those substitutions that are
predicted to least
interfere with the properties of the original protein, i.e., the structure and
especially the function of
the protein is conserved and not significantly changed by such substitutions.
The table below shows
amino acids which may be substituted for an original amino acid in a protein
and which are regarded
as conservative amino acid substitutions.
Original Residue Conservative Substitution
Ala Gly, Ser
Arg His, Lys
Asn Asp, Gln, His
Asp Asn, Glu
Cys Ala, Ser
Gln Asn, Glu, His
Glu Asp, Gln, His
Gly Ala
His Asn, Arg, Gln, Glu
Ile Leu, Val
Leu Ile, Val
Lys Arg, Gln, Glu
14
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Met Leu, Ile
Phe His, Met, Leu, Trp, Tyr
Ser Cys, Thr
Thr Ser, Val
Trp Phe, Tyr
Tyr His, Phe, Trp
Val Ile, Leu, Thr
Conservative amino acid substitutions generally maintain (a) the structure of
the polypeptide
backbone in the area of the substitution, for example, as a beta sheet or
alpha helical conformation,
(b) the charge or hydrophobicity of the molecule at the site of the
substitution, and/or (c) the bulk of
the side chain.
A "deletion" refers to a change in the amino acid or nucleotide sequence that
results in the
absence of one or more amino acid residues or nucleotides.
The term "derivative" refers to a chemically modified polynucleotide or
polypeptide.
Chemical modifications of a polynucleotide can include, for example,
replacement of hydrogen by an
alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a
polypeptide which
retains at least one biological or immunological function of the natural
molecule. A derivative
polypeptide is one modified by glycosylation, pegylation, or any similar
process that retains at least
one biological or immunological function of the polypeptide from which it was
derived.
A "detectable label" refers to a reporter molecule or enzyme that is capable
of generating a
measurable signal and is covalently or noncovalently joined to a
polynucleotide or polypeptide.
"Differential expression" refers to increased or upregulated; or decreased,
downregulated, or
absent gene or protein expression, determined by comparing at least two
different samples. Such
comparisons may be carried out between, for example, a treated and an
untreated sample, or a
diseased and a normal sample.
A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC
which is
identical in sequence to but shorter in length than the parent sequence. A
fragment may comprise up
to the entire length of the defined sequence, minus one nucleotide/amino acid
residue. For example,
a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid
residues. A fragment
used as a probe, primer, antigen, therapeutic molecule, or for other purposes,
may be at least 5, 10,
15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous
nucleotides or amino acid
residues in length. Fragments may be preferentially selected from certain
regions of a molecule. For
example, a polypeptide fragment may comprise a certain length of contiguous
amino acids selected
from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide
as shown in a certain
defined sequence. Clearly these lengths are exemplary, and any length that is
supported by the
specification, including the Sequence Listing, tables, and figures, may be
encompassed by the present
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
embodiments.
A fragment of SEQ ID N0:24-46 comprises a region of unique polynucleotide
sequence that
specifically identifies SEQ ID N0:24-46, for example, as distinct from any
other sequence in the
genome from which the fragment was obtained. A fragment of SEQ ID N0:24-46 is
useful, for
example, in hybridization and amplification technologies and in analogous
methods that distinguish
SEQ ID N0:24-46 from related polynucleotide sequences. The precise length of a
fragment of SEQ
>D N0:24-46 and the region of SEQ ID N0:24-46 to which the fragment
corresponds are routinely
determinable by one of ordinary skill in the art based on the intended purpose
for the fragment.
A fragment of SEQ ID NO:1-23 is encoded by a fragment of SEQ ID N0:24-46. A
fragment
of SEQ ID NO:1-23 comprises a region of unique amino acid sequence that
specifically identifies
SEQ ID NO:1-23. For example, a fragment of SEQ ID NO: l-23 is useful as an
immunogenic peptide
for the development of antibodies that specifically recognize SEQ ID NO:1-23.
The precise length of
a fragment of SEQ ID NO:1-23 and the region of SEQ ID NO:1-23 to which the
fragment
corresponds are routinely determinable by one of ordinary skill in the art
based on the intended
purpose for the fragment.
A "full length" polynucleotide sequence is one containing at least a
translation initiation
codon (e.g., methionine) followed by an open reading frame and a translation
termination codon. A
"full length" polynucleotide sequence encodes a "full length" polypeptide
sequence.
"Homology" refers to sequence similarity or, interchangeably, sequence
identity, between
two or more polynucleotide sequences or two or more polypeptide sequences.
The teems "percent identity" and "% identity," as applied to polynucleotide
sequences, refer
to the percentage of residue matches between at least two polynucleotide
sequences aligned using a
standardized algorithm. Such an algorithm may insert, in a standardized and
reproducible way, gaps
in the sequences being compared in order to optimize alignment between two
sequences, and
therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the
default
parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e
sequence alignment program. This program is part of the LASERGENE software
package, a suite of
molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is
described in
Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et
al. (1992) CABIOS
8:189-191. For pairwise alignments of polynucleotide sequences, the default
parameters are set as
follows: I~tuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The
"weighted" residue
weight table is selected as the default. Percent identity is reported by
CLUSTAL V as the "percent
similarity" between aligned polynucleotide sequences.
Alternatively, a suite of commonly used and freely available sequence
comparison algorithms
16
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
is provided by the National Center for Biotechnology Information (NCBI) Basic
Local Alignment
Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410),
which is available
from several sources, including the NCBI, Bethesda, MD, and on the Internet at
http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various
sequence
analysis programs including "blastn," that is used to align a known
polynucleotide sequence with
other polynucleotide sequences from a variety of databases. Also available is
a tool called "BLAST 2
Sequences" that is used for direct pairwise comparison of two nucleotide
sequences. "BLAST 2
Sequences" can be accessed and used interactively at
http:l/www.ncbi.nlm.nih.gov/gorf/bl2.html.
The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed
below). BLAST
programs are commonly used with gap and other parameters set to default
settings. For example, to
compare two nucleotide sequences, one may use blastn with the "BLAST 2
Sequences" tool Version
2Ø12 (April-21-2000) set at default parameters. Such default parameters may
be, for example:
Matrix: BLOSUM62
Reward for zzzatch: 1
Penalty for misznatclz: -2 '
Operz Gap: 5 and Extension Gap: 2 penalties
Gap x drop-off. SO
Expect: 10
Word Size: 11
Filter: on
Percent identity may be measured over the length of an entire defined
sequence, for example,
as defined by a particular SEQ ID number, or may be measured over a shorter
length, for example,
over the length of a fragment taken from a larger, defined sequence, for
instance, a fragment of at
least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or
at least 200 contiguous
nucleotides. Such lengths are exemplary only, and it is understood that any
fragment length
supported by the sequences shown herein, in the tables, figures, or Sequence
Listing, may be used to
describe a length over which percentage identity may be measured.
Nucleic acid sequences that do not show a high degree of identity may
nevertheless encode
similar amino acid sequences due to the degeneracy of the genetic code. It is
understood that changes
in a nucleic acid sequence can be made using this degeneracy to produce
multiple nucleic acid
sequences that all encode substantially the same protein.
The phrases "percent identity" and "% identity," as applied to polypeptide
sequences, refer to
the percentage of residue matches between at Least two polypeptide sequences
aligned using a
standardized algorithm. Methods of polypeptide sequence alignment are well-
known. Some
alignment methods take into account conservative amino acid substitutions.
Such conservative
17
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
substitutions, explained in more detail above, generally preserve the charge
and hydrophobicity at the
site of substitution, thus preserving the structure (and therefore function)
of the polypeptide.
Percent identity between polypeptide sequences may be determined using the
default
parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e
sequence alignment program (described and referenced above). For pairwise
alignments of
polypeptide sequences using CLUSTAL V, the default parameters are set as
follows: I~tuple=l, gap
penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as
the default
residue weight table. As with polynucleotide alignments, the percent identity
is reported by
CLUSTAL V as the "percent similarity" between aligned polypeptide sequence
pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a
pairwise
comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences"
tool Version
2Ø12 (April-21-2000) with blastp set at default parameters. Such default
parameters may be, for
example:
Matrix: BLOSUM62
Open Gap: 11 and Extezzsiozz Gap: 1 penalties
Gap x drop-off.' S0
Expect: 10
Word Size: 3
Filter: on
Percent identity may be measured over the length of an entire defined
polypeptide sequence,
for example, as defined by a particular SEQ ID number, or may be measured over
a shorter length, for
example, over the length of a fragment taken from a larger, defined
polypeptide sequence, for
instance, a fragment of at least 15, at least 20, at least 30, at least 40, at
least 50, at least 70 or at least
150 contiguous residues. Such lengths are exemplary only, and it is understood
that any fragment
length supported by the sequences shown herein, in the tables, figures or
Sequence Listing, may be
used to describe a length over which percentage identity may be measured.
"Human artificial chromosomes" (HACs) are linear microchromosomes which may
contain
DNA sequences of about 6 kb to 10 Mb in size and which contain all of the
elements required for
chromosome replication, segregation and maintenance.
The term "humanized antibody" refers to an antibody molecule in which the
amino acid
sequence in the non-antigen binding regions has been altered so that the
antibody more closely
resembles a human antibody, and still retains its original binding ability.
"Hybridization" refers to the process by which a polynucleotide strand anneals
with a
complementary strand through base pairing under defined hybridization
conditions. Specific
hybridization is an indication that two nucleic acid sequences share a high
degree of complementarity.
18
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Specific hybridization complexes form under permissive annealing conditions
and remain hybridized
after the "washing" step(s). The washing steps) is particularly important in
determining the
stringency of the hybridization process, with more stringent conditions
allowing less non-specific
binding, i.e., binding between pairs of nucleic acid strands that are not
perfectly matched. Permissive
conditions for annealing of nucleic acid sequences are routinely determinable
by one of ordinary skill
in the art and may be consistent among hybridization experiments, whereas wash
conditions may be
varied among experiments to achieve the desired stringency, and therefore
hybridization specificity.
Permissive annealing conditions occur, for example, at 68°C in the
presence of about 6 x SSC, about
1 % (w/v) SDS, and about 100 p g/ml sheared, denatured salmon sperm DNA.
Generally, stringency of hybridization is expressed, in part, with reference
to the temperature
under which the wash step is carried out. Such wash temperatures are typically
selected to be about
5°C to 20°C lower than the thermal melting point (Tm) for the
specific sequence at a defined ionic
strength and pH. The Tm is the temperature (under defined ionic strength and
pH) at which 50% of
the target sequence hybridizes to a perfectly matched probe. An equation for
calculating Tm and
conditions for nucleic acid hybridization are well known and can be found in
Sambrook, J. et al.
(1989) Molecular Cloning: A Laboratory Manual, 2°a ed., vol. 1-3, Cold
Spring Harbor Press,
Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the
present
invention include wash conditions of 68°C in the presence of about 0.2
x SSC and about 0.1% SDS,
for 1 hour. Alternatively, temperatures of about 65°C, 60°C,
55°C, or 42°C may be used. SSC
concentration may be varied from about 0.1 to 2 x SSC, with SDS being present
at about 0.1 %.
Typically, blocking reagents are used to block non-specific hybridization.
Such blocking reagents
include, for instance, sheared and denatured salmon sperm DNA at about 100-200
pg/ml. Organic
solvent, such as formamide at a concentration of about 35-50% v/v, may also be
used under particular
circumstances, such as for RNA:DNA hybridizations. Useful variations on these
wash conditions
will be readily apparent to those of ordinary skill in the art. Hybridization,
particularly under high
stringency conditions, may be suggestive of evolutionary similarity between
the nucleotides. Such
similarity is strongly indicative of a similar role for the nucleotides and
their encoded polypeptides.
The term "hybridization complex" refers to a complex formed between two
nucleic acid
sequences by virtue of the formation of hydrogen bonds between complementary
bases. A
hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or
formed between one
nucleic acid sequence present in solution and another nucleic acid sequence
immobilized on a solid
support (e.g., paper, membranes, filters, chips, pins or glass slides, or any
other appropriate substrate
to which cells or their nucleic acids have been fixed).
The words "insertion" and "addition" refer to changes in an amino acid or
nucleotide
19
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
sequence resulting in the addition of one or more amino acid residues or
nucleotides, respectively.
"Immune response" can refer to conditions associated with inflammation,
trauma, immune
disorders, or infectious or genetic disease, etc. These conditions can be
characterized by expression
of various factors, e.g., cytokines, chemokines, and other signaling
molecules, which may affect
cellular and systemic defense systems.
An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC
which is
capable of eliciting an immune response when introduced into a living
organism, for example, a
mammal. The term "immunogenic fragment" also includes any polypeptide or
oligopeptide fragment
of GCREC which is useful in any of the antibody production methods disclosed
herein or known in
the art.
The term "microarray" refers to an arrangement of a plurality of
polynucleotides,
polypeptides, or other chemical compounds on a substrate.
The terms "element" and "array element" refer to a polynucleotide,
polypeptide, or other
chemical compound having a unique and defined position on a microarray.
The term "modulate" refers to a change in the activity of GCREC. For example,
modulation
may cause an increase or a decrease in protein activity, binding
characteristics, or any other
biological, functional, or immunological properties of GCREC
The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide,
oligonucleotide,
polynucleotide, or any fragment thereof. These phrases also refer to DNA or
RNA of genomic or
synthetic origin which may be single-stranded or double-stranded and may
represent the sense or the
antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-
like material.
"Operably linked" refers to the situation in which a first nucleic acid
sequence is placed in a
functional relationship with a second nucleic acid sequence. For instance, a
promoter is operably
linked to a coding sequence if the promoter affects the transcription or
expression of the coding
sequence. Operably linked DNA sequences may be in close proximity or
contiguous and, where
necessary to join two protein coding regions, in the same reading frame.
"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene
agent which
comprises an oligonucleotide of at least about 5 nucleotides in length linked
to a peptide backbone of
amino acid residues ending in lysine. The terminal lysine confers solubility
to the composition.
PNAs preferentially bind complementary single stranded DNA or RNA and stop
transcript
elongation, and may be pegylated to extend their lifespan in the cell.
"Post-translational modification" of an GCREC may involve lipidation,
glycosylation,
phosphorylation, acetylation, racemization, proteolytic cleavage, and other
modifications known in
the art. These processes may occur synthetically or biochemically. Biochemical
modifications will
vary by cell type depending on the enzymatic milieu of GCREC.
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or
fragments
thereof, which are used to detect identical, allelic or related nucleic acid
sequences. Probes are
isolated oligonucleotides or polynucleotides attached to a detectable label or
reporter molecule.
Typical labels include radioactive isotopes, ligands, chemiluminescent agents,
and enzymes.
"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be
annealed to a target
polynucleotide by complementary base-pairing. The primer may then be extended
along the target
DNA strand by a DNA polymerise enzyme. Primer pairs can be used for
amplification (and
identification) of a nucleic acid sequence, e.g., by the polymerise chain
reaction (PCR).
Probes and primers as used in the present invention typically comprise at
least 15 contiguous
nucleotides of a known sequence. In order to enhance specificity, longer
probes and primers may also
be employed, such as probes and primers that comprise at least 20, 25, 30, 40,
50, 60, 70, 80, 90, 100,
or at least 150 consecutive nucleotides of the disclosed nucleic acid
sequences. Probes and primers
may be considerably longer than these examples, and it is understood that any
length supported by the
specification, including the tables, figures, and Sequence Listing, may be
used.
Methods for preparing and using probes and primers are described in the
references, for
example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2"d
ed., vol. 1-3, Cold
Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. ( 1987) Current
Protocols in Molecular
Biolo~y, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et
al. (1990) PCR
Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA.
PCR primer pairs
can be derived from a known sequence, for example, by using computer programs
intended for that
purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical
Research, Cambridge
MA).
Oligonucleotides for use as primers are selected using software known in the
art for such
purpose. For example, OLIGO 4.06 software is useful for the selection of PCR
primer pairs of up to
100 nucleotides each, and for the analysis of oligonucleotides and larger
polynucleotides of up to
5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases.
Similar primer
selection programs have incorporated additional features for expanded
capabilities. For example, the
PrimOU primer selection program (available to the public from the Genome
Center at University of
Texas South West Medical Center, Dallas TX) is capable of choosing specific
primers from
megabase sequences and is thus useful for designing primers on a genome-wide
scope. The Primer3
primer selection program (available to the public from the Whitehead
Institute/MIT Center for
Genome Research, Cambridge MA) allows the user to input a "mispriming
library," in which
sequences to avoid as primer binding sites are user-specified. Primer3 is
useful, in particular, for the
selection of oligonucleotides for microarrays. (The source code for the latter
two primer selection
programs may also be obtained from their respective sources and modified to
meet the user's specific
21
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
needs.) The PrimeGen program (available to the public from the UK Human Genome
Mapping
Project Resource Centre, Cambridge UK) designs primers based on multiple
sequence alignments,
thereby allowing selection of primers that hybridize to either the most
conserved or least conserved
regions of aligned nucleic acid sequences. Hence, this program is useful for
identification of both
unique and conserved oligonucleotides and polynucleotide fragments. The
oligonucleotides and
polynucleotide fragments identified by any of the above selection methods are
useful in hybridization
technologies, for example, as PCR or sequencing primers, microarray elements,
or specific probes to
identify fully or partially complementary polynucleotides in a sample of
nucleic acids. Methods of
oligonucleotide selection are not limited to those described above.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or
has a sequence
that is made by an artificial combination of two or more otherwise separated
segments of sequence.
This artificial combination is often accomplished by chemical synthesis or,
more commonly, by the
artificial manipulation of isolated segments of nucleic acids, e.g., by
genetic engineering techniques
such as those described in Sambrook, supra,. The term recombinant includes
nucleic acids that have
been altered solely by addition, substitution, or deletion of a portion of the
nucleic acid. Frequently, a .
recombinant nucleic acid may include a nucleic acid sequence operably linked
to a promoter
sequence. Such a recombinant nucleic acid may be part of a vector that is
used, for example, to
transform a cell.
Alternatively, such recombinant nucleic acids may be part of a viral vector,
e.g., based on a
vaccinia virus, that could be use to vaccinate a mammal wherein the
recombinant nucleic acid is
expressed, inducing a protective immunological response in the mammal.
A "regulatory element" refers to a nucleic acid sequence usually derived from
untranslated
regions of a gene and includes enhancers, promoters, introns, and 5' and 3'
untranslated regions
(UTRs). Regulatory elements interact with host or viral proteins which control
transcription,
translation, or RNA stability.
"Reuorter molecules" are chemical or biochemical moieties used for labeling a
nucleic acid_
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic
DNA, RNA, or
cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.
The terms "specific binding" and "specifically binding" refer to that
interaction between a
protein or peptide and an agonist, an antibody, an antagonist, a small
molecule, or any natural or
synthetic binding composition. The interaction is dependent upon the presence
of a particular
structure of the protein, e.g., the antigenic determinant or epitope,
recognized by the binding
molecule. For example, if an antibody is specific for epitope "A," the
presence of a polypeptide
comprising the epitope A, or the presence of free unlabeled A, in a reaction
containing free labeled A
and the antibody will reduce the amount of labeled A that binds to the
antibody.
The term "substantially purified" refers to nucleic acid or amino acid
sequences that are
removed from their natural environment and are isolated or separated, and are
at least 60% free,
preferably at least 75% free, and most preferably at least 90% free from other
components with which
they are naturally associated.
A "substitution" refers to the replacement of one or more amino acid residues
or nucleotides
by different amino acid residues or nucleotides, respectively.
"Substrate" refers to any suitable rigid or semi-rigid support including
membranes, filters,
chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing,
plates, polymers,
microparticles and capillaries. The substrate can have a variety of surface
forms, such as wells,
trenches, pins, channels and pores, to which polynucleotides or polypeptides
are bound.
A "transcript image" refers to the collective pattern of gene expressionby a
particular cell
type or tissue under given conditions at a given time.
"Transformation" describes a process by which exogenous DNA is introduced into
a recipient
cell. Transformation may occur under natural or artificial conditions
according to various methods
well known in the art, and may rely on any known method for the insertion of
foreign nucleic acid
; sequences into a prokaryotic or eukaryotic host cell. The method for
transformation is selected based
on the type of host cell being transformed and may include, but is not limited
to, bacteriophage or
viral infection, electroporation, heat shock, lipofection, and particle
bombardment. The term
"transformed cells" includes stably transformed cells in which the inserted
DNA is capable of
replication either as an autonomously replicating plasmid or as part of the
host chromosome, as well
as transiently transformed cells which express the inserted DNA or RNA for
limited periods of time.
A "transgenic organism," as used herein, is any organism, including but not
limited to
animals and plants, in which one or more of the cells of the organism contains
heterologous nucleic
acid introduced by way of human intervention, such as by transgenic techniques
well known in the
art. The nucleic acid is introduced into the cell, directly or indirectly by
introduction into a precursor
of the cell, by way of deliberate genetic manipulation, such as by
microinjection or by infection with
23
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
a recombinant virus. The term genetic manipulation does not include classical
cross-breeding, or in
vitro fertilization, but rather is directed to the introduction of a
recombinant DNA molecule. The
transgenic organisms contemplated in accordance with the present invention
include bacteria,
cyanobacteria, fungi, plants and animals. The isolated DNA of the present
invention can be
introduced into the host by methods known in the art, for example infection,
transfection,
transformation or transconjugation. Techniques for transferring the DNA of the
present invention
into such organisms are widely known and provided in references such as
Sambrook et al. (1989),
supra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid
sequence having
at least 40% sequence identity to the particular nucleic acid sequence over a
certain length of one of
the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool
Version 2Ø9 (May-07-
1999) set at default parameters. Such a pair of nucleic acids may show, for
example, at least 50%, at
least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or
at least 99% or greater
sequence identity over a certain defined length. A variant may be described
as, for example, an
"allelic" (as defined above), "splice," "species," or "polymorphic" variant. A
splice variant may have
significant identity to a reference molecule, but will generally have a
greater or lesser number of
polynucleotides due to alternative splicing of exons during mRNA processing.
The corresponding
polypeptide may possess additional functional domains or lack domains that are
present in the
reference molecule. Species variants are polynucleotide sequences that vary
from one species to
another. The resulting polypeptides will generally have significant amino acid
identity relative to
each other. A polymorphic variant is a variation in the polynucleotide
sequence of a particular gene
between individuals of a given species. Polymorphic variants also may
encompass "single nucleotide
polymorphisms" (SNPs) in which the polynucl'eotide sequence varies by one
nucleotide base. The
presence of SNPs may be indicative of, for example, a certain population, a
disease state, or a
propensity for a disease state.
A "variant" of a particular polypeptide sequence is defined as a polypeptide
sequence having
at least 40% sequence identity to the particular polypeptide sequence over a
certain length of one of
the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool
Version 2Ø9 (May-07-
1999) set at default parameters. Such a pair of polypeptides may show, for
example, at least .50%, at
least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least
92%, at least 93%, at least
94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%
or greater sequence
identity over a certain defined length of one of the polypeptides.
THE INVENTION
24
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
The invention is based on the discovery of new human G-protein coupled
receptors
(GCREC), the polynucleotides encoding GCREC, and the use of these compositions
for the diagnosis,
treatment, or prevention of cell proliferative, neurological, cardiovascular,
gastrointestinal,
autoimmune/inflammatory, and metabolic disorders, and viral infections.
Table 1 summarizes the nomenclature for the full length polynucleotide and
polypeptide
sequences of the invention. Each polynucleotide and its corresponding
polypeptide are correlated to a
single Incyte project identification number (Incyte Project ID). Each
polypeptide sequence is denoted
by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:)
and an Incyte
polypeptide sequence number (Incyte Polypeptide )D) as shown. Each
polynucleotide sequence is
denoted by both a polynucleotide sequence identification number
(Polynucleotide SEQ ID NO:) and
an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID)
as shown.
Table 2 shows sequences with homology to the polypeptides of the invention as
identified by
BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2
show the
polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the
corresponding Incyte
polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the
invention. Column 3
shows the GenBank identification number (Genbank ID NO:) of the nearest
GenBank homolog.
Column 4 shows the probability score for the match between each polypeptide
and its GenBank
homolog. Column 5 shows the annotation of the GenBank homolog along with
relevant citations
where applicable, all of which are expressly incorporated by reference herein.
Table 3 shows various structural features of the polypeptides of the
invention. Columns 1 and
2 show the polypeptide sequence identification number (SEQ ID NO:) and the
corresponding Incyte
polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of
the invention. Column
3 shows the number of amino acid residues in each polypeptide. Column 4 shows
potential
phosphorylation sites, and column 5 shows potential glycosylation sites, as
determined by the
MOTIFS program of the GCG sequence analysis software package (Genetics
Computer Group,
Madison WI). Column 6 shows amino acid residues comprising signature
sequences, domains, and
motifs. Column 7 shows analytical methods for protein structure/function
analysis and in some cases, .
searchable databases to which the analytical methods were applied.
Together, Tables 2 and 3 summarize the properties of polypeptides of the
invention, and these
properties establish that the claimed polypeptides are G-protein coupled
receptors. For example, SEQ
ID N0:2 is 59% identical to rat taste bud receptor protein (GenBank ID
g1256389) as determined by
the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST
probability score is
5.7e-95, which indicates the probability of obtaining the observed polypeptide
sequence alignment by
chance. SEQ ID N0:2 also contains a seven transmembrane receptor (rhodopsin
family) domain as
determined by searching for statistically significant matches in the hidden
Markov model (HMM)-
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
based PFAM database of conserved protein family domains. The score is 146.3
and the probability
value is 2.2e-45. (See Table 3.) In addition, SEQ )D N0:2 contains G-protein
coupled receptor
signatures as determined by BLIMPS analysis of the BLOCKS (BL00237) and PRINTS
(PR00237)
databaes, and by ProfileScan analysis of the Prosite database, as well as an
olfactory receptor
signature (PR00245) as determined by BLIMPS analysis of the PRINTS database.
Based on BLAST,
BLIMPS, ProfileScan, and HMM-based analyses, SEQ ID N0:2 is an olfactory G-
protein coupled
receptor. In an alternative example, SEQ )D N0:15 is 85% identical to murine
odorant receptor
MOR18 (GenBank ID 86178008) as determined by BLAST. (See Table 2.) The BLAST
probability
score is 4.6e-138. SEQ >D N0:15 also contains a seven transmembrane receptor
domain as
determined by searching for statistically significant matches in the hidden
Markov model (HMM)-
based PFAM database of conserved protein family domains. Data from BLIMPS,
MOTIFS, and
PROFILESCAN analyses provide further corroborative evidence that SEQ ID N0:15
is a G-protein
coupled receptor. In alternative examples, SEQ ID N0:16 is 72% identical to a
mouse olfactory
receptor (GenBank ID 83983392) as determined by BLAST analysis, with a
probability score of 2.7e-
85; SEQ ID N0:17 is 97% identical to a gorilla olfactory receptor (GenBank ID
87211257), with a
probability score of 1.2e-109; and SEQ ID N0:18 is 51 % identical to a canine
olfactory receptor
(GenBank ID 81314663), with a probability score of 4.1e-82. (See Table 2.) SEQ
>D NO:I7 and
SEQ ID N0:18 also contain G-protein coupled receptor domains and signature
sequences as
determined by searching for statistically significant matches in the hidden
Markov model (HMM)-
based PFAM database of conserved protein family domains. (See Table 3.) Data
from BUMPS,
MOTIFS, and PROF1LESCAN analyses provide further corroborative evidence that
SEQ ID NO: I6-
18 are G-protein coupled receptors. In an alternative example, SEQ >D N0:19 is
56% identical to
mouse odorant receptor S 19 (GenBank ID 86532001) as determined by BLAST. (See
Table 2.) The
BLAST probability score is 1.4e-88. SEQ ID N0:19 also contains a seven
transmembrane receptor
(rhodopsin family) domain as determined by searching for statistically
significant matches in the
hidden Markov model (HMM)-based PFAM database of conserved protein family
domains: Data
from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative
evidence that
SEQ )D N0:19 is a G-protein coupled receptor. SEQ ID NO:1, SEQ )D N0:3-14, and
SEQ ID
N0:20-23 were analyzed and annotated in a similar manner. The algorithms and
parameters for the
analysis of SEQ ID NO:l-23 are described in Table 7.
As shown in Table 4, the full length polynucleotide sequences of the present
invention were
assembled using cDNA sequences or coding (exon) sequences derived from genomic
DNA, or any
combination of these two types of sequences. Columns 1 and 2 list the
polynucleotide sequence
identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte
polynucleotide
consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide
of the invention.
26
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Column 3 shows the length of each polynucleotide sequence in basepairs. Column
4 lists fragments
of the polynucleotide sequences which are useful, for example, in
hybridization or amplification
technologies that identify SEQ ID N0:24-46 or that distinguish between SEQ ID
N0:24-46 and
related polynucleotide sequences. Column 5 shows identification numbers
corresponding to cDNA
sequences, coding sequences (exons) predicted from genomic DNA, and/or
sequence assemblages
comprised of both cDNA and genomic DNA. These sequences were used to assemble
the full length
polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the
nucleotide start (5')
and stop (3') positions of the cDNA and/or genomic sequences in column 5
relative to their respective
full length sequences.
The identification numbers in Column 5 of Table 4 may refer specifically, for
example, to
Incyte cDNAs along with their corresponding cDNA libraries. For example,
7669623H1 is the
identification number of an Incyte cDNA sequence, and NOSEDIC02 is the cDNA
library from
which it is derived. Incyte cDNAs for which cDNA libraries are not indicated
were derived from
pooled cDNA libraries. Alternatively, the identification numbers in column 5
may refer to GenBank
cDNAs or ESTs (e.g., 82525800) which contributed to the assembly of the full
length polynucleotide
sequences. Alternatively, the identification numbers in column 5 may refer to
coding regions
predicted by Genscan analysis of genomic DNA. For example,
GNN.g7329615_000006_002 is the
identification number of a Genscan-predicted coding sequence, with 87329615
being the GenBank
identification number of the sequence to which Genscan was applied. The
Genscan-predicted coding
sequences may have been edited prior to assembly. (See Example IV.)
Alternatively, the
identification numbers in column 5 may refer to assemblages of both cDNA and
Genscan-predicted
exons brought together by an "exon stitching" algorithm. (See Example V.)
Alternatively, the
identification numbers in column 5 may refer to assemblages of both cDNA and
Genscan=predicted
exons brought together by an "exon-stretching" algorithm. (See Example V.) In
some cases, Incyte
cDNA coverage redundant with the sequence coverage shown in column 5 was
obtained to confirm
the final consensus polynucleotide sequence, but the relevant Incyte cDNA
identification numbers are
not shown.
Table 5 shows the representative cDNA libraries for those full length
polynucleotide
sequences which were assembled using Incyte cDNA sequences. The representative
cDNA library is
the Incyte cDNA library which is most frequently represented by the Incyte
cDNA sequences which
were used to assemble and confirm the above polynucleotide sequences. The
tissues and vectors
which were used to construct the cDNA libraries shown in Table 5 are described
in Table 6.
Table 8 shows tissue-specific expression of polynucleotides of the invention.
Column 1 lists
groups of tissues which were tested by polymerase chain reaction (PCR) for
expression of the
polynucleotides. The remaining columns indicate whether a particular
polynucleotide was expressed
27
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
in each tissue group. Detection of a PCR product indicated positive
expression, denoted by a "+"
sign, while inability to detect a PCR product indicated a lack of expression,
denoted by a "-" sign.
The invention also encompasses GCREC variants. A preferred GCREC variant is
one which
has at least about 80%, or alternatively at least about 90%, or even at least
about 95% amino acid
sequence identity to the GCREC amino acid sequence, and which contains at
least one functional or
structural characteristic of GCREC.
The invention also encompasses polynucleotides which encode GCREC. In a
particular
embodiment, the invention encompasses a polynucleotide sequence comprising a
sequence selected
from the group consisting of SEQ ID N0:24-46, which encodes GCREC. The
polynucleotide
sequences of SEQ ID N0:24-46, as presented in the Sequence Listing, embrace
the equivalent RNA
sequences, wherein occurrences of the nitrogenous base thymine are replaced
with uracil, and the
sugar backbone is composed of ribose instead of deoxyribose.
The invention also encompasses a variant of a polynucleotide sequence encoding
GCREC. In
particular, such a variant polynucleotide sequence will have at least about
70%, or alternatively at
least about 85%, or even at least about 95% polynucleotide sequence identity
to the polynucleotide
sequence encoding GCREC. A particular aspect of the invention encompasses a
variant of a
polynucleotide sequence comprising a sequence selected from the group
consisting of SEQ ID
N0:24-46 which has at least about 70%, or alternatively at least about 85%, or
even at least about
95% polynucleotide sequence identity to a nucleic acid sequence selected from
the group consisting
of SEQ ID N0:24-46. Any one of the polynucleotide variants described above can
encode an amino
acid sequence which contains at least one functional or structural
characteristic of GCREC.
It will be appreciated by those skilled in the art that as a result of the
degeneracy of the
genetic code, a multitude of polynucleotide sequences encoding GCREC, some
bearing minimal
similarity to the polynucleotide sequences of any known and naturally
occurring gene, may be
produced. Thus, the invention contemplates each and every possible variation
of polynucleotide
sequence that could be made by selecting combinations based on possible codon
choices. These
combinations are made in accordance with the standard triplet genetic code as
applied to the
polynucleotide sequence of naturally occurring GCREC, and all such variations
are to be considered
as being specifically disclosed.
Although nucleotide sequences which encode GCREC and its variants are
generally capable
of hybridizing to the nucleotide sequence of the naturally occurring GCREC
under appropriately
selected conditions of stringency, it may be advantageous to produce
nucleotide sequences encoding
GCREC or its derivatives possessing a substantially different codon usage,
e.g., inclusion of non-
naturally occurring codons. Codons may be selected to increase the rate at
which expression of the
peptide occurs in a particular prokaryotic or eukaryotic host in accordance
with the frequency with
28
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
which particular codons are utilized by the host. Other reasons for
substantially altering the
nucleotide sequence encoding GCREC and its derivatives without altering the
encoded amino acid
sequences include the production of RNA transcripts having more desirable
properties, such as a
greater half life, than transcripts produced from the naturally occurring
sequence.
The invention also encompasses production of DNA sequences which encode GCREC
and
GCREC derivatives, or fragments thereof, entirely by synthetic chemistry.
After production, the
synthetic sequence may be inserted into any of the many available expression
vectors and cell
systems using reagents well known in the art. Moreover, synthetic chemistry
may be used to
introduce mutations into a sequence encoding GCREC or any fragment thereof.
Also encompassed by the invention are polynucleotide sequences that are
capable of
hybridizing to the claimed polynucleotide sequences, and, in particular, to
those shown in SEQ ID
N0:24-46 and fragments thereof under various conditions of stringency. (See,
e.g., Wahl, G.M. and
S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods
Enzymol.
152:507-511.) Hybridization conditions, including annealing and wash
conditions, are described,in
"Definitions."
Methods for DNA sequencing are well known in the art and may be used to
practice any of
the embodiments of the invention. The methods may employ such enzymes as the
Klenow fragment
of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase
(Applied
Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech,
Piscataway NJ), or
combinations of polymerases and proofreading exonucleases such as those found
in the ELONGASE
amplification system (Life Technologies, Gaithersburg MD). Preferably,
sequence preparation is
automated with machines such as the MICROLAB 2200 liquid transfer system
(Hamilton, Reno NV),
PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal
cycler
(Applied Biosystems). Sequencing is then carried out using either the ABI 373
or 377 DNA
sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing
system
(Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The
resulting sequences
are analyzed using a variety of algorithms which are well known in the art.
(See, e.g., Ausubel, F.M.
(1997) Short Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY,
unit 7.7; Meyers,
R.A. (1995) Molecular Biolo~y and Biotechnologx, Wiley VCH, New York NY, pp.
856-853.)
The nucleic acid sequences encoding GCREC may be extended utilizing a partial
nucleotide
sequence and employing various PCR-based methods known in the art to detect
upstream sequences,
such as promoters and regulatory elements. For example, one method which may
be employed,
restriction-site PCR, uses universal and nested primers to amplify unknown
sequence from genonnic
DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic.
2:318-322.)
Another method, inverse PCR, uses primers that extend in divergent directions
to amplify unknown
29
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
sequence from a circularized template. The template is derived from
restriction fragments comprising
a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et
al. (1988) Nucleic Acids
Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA
fragments
adjacent to known sequences in human and yeast artificial chromosome DNA.
(See, e.g., Lagerstrom,
M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple
restriction enzyme
digestions and ligations may be used to insert an engineered double-stranded
sequence into a region
of unknown sequence before performing PCR. Other methods which may be used to
retrieve
unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991)
Nucleic Acids Res.
19:3055-3060). Additionally, one may use PCR, nested primers, and
PROMOTERFINDER libraries
(Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need
to screen libraries
and is useful in finding intron/exon junctions. For all PCR-based methods,
primers may be designed
using commercially available software, such as OLIGO 4.06 primer analysis
software (National
Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30
nucleotides in
length, to have a GC content of about 50% or more, and to anneal to the
template at temperatures of
about 68°C to 72°C.
When screening for full length cDNAs, it is preferable to use libraries that
have been
size-selected to include larger cDNAs. In addition, random-primed libraries,
which often. include
sequences containing the 5' regions of genes, are preferable for situations in
which an oligo d(T)
library does not yield a full-length cDNA. Genomic libraries may be useful for
extension of sequence
into 5' non-transcribed regulatory regions.
Capillary electrophoresis systems which are commercially available may be used
to analyze
the size or confirm the nucleotide sequence of sequencing or PCR products. In
particular, capillary
sequencing may employ flowable polymers for electrophoretic separation, four
different nucleotide-
specific, laser-stimulated fluorescent dyes, and a charge coupled device
camera for detection of the
emitted wavelengths. Output/light intensity may be converted to electrical
signal using appropriate
software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the
entire
process from loading of samples to computer analysis and electronic data
display may be computer
controlled. Capillary electrophoresis is especially preferable for sequencing
small DNA fragments
which may be present in limited amounts in a particular sample.
In another embodiment of the invention, polynucleotide sequences or fragments
thereof
which encode GCREC may be cloned in recombinant DNA molecules that direct
expression of
GCREC, or fragments or functional equivalents thereof, in appropriate host
cells. Due to the inherent
degeneracy of the genetic code, other DNA sequences which encode substantially
the same or a
functionally equivalent amino acid sequence may be produced and used to
express GCREC.
The nucleotide sequences of the present invention can be engineered using
methods generally
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
known in the art in order to alter GCREC-encoding sequences for a variety of
purposes including, but
not limited to, modification of the cloning, processing, and/or expression of
the gene product. DNA
shuffling by random fragmentation and PCR reassembly of gene fragments and
synthetic
oligonucleotides may be used to engineer the nucleotide sequences. For
example, oligonucleotide-
mediated site-directed mutagenesis may be used to introduce mutations that
create new restriction
sites, alter glycosylation patterns, change codon preference, produce splice
variants, and so forth.
The nucleotides of the present invention may be subjected to DNA shuffling
techniques such
as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent
Number.
5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians,
F.C. et al. (1999) Nat.
Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-
319) to alter or
improve the biological properties of GCREC, such as its biological or
enzymatic activity or its ability
to bind to other molecules or compounds. DNA shuffling is a process by which a
library of gene
variants is produced using PCR-mediated recombination of gene fragments. The
library is then
subjected to selection or screening procedures that identify those gene
variants with the desired
properties. These preferred variants may then be pooled and further subjected
to recursive rounds of
DNA shuffling and selection/screening. Thus, genetic diversity is created
through "artificial."
breeding and rapid molecular evolution. For example, fragments of a single
gene containing random
point mutations may be recombined, screened, and then reshuffled until the
desired properties are
optimized. Alternatively, fragments of a given gene may be recombined with
fragments of
homologous genes in the same gene family, either from the same or different
species, thereby
maximizing the genetic diversity of multiple naturally occurring genes in a
directed and controllable
manner.
In another embodiment, sequences encoding GCREC may be synthesized, in whole
or in part,
using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et
al. (1980) Nucleic Acids
Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser.
7:225-232.)
Alternatively, GCREC itself or a fragment thereof may be synthesized using
chemical methods. For
example, peptide synthesis can be performed using various solution-phase or
solid-phase techniques.
(See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular
Properties, WH Freeman, New
York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.)
Automated synthesis
may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems).
Additionally, the
amino acid sequence of GCREC, or any part thereof, may be altered during
direct synthesis and/or
combined with sequences from other proteins, or any part thereof, to produce a
variant polypeptide or
a polypeptide having a sequence of a naturally occurring polypeptide.
The peptide may be substantially purified by preparative high performance
liquid
chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier ( 1990) Methods
Enzymol. 182:392-421.)
31
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
The composition of the synthetic peptides may be confirmed by amino acid
analysis or by
sequencing. (See, e.g., Creighton, supra, pp. 28-53.)
In order to express a biologically active GCREC, the nucleotide sequences
encoding GCREC
or derivatives thereof may be inserted into an appropriate expression vector,
i.e., a vector which
contains the necessary elements for transcriptional and translational control
of the inserted coding
sequence in a suitable host. These elements include regulatory sequences, such
as enhancers,
constitutive and inducible promoters, and 5' and 3' untranslated regions in
the vector and in
polynucleotide sequences encoding GCREC. Such elements may vary in their
strength and
specificity: Specific initiation signals may also be used to achieve more
efficient translation of
sequences encoding GCREC. Such signals include the ATG initiation codon and
adjacent sequences,
e.g. the Kozak sequence. In cases where sequences encoding GCREC and its
initiation codon and
upstream regulatory sequences are inserted into the appropriate expression
vector, no additional
transcriptional or translational control signals may be needed. However, in
cases where only coding
sequence, or a fragment thereof, is inserted, exogenous translational control
signals including an in-
frame ATG initiation codon should be provided by the vector. Exogenous
translational elements and
initiation codons may be of various origins, both natural and synthetic. The
efficiency of expression
may be enhanced by the inclusion of enhancers appropriate for the particular
host cell system used.
(See, e.g., Scharf, D. et al. ( 1994) Results Probl. Cell Differ. 20:125-162.)
Methods which are well known to those skilled in the art may be used to
construct expression
, vectors containing sequences encoding GCREC and appropriate transcriptional
and translational
control elements. These methods include in vitro recombinant DNA techniques,
synthetic techniques,
and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989)
Molecular Cloning, A
Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-
17; Ausubel, P.M. et
al. (1995) Current Protocols in Molecular Biolo~y, John Wiley & Sons, New York
NY, ch. 9, 13, and
16.)
A variety of expression vector/host systems may be utilized to contain and
express .sequences
encoding GCREC. These include, but are not limited to, microorganisms such as
bacteria
transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression
vectors; yeast
transformed with yeast expression vectors; insect cell systems infected with
viral expression vectors
(e.g., baculovirus); plant cell systems transformed with viral expression
vectors (e.g., cauliflower
mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression
vectors (e.g., Ti or
pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra;
Ausubel, supra; Van Heeke,
G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et
al. (1994) Proc. Natl.
Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-
1945; Takamatsu,
N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and
Technolo~y (1992)
32
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
McGraw Hill, New York NY, p~. 191-196; Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA
81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)
Expression vectors derived
from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from
various bacterial plasmids,
may be used for delivery of nucleotide sequences to the targeted organ,
tissue, or cell population.
(See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M.
et al. (1993) Proc.
Natl. Acad. Sci. USA 90(13):6340-6344; Butler, R.M. et al. (1985) Nature
317(6040):813-815;
McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, LM. and
N. Somia (1997)
Nature 389:239-242.) The invention is not limited by the host cell employed.
In bacterial systems, a number of cloning and expression vectors may be
selected depending
upon the use intended for polynucleotide sequences encoding GCREC. For
example, routine cloning,
subcloning, and propagation of polynucleotide sequences encoding GCREC can be
achieved using a
multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA)
or PSPORTl
plasmid (Life Technologies). Ligation of sequences encoding GCREC into the
vector's multiple
cloning site disrupts the lacZ gene, allowing a colorimetric screening
procedure for identification of
transformed bacteria containing recombinant molecules. In addition, these
vectors may be useful for
in vitro transcription, dideoxy sequencing, single strand rescue with helper
phage, and creation of
nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.
Schuster (1989) J. Biol.
Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the
production of
antibodies, vectors which direct high level expression of GCREC may be used.
For example, vectors
containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.
Yeast expression systems may be used for production of GCREC. A number of
vectors
containing constitutive or inducible promoters, such as alpha factor, alcohol
oxidase, and PGH
promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia
astoris. In addition, such
vectors direct either the. secretion or intracellular retention of expressed
proteins and enable
integration of foreign sequences into the host genome for stable propagation.
(See, e.g., Ausubel,
1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and
Scorer, C.A. et al. (1994)
Bio/Technology 12:181-184.)
Plant systems may also be used for expression of GCREC. Transcription of
sequences
encoding GCREC may be driven by viral promoters, e.g., the 35S and 19S
promoters of CaMV used
alone or in combination with the omega leader sequence from TMV (Takamatsu, N.
(1987) EMBO J.
6:307-311). Alternatively, plant promoters such as the small subunit of
RUBISCO or heat shock
promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-
1680; Brogue, R. et al.
(1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell
Differ. 17:85-105.)
These constructs can be introduced into plant cells by direct DNA
transformation or
pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of
Science and Technolo~y
33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
(1992) McGraw Hill, New York NY, pp. 191-196.)
In mammalian cells, a number of viral-based expression systems may be
utilized. In cases
where an adenovirus is used as an expression vector, sequences encoding GCREC
may be ligated into
an adenovirus transcription/translation complex consisting of the late
promoter and tripartite leader
sequence. Insertion in a non-essential E1 or E3 region of the viral genome may
be used to obtain
infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and
T. Shenk (1984) Proc.
Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such
as the Rous sarcoma
virus (RSV) enhancer, may be used to increase expression in mammalian host
cells. SV40 or EBV-
based vectors may also be used for high-level protein expression.
Human artificial chromosomes (HACs) may also be employed to deliver larger
fragments of
DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb
to 10 Mb are
constructed and delivered via conventional delivery methods (liposomes,
polycationic amino
polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J.
et al. (1997) Nat. Genet.
15:345-355.)
For long term production of recombinant proteins in mammalian systems, stable
expression
of GCREC in cell lines is preferred. For example, sequences encoding GCREC can
be transformed
into cell lines using expression vectors which may contain viral origins of
replication andlor
endogenous expression elements and a selectable marker gene on the same or on
a separate vector.
Following the introduction of the vector, cells may be allowed to grow for
about 1 to 2 days in
enriched media before being switched to selective media. The purpose of the
selectable marker is to
confer resistance to a selective agent, and its presence allows growth and
recovery of cells which
successfully express the introduced sequences. Resistant clones of stably
transformed cells may be
propagated using tissue culture techniques appropriate to the cell type.
Any number of selection systems may be used to recover transformed cell lines.
These
include, but are not limited to, the herpes simplex virus thymidine kinase and
adenine
phosphoribosyltransferase genes, for use in tk- and apr cells, respectively.
(See, e.g., Wigler, M. et
al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also,
antimetabolite, antibiotic,
or herbicide resistance can be used as the basis for selection. For example,
dhfr confers resistance to
methotrexate; zzeo confers resistance to the aminoglycosides neomycin and G-
418; and als and pat
confer resistance to chlorsulfuron and phosphinotricin acetyltransferase,
respectively. (See, e.g.,
Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-
Garapin, F. et al. (1981)
J. Mol. Biol. 150:1-14.) Additional selectable genes have been described,
e.g., trpB and lzisD, which
alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and
R.C. Mulligan (1988) Proc.
Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green
fluorescent proteins
(GFP; Clontech),13 glucuronidase and its substrate 13-glucuronide, or
luciferase and its substrate
34
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
luciferin may be used. These markers can be used not only to identify
transformants, but also to
quantify the amount of transient or stable protein expression attributable to
a specific vector system.
(See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)
Although the presence/absence of marker gene expression suggests that the gene
of interest is
also present, the presence and expression of the gene may need to be
confirmed. For example, if the
sequence encoding GCREC is inserted within a marker gene sequence, transformed
cells containing
sequences encoding GCREC can be identified by the absence of marker gene
function. Alternatively,
a marker gene can be placed in tandem with a sequence encoding GCREC under the
control of a
single promoter. Expression of the marker gene in response to induction or
selection usually
' indicates expression of the tandem gene as well.
In general, host cells that contain the nucleic acid sequence encoding GCREC
and that
express GCREC may be identified by a variety of procedures known to those of
skill in the art. These
procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations,
PCR
amplification, and protein bioassay or immunoassay techniques which include
membrane, solution, or
chip based technologies for the detection and/or quantification of nucleic
acid or protein sequences.
Immunological methods for detecting and measuring the expression of GCREC
using either
specific polyclonal or monoclonal antibodies are known in the art. Examples of
such techniques
include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs),
and
fluorescence activated cell sorting (FACS). A two-site, monoclonal-based
immunoassay utilizing
monoclonal antibodies reactive to two non-interfering epitopes on GCREC is
preferred, but a
competitive binding assay may be employed. These and other assays are well
known in the art. (See,
e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS
Press, St. Paul MN,
Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunolo~y, Greene
Pub. Associates and
Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical
Protocols, Humana
Press, Totowa NJ.)
A wide variety of labels and conjugation techniques are known by those skilled
in the art and
may be used in various nucleic acid and amino acid assays. Means for producing
labeled
hybridization or PCR probes for detecting sequences related to polynucleotides
encoding GCREC
include oligolabeling, nick translation, end-labeling, or PCR amplification
using a labeled nucleotide.
Alternatively, the sequences encoding GCREC, or any fragments thereof, may be
cloned into a vector
for the production of an mRNA probe. Such vectors are known in the art, are
comnnercially available,
and may be used to synthesize RNA probes in vitro by addition of an
appropriate RNA polymerase
such as T7, T3, or SP6 and labeled nucleotides. These procedures may be
conducted using a variety
of commercially available kits, such as those provided by Amersham Pharmacia
Biotech, Promega
(Madison WI), and US Biochemical. Suitable reporter molecules or labels which
may be used for
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
ease of detection include radionuclides, enzymes, fluorescent,
chemiluminescent, or chromogenic
agents, as well as substrates, cofactors, inhibitors, magnetic particles, and
the like.
Host cells transformed with nucleotide sequences encoding GCREC may be
cultured under
conditions suitable for the expression and recovery of the protein from cell
culture. The protein
produced by a transformed cell may be secreted or retained intracellularly
depending on the sequence
andlor the vector used. As will be understood by those of skill in the art,
expression vectors
containing polynucleotides which encode GCREC may be designed to contain
signal sequences
which direct secretion of GCREC through a prokaryotic or eukaryotic cell
membrane.
In addition, a host cell strain may be chosen for its ability to modulate
expression of the
inserted sequences or to process the expressed protein in the desired fashion.
Such modifications of
the polypeptide include, but are not limited to, acetylation, carboxylation,
glycosylation,
phosphorylation, lipidation, and acylation. Post-translational processing
which cleaves a "prepro" or
"pro" form of the protein may also be used to specify protein targeting,
folding, andlor activity.
Different host cells which have specific cellular machinery and characteristic
mechanisms for
post-translational activities (e.g., CHO, HeLa, MDCI~, HEI~293, and WI38) are
available from the
American Type Culture Collection (ATCC, Manassas VA) and may be chosen to
ensure the correct
modification and processing of the foreign protein.
In another embodiment of the invention, natural, modified, or recombinant
nucleic acid
sequences encoding GCREC may be ligated to a heterologous sequence resulting
in translation of a
fusion protein in any of the aforementioned host systems. For example, a
chimeric GCREC protein
containing a heterologous moiety that can be recognized by a commercially
available antibody may
facilitate the screening of peptide libraries for inhibitors of GCREC
activity. Heterologous protein
and peptide moieties may also facilitate purification of fusion proteins using
commercially available
affinity matrices. Such moieties include, but are not limited to, glutathione
S-transferase (GST),
maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide
(CBP), 6-His, FLAG,
c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable
purification of their
cognate fusion proteins on irrunobilized glutathione, maltose, phenylarsine
oxide, calmodulin, and
metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable
immunoaffinity
purification of fusion proteins using commercially available monoclonal and
polyclonal antibodies
that specifically recognize these epitope tags. A fusion protein may also be
engineered to contain a
proteolytic cleavage site located between the GCREC encoding sequence and the
heterologous
protein sequence, so that GCREC may be cleaved away from the heterologous
moiety following
purification. Methods for fusion protein expression and purification are
discussed in Ausubel (1995,
sera, ch. 10). A variety of commercially available kits may also be used to
facilitate expression and
purification of fusion proteins.
36
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
In a further embodiment of the invention, synthesis of radiolabeled GCREC may
be achieved
in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system
(Promega). These
systems couple transcription and translation of protein-coding sequences
operably associated with the
T7, T3, or SP6 promoters. Translation takes place in the presence of a
radiolabeled amino acid
precursor, for example, 35S-methionine.
GCREC of the present invention or fragments thereof may be used to screen for
compounds
that specifically bind to GCREC. At least one and up to a plurality of test
compounds may be
screened for specific binding to GCREC. Examples of test compounds include
antibodies,
oligonucleotides, proteins (e.g., receptors), or small molecules.
In one embodiment, the compound thus identified is closely related to the
natural ligand of
GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural
or functional mimetic, or a
natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current
Protocols in Immunolo~y 1(2):
Chapter 5.) Similarly, the compound can be closely related to the natural
receptor to which GCREC
binds, or to at least a fragment of the receptor, e.g., the ligand binding
site. In either case, the
compound can be rationally designed using known techniques. In one embodiment,
screening for
these compounds involves producing appropriate cells which express GCREC,
either as a secreted
protein or on the cell membrane. Preferred cells include cells from mammals,
yeast, Drosophila, or
E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC
are. then
contacted with a test compound and binding, stimulation, or inhibition of
activity of either GCREC or
the compound is analyzed.
An assay may simply test binding of a test compound to the polypeptide,
wherein binding is
detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable
label. For example,
the assay may comprise the steps of combining at least one test compound with
GCREC, either in
solution or affixed to a solid support, and detecting the binding of GCREC to
the compound.
Alternatively, the assay may detect or measure binding of a test compound in
the presence of a
labeled competitor. Additionally, the assay may be carried out using cell-free
preparations, chemical
libraries, or natural product mixtures, and the test compounds) may be free in
solution or affixed to a
solid support.
GCREC of the present invention or fragments thereof may be used to screen for
compounds
that modulate the activity of GCREC. Such compounds may include agonists,
antagonists, or partial
or inverse agonists. In one embodiment, an assay is performed under conditions
permissive for
GCREC activity, wherein GCREC is combined with at least one test compound, and
the activity of
GCREC in the presence of a test compound is compared with the activity of
GCREC in the absence
of the test compound. A change in the activity of GCREC in the presence of the
test compound is
indicative of a compound that modulates the activity of GCREC. Alternatively,
a test compound is
si
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
combined with an in vitro or cell-free system comprising GCREC under
conditions suitable for
GCREC activity, and the assay is performed. In either of these assays, a test
compound which
modulates the activity of GCREC may do so indirectly and need not come in
direct contact with the
test compound. At least one and up to a plurality of test compounds may be
screened.
In another embodiment, polynucleotides encoding GCREC or their mammalian
homologs
may be "knocked out" in an animal model system using homologous recombination
in embryonic
stem (ES) cells. Such techniques are well known in the art and are useful for
the generation of animal
models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S.
Patent Number
5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line,
are derived from the
early mouse embryo and grown in culture. The ES cells are transformed with a
vector containing the
gene of interest disrupted by a marker gene, e.g., the neomycin
phosphotransferase gene (neo;
Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the
corresponding region
of the host genome by homologous recombination. Alternatively, homologous
recombination takes
place using the Cre-loxP system to knockout a gene of interest in a tissue- or
developmental stage-
specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U.
et al. (1997) Nucleic
Acids Res. 25:4323-4330). Transformed ES cells are identified and
microinjected into mouse cell
blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are
surgically transferred
to pseudopregnant dams, and the resulting chimeric progeny are genotyped and
bred to produce
heterozygous or homozygous strains. Transgenic animals thus generated may be
tested with potential
therapeutic or toxic agents.
Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells
derived from
human blastocysts. Human ES cells have the potential to differentiate into at
least eight separate cell
lineages including endoderm, mesoderm, and ectodermal cell types. These cell
lineages differentiate
into, for example, neural cells, hematopoietic lineages, and cardiomyocytes
(Thomson, J.A. et al.
(1998) Science 282:1145-1147).
Polynucleotides encoding GCREC can also be used to create "knockin" humanized
animals
(pigs) or transgenic animals (mice or rats) to model human disease. With
knockin technology, a
region of a polynucleotide encoding GCREC is injected into animal ES cells,
and the injected
sequence integrates into the animal cell genome. Transformed cells are
injected into blastulae, and
the blastulae are implanted as described above. Transgenic progeny or inbred
lines are studied and
treated with potential pharmaceutical agents to obtain information on
treatment of a human disease.
Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC
in its milk, may
also serve as a convenient source of that protein (Janne, J. et al. (1998)
Biotechnol. Annu. Rev. 4:55-
74).
THERAPEUTICS
5 tS
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Chemical and structural similarity, e.g., in the context of sequences and
motifs, exists
between regions of GCREC and G-protein coupled receptors. In addition,
the.expression of GCREC
is closely associated with nasal polyp tissue. Therefore, GCREC appears to
play a role in cell
proliferative, neurological, cardiovascular, gastrointestinal,
autoimmune/inflammatory, and metabolic
disorders, and viral infections. In the treatment of disorders associated with
increased GCREC
expression or activity, it is desirable to decrease the expression or activity
of GCREC. In the
treatment of disorders associated with decreased GCREC expression or activity,
it is desirable to
increase the expression or activity of GCREC.
Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be
administered to a subject to treat or prevent a disorder associated with
decreased expression or
activity of GCREC. Examples of such disorders include, but are not limited to,
a cell proliferative
disorder such as actinic keratosis, arteriosclerosis, atherosclerosis,
bursitis, cirrhosis, hepatitis, mixed
connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal
hemoglobinuria,
polycythemia vera, psoriasis, primary thrombocythemia, and cancers including
adenocarcinoma,
leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in
particular, cancers of
the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall
bladder, ganglia,
gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas,
parathyroid, penis, prostate,
salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a
neurological disorder such as
epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms,
Alzheimer's disease, Pick's
disease, Huntington's disease, dementia, Parkinson's disease and other
extrapyramidal disorders,
amyotrophic lateral sclerosis and other motor neuron disorders, progressive
neural muscular atrophy,
retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other
demyelinating diseases, bacterial
and viral meningitis, brain abscess, subdural empyema, epidural abscess,
suppurative intracranial
thrombophlebitis, myelitis and radiculitis, viral central nervous system
disease, prion diseases
including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker
syndrome, fatal
familial insomnia, nutritional and metabolic diseases of the nervous system,
neurofibromatosis,
tuberous sclerosis, cerebelloretinal hemangioblastomatosis,
encephalotrigeminal syndrome, mental
retardation and other developmental disorders of the central nervous system,
cerebral palsy,
neuroskeletal disorders, autonomic nervous system disorders, cranial nerve
disorders, spinal cord
diseases, muscular dystrophy and other neuromuscular disorders, peripheral
nervous system
disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine,
and toxic myopathies,
myasthenia gravis, periodic paralysis, mental disorders including mood,
anxiety, and schizophrenic
disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia,
diabetic neuropathy,
tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia,
Tourette's disorder,
progressive supranuclear palsy, corticobasal degeneration, and familial
frontotemporal dementia; a
39
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
cardiovascular disorder such as arteriovenous fistula, atherosclerosis,
hypertension, vasculitis,
Raynaud's disease, aneurysms, arterial dissections, varicose veins,
thrombophlebitis and
phlebothrombosis, vascular tumors, complications of thrombolysis, balloon
angioplasty, vascular
replacement, and coronary artery bypass graft surgery, congestive heart
failure, ischemic heart
disease, angina pectoris, myocardial infarction, hypertensive heart disease,
degenerative valvular
heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic
valve, mitral annular
calcification, mitral valve prolapse, rheumatic fever and rheumatic heart
disease, infective
endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic
lupus erythematosus,
carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic
heart disease,
congenital heart disease, and complications of cardiac transplantation; a
gastrointestinal disorder such
as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture,
esophageal carcinoma,
dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea,
emesis, gastroparesis, antral or
pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal
obstruction, infections of the
intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis,
pancreatitis, pancreatic
carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis,
passive congestion of the
liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis,
Crohn's disease, Whipple's
disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction,
irritable bowel syndrome,
short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage,
acquired
immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic
encephalopathy, hepatorenal
syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha 1-
antitrypsin deficiency,
Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein
obstruction and
thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis,
veno-occlusive disease,
preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic
cholestasis of pregnancy, and
hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an
autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome
(AIDS),
Addison's disease, adult respiratory distress syndrome, allergies, ankylosing
spondylitis, amyloidosis,
anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune
thyroiditis,
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED),
bronchitis,
cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis,
dermatomyositis, diabetes
mellitus, emphysema, episodic lymphopenia with lymphocytotoxins,
erythroblastosis fetalis, '
erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's
syndrome, gout, Graves'
disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome,
multiple sclerosis,
myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis,
osteoporosis, pancreatitis,
polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma,
Sjogren's syndrome,
systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis,
thrombocytopenic purpura,
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
ulcerative colitis, uveitis, Werner syndrome, complications of cancer,
hemodialysis, and
extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal,
and helminthic infections, and
trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and
an infection by a viral
agent classified as adenovirus, arenavirus, bunyavirus, calicivirus,
coronavirus, filovirus,
hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus,
papovavirus, paramyxovirus,
picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus.
In another embodiment, a vector capable of expressing GCREC or a fragment or
derivative
thereof may be administered to a subject to treat or prevent a disorder
associated with decreased
expression or activity of GCREC including, but not limited to, those described
above.
In a further embodiment, a composition comprising a substantially purified
GCREC in
conjunction with a suitable pharmaceutical Barrier may be administered to a
subject to treat or prevent
a disorder associated with decreased expression or activity of GCREC
including, but not limited to,
those provided above.
In still another embodiment, an agonist which modulates the activity of GCREC
may be
administered to a subject to treat or prevent a disorder associated with
decreased expression or
activity of GCREC including, but not limited to, those listed above.
In a further embodiment, an antagonist of GCREC may be administered to a
subject to treat
or prevent a disorder associated with increased expression or activity of
GCREC. Examples of such
disorders include, but are not limited to, those cell proliferative,
neurological, cardiovascular,
gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral
infections, described
above. In one aspect, an antibody which specifically binds GCREC may be used
directly as an
antagonist or indirectly as a targeting or delivery mechanism for bringing a
pharmaceutical agent to
cells or tissues which express GCREC.
In an additional embodiment, a vector expressing the complement of the
polynucleotide
encoding GCREC may be administered to a subject to treat or prevent a disorder
associated with
increased expression or activity of GCREC including, but not limited to, those
described above.
In other embodiments, any of the proteins, antagonists, antibodies, agonists,
complementary
sequences, or vectors of the invention may be administered in combination with
other appropriate
therapeutic agents. Selection of the appropriate agents for use in combination
therapy may be made
by one of ordinary skill in the art, according to conventional pharmaceutical
principles. The
combination of therapeutic agents may act synergistically to effect the
treatment or prevention of the
various disorders described above. Using this approach, one may be able to
achieve therapeutic
efficacy with lower dosages of each agent, thus reducing the potential for
adverse side effects.
An antagonist of GCREC may be produced using methods which are generally known
in the
art. In particular, purified GCREC may be used to produce antibodies or to
screen libraries of
41
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
pharmaceutical agents to identify those which specifically bind GCREC.
Antibodies to GCREC may
also be generated using methods that are well known in the art. Such
antibodies may include, but are
not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies,
Fab fragments, and
fragments produced by a Fab expression library. Neutralizing antibodies (i.e.,
those which inhibit
dimer formation) are generally preferred for therapeutic use.
For the production of antibodies, various hosts including goats, rabbits,
rats, mice, humans,
and others may be immunized by injection with GCREC or with any fragment or
oligopeptide thereof
which has immunogenic properties. Depending on the host species, various
adjuvants rnay be used to
increase immunological response. Such adjuvants include, but are not limited
to, Freund's, mineral
gels such as aluminum hydroxide, and surface active substances such as
lysolecithin, pluronic
polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among
adjuvants used in
humans, BCG (bacilli Calmette-Guerin) and Cor~ebacterium parvum are especially
preferable.
It is preferred that the oligopeptides, peptides, or fragments used to induce
antibodies to
GCREC have an amino acid sequence consisting of at least about 5 amino acids,
and generally will
consist of at least about 10 amino acids. It is also preferable that these
oligopeptides, peptides, or
fragments are identical to a portion of the amino acid sequence of the natural
protein. Short stretches
of GCREC amino acids may be fused with those of another protein; such as KLH,
and antibodies to
the chimeric molecule may be produced.
Monoclonal antibodies to GCREC may be prepared using any technique which
provides for
the production of antibody molecules by continuous cell lines in culture.
These include, but are not
limited to, the hybridoma technique, the human B-cell hybridoma technique, and
the EBV-hybridoma
technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D.
et al. (1985) J.
Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA
80:2026-2030; and
Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)
In addition, techniques developed for the production of "chimeric antibodies,"
such as the
splicing of mouse antibody genes to human antibody genes to obtain a molecule
with appropriate
antigen specificity and biological activity, can be used. (See, e.g.,
Morrison, S.L. et al. (1984) Proc.
Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature
312:604-608; and Takeda,
S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for
the production of single
chain antibodies may be adapted, using methods known in the art, to produce
GCREC-specific single
chain antibodies. Antibodies with related specificity, but of distinct
idiotypic composition, may be
generated by chain shuffling from random combinatorial immunoglobulin
libraries. (See, e.g.,
Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)
Antibodies may also be produced by inducing in vivo production in the
lymphocyte
population or by screening immunoglobulin libraries or panels of highly
specific binding reagents as
'YG
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc.
Natl..Acad. Sci. USA
86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)
Antibody fragments which contain specific binding sites for GCREC may also be
generated.
For example, such fragments include, but are not limited to, F(ab~2 fragments
produced by pepsin
digestion of the antibody molecule and Fab fragments generated by reducing the
disulfide bridges of
the F(ab~2 fragments. Alternatively, Fab expression libraries may be
constructed to allow rapid and
easy identification of monoclonal Fab fragments with the desired specificity.
(See, e.g., Huse, W.D.
et al. (1989) Science 246:1275-1281.)
Various immunoassays may be used for screening to identify antibodies having
the desired
specificity. Numerous protocols for competitive binding or immunoradiometric
assays using either
polyclonal or monoclonal antibodies with established specificities are well
known in the art. Such
immunoassays typically involve the measurement of complex formation between
GCREC and its
specific antibody. A two-site, monoclonal-based immunoassay utilizing
monoclonal antibodies
reactive to two non-interfering GCREC epitopes is generally used, but a
competitive binding assay
may also be employed (Pound, sue).
Various methods such as Scatchard analysis in conjunction with
radioimmunoassay
techniques may be used to assess the affinity of antibodies for GCREC.
Affinity is expressed as an
association constant, K~, which is defined as the molar concentration of GCREC-
antibody complex
divided by the molar concentrations of free antigen and free antibody under
equilibrium conditions.
The Ka determined for a preparation of polyclonal antibodies, which are
heterogeneous in their
affinities for multiple GCREC epitopes, represents the average affinity, or
avidity, of the antibodies
for GCREC. The Ka determined for a preparation of monoclonal antibodies, which
are monospecific
for a particular GCREC epitope, represents a true measure of affinity. High-
affinity antibody
preparations with Ka ranging from about 109 to 10'Z L/mole are preferred for
use in immunoassays in
which the GCREC-antibody complex must withstand rigorous manipulations. Low-
affinity antibody
preparations with Ka ranging from about 106 to 10' L/mole are preferred for
use in
immunopurification and similar procedures which ultimately require
dissociation of GCREC,
preferably in active form, from the antibody (Catty, D. (1988) Antibodies,
Volume I: A Practical
Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A
Practical Guide to
Monoclonal Antibodies, John Wiley & Sons, New York NY).
The titer and avidity of polyclonal antibody preparations may be further
evaluated to
determine the quality and suitability of such preparations for certain
downstream applications. For
example, a polyclonal antibody preparation containing at least 1-2 mg specific
antibody/ml,
preferably 5-10 mg specific antibodylml, is generally employed in procedures
requiring precipitation
of GCREC-antibody complexes. Procedures for evaluating antibody specificity,
titer, and avidity,
43
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
and guidelines for antibody quality and usage in various applications, are
generally available. (See,
e.g., Catty, supra, and Coligan et al. supra.)
In another embodiment of the invention, the polynucleotides encoding GCREC, or
any
fragment or complement thereof, may be used for therapeutic purposes. In one
aspect, modifications
of gene expression can be achieved by designing complementary sequences or
antisense molecules
(DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory
regions of the gene
encoding GCREC. Such technology is well known in the art, and antisense
oligonucleotides or larger
fragments can be designed from various locations along the coding or control
regions of sequences
encoding GCREC. (See, e.g., Agrawal, S., ed. (1996) Antisense Thera et~ utics,
Humana Press Inc.,
Totawa NJ.) .
In therapeutic use, any gene delivery system suitable for introduction of the
antisense
sequences into appropriate target cells can be used. Antisense sequences can
be delivered
intracellularly in the form of an expression plasmid which, upon
transcription, produces a sequence
complementary to at least a portion of the cellular sequence encoding the
target protein. (See, e.g.,
Slater, J.E. et al. (1998) J. Allergy Cli. Immunol. 102(3):469-475; and
Scanlon, K.J. et al. (1995)
9(13):1288-1296.) Antisense sequences can also be introduced intracellularly
through the use of viral
vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g.,
Miller, A.D. (1990) Blood
76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther.
63(3):323-347.) Other
gene delivery mechanisms include liposome-derived systems, artificial viral
envelopes, and other
systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull.
51(1):217-225; Boado, R.J. et
al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997)
Nucleic Acids Res.
25(14):2730-2736.)
In another embodiment of the invention, polynucleotides encoding GCREC may be
used for
somatic or germline gene therapy. Gene therapy may be performed to (i) correct
a genetic deficiency
(e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease
characterized by X
linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672),
severe combined
immunodeficiency syndrome associated with an inherited adenosine deaminase
(ADA) deficiency
(Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995)
Science 270:470-475),
cystic fibrosis (Zabner, J. et al. (1993) Cel175:207-216; Crystal, R.G. et al.
(1995) Hum. Gene
Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703),
thalassamias, familial
hypercholesterolemia, and hemophilia resulting from Factor VItI or Factor IX
deficiencies (Crystal,
R.G. (1995) Science 270:404-410; Verma, LM. and N. Somia (1997) Nature 389:239-
242)), (ii)
express a conditionally lethal gene product (e.g., in the case of cancers
which result from unregulated
cell proliferation), or (iii) express a protein Which affords protection
against intracellular parasites
(e.g., against human retroviruses, such as human immunodeficiency virus (HIV)
(Baltimore, D.
44
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
(1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci.
USA. 93:11395-11399),
hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans
and Paracoccidioides
brasiliensis; and protozoan parasites such as Plasmodium falciparum and
Trypanosoma cruzi). In the
case where a genetic deficiency in GCREC expression or regulation causes
disease, the expression of
GCREC from an appropriate population of transduced cells may alleviate the
clinical manifestations
caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by
deficiencies in
GCREC are treated by constructing mammalian expression vectors encoding GCREC
and introducing
these vectors by mechanical means into GCREC-deficient cells. Mechanical
transfer technologies for
use with cells in vivo or ex vitro include (i) direct DNA microinjection into
individual cells, (ii)
ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv)
receptor-mediated gene
transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson
(1993) Annu. Rev.
Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H.
Recipon (1998) Curr.
Opin. Biotechnol. 9:445-450).
Expression vectors that may be effective for the expression of GCREC include,
but are not
.limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen,
Carlsbad CA),
PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF,
PTET-ON,
PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GCREC may be expressed
using (i) a
constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous
sarcoma virus (RSV), SV40
virus, thymidine kinase (TK), or (3-actin genes), (ii) an inducible promoter
(e.g., the
tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl.
Acad. Sci. USA
89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V.
and H.M. Blau (1998)
Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX
plasmid (Invitrogen)); the
ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND;
Invitrogen); the
FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible
promoter (Rossi, F.M.V.
and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native
promoter of the endogenous
gene encoding GCREC from a normal individual.
Commercially available liposome transformation kits (e.g., the PERFECT LIPID
TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in
the art to deliver
polynucleotides to target cells in culture and require minimal effort to
optimize experimental
parameters. In the alternative, transformation is performed using the calcium
phosphate method
(Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation
(Neumann, E. et al.
(1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires
modification of
these standardized mammalian transfection protocols. .
In another embodiment of the invention, diseases or disorders caused by
genetic defects with
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
respect to GCREC expression are treated by constructing a retrovirus vector
consisting of (i) the
polynucleotide encoding GCREC under the control of an independent promoter or
the retrovirus long
terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and
(iii) a Rev-responsive
element (RRE) along with additional retrovirus cis-acting RNA sequences and
coding sequences
required for efficient vector propagation. Retrovirus vectors (e.g., PFB and
PFBNEO) are
commercially available (Stratagene) and are based on published data (Riviere,
I. et al. (1995) Proc.
Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The
vector is propagated in
an appropriate vector producing cell line (VPCL) that expresses an envelope
gene with a tropism for
receptors on the target cells or a promiscuous envelope protein such as VSVg
(Armentano, D. et al.
(1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-
1646; Adam, M.A. and
A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol.
72:8463-8471; Zufferey, R.
et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg
("Method for obtaining
retrovirus packaging cell lines producing high transducing efficiency
retroviral supernatant")
discloses a method for obtaining retrovirus packaging cell lines and is hereby
incorporated by
reference. Propagation of retrovirus vectors, transduction of a population of
cells (e.g., CD4+ T-
cells), and the return of transduced cells to a patient are procedures well
known to persons skilled in
the art of gene therapy and have been well documented (Ranga, U. et al. (1997)
J. Virol. 71:7020-
7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J.
Virol. 71:4707-4716;
Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997)
Blood 89:2283-
2290).
In the alternative, an adenovirus-based gene therapy delivery system is used
to deliver
polynucleotides encoding GCREC to cells which have one or more genetic
abnormalities with respect
to the expression of GCREC. The construction and packaging of adenovirus-based
vectors are well
known to those with ordinary skill in the art. Replication defective
adenovirus vectors have proven to
be versatile for importing genes encoding immunoregulatory proteins into
intact islets in the pancreas
(Crete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful
adenoviral vectors are
described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors
for gene therapy"),
hereby incorporated by reference. For adenoviral vectors, see also Antinozzi,
P.A. et al. (1999)
Annu. Rev. Nutr. 19:511-544 and Verma, LM. and N. Somia (1997) Nature
18:389:239-242, both
incorporated by reference herein.
In another alternative, a herpes-based, gene therapy delivery system is used
to deliver
polynucleotides encoding GCREC to target cells which have one or more genetic
abnormalities with
respect to the expression of GCREC. The use of herpes simplex virus (HSV)-
based vectors may be
especially valuable for introducing GCREC to cells of the central nervous
system, for which HSV has
a tropism. The construction and packaging of herpes-based vectors are well
known to those with
46
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
ordinary skill in the art. A replication-competent herpes simplex virus (HSV)
type 1-based vector has
been used to deliver a reporter gene to the eyes of primates (Liu, X. et al.
(1999) Exp. Eye Res.
169:385-395). The construction of a HSV-1 virus vector has also been disclosed
in detail in U.S.
Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene
transfer"), which is
hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use
of recombinant
HSV d92 which consists of a genome containing at least one exogenous gene to
be transferred to a
cell under the control of the appropriate promoter for purposes including
human gene therapy. Also
taught by this patent are the construction and use of recombinant HSV strains
deleted for ICP4, ICP27
and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol.
73:519-532 and Xu, H. et al.
(1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The
manipulation of cloned.
herpesvirus sequences, the generation of recombinant virus following the
transfection of multiple
plasmids containing different segments of the large herpesvirus genomes, the
growth and propagation
of herpesvirus, and the infection of cells with herpesvirus are techniques
well known to those of
ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus)
vector is used to
deliver polynucleotides encoding GCREC to target cells. The biology of the
prototypic alphavirus,
Semliki Forest Virus (SFV), has been studied extensively and gene transfer
vectors have been based
on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol.
9:464-469). During
alphavirus RNA replication, a subgenomic RNA is generated that normally
encodes the viral capsid
proteins. This subgenomic RNA replicates to higher levels than the full length
genomic RNA,
resulting in the overproduction of capsid proteins relative to the viral
proteins with enzymatic activity
(e.g., protease and polymerase). Similarly, inserting the coding sequence for
GCREC into the
alphavirus genome in place of the capsid-coding region results in the
production of a large number of
GCREC-coding RNAs and the synthesis of high levels of GCREC in vector
transduced cells. While
alphavirus infection is typically associated with cell lysis within a few
days, the ability to establish a
persistent infection in hamster normal kidney cells (BHK-21) with a variant of
Sindbis virus (SIN)
indicates that the lytic replication of alphaviruses can be altered to suit
the needs of the gene therapy
application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host
range of alphaviruses will
allow the introduction of GCREC into a variety of cell types. The specific
transduction of a subset of
cells in a population may require the sorting of cells prior to transduction.
The methods of
manipulating infectious cDNA clones of alphaviruses, performing alphavirus
cDNA and RNA
transfections, and performing alphavirus infections, are well known to those
with ordinary skill in the
art.
Oligonucleotides derived from the transcription initiation site, e.g., between
about positions
-10 and +10 from the start site, may also be employed to inhibit gene
expression. Similarly,
47
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
inhibition can be achieved using triple helix base-pairing methodology. Triple
helix pairing is useful
because it causes inhibition of the ability of the double helix to open
sufficiently for the binding of
polymerases, transcription factors, or regulatory molecules. Recent
therapeutic advances using
triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et
al. (1994) in Huber, B.E.
and B.I. Carr, Molecular and Immunolo~Yc Approaches, Futura Publishing, Mt.
Disco NY, pp. 163-
177.) A complementary sequence or antisense molecule may also be designed to
block translation of
mRNA by preventing the transcript from binding to ribosomes.
Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific
cleavage of
RNA. The mechanism of ribozyme action involves sequence-specific hybridization
of the ribozyme
molecule to complementary target RNA, followed by endonucleolytic cleavage.
For example,
engineered hammerhead motif ribozyme molecules may specifically and
efficiently catalyze
endonucleolytic cleavage of sequences encoding GCREC.
Specific ribozyme cleavage sites within any potential RNA target are initially
identified by
scanning the target molecule for ribozyme cleavage sites, including the
following sequences: GUA,
GUU, and GUC. Once identified, short RNA sequences of between 15 and 20
ribonucleotides,
corresponding to the region of the target gene containing the cleavage site,
may be evaluated for
secondary structural features which may render the oligonucleotide inoperable.
The suitability of
candidate targets may also be evaluated by testing accessibility to
hybridization with complementary
oligonucleotides using ribonuclease protection assays.
Complementary ribonucleic acid molecules and ribozymes of the invention may be
prepared
by any method known in the art for the synthesis of nucleic acid molecules.
These include techniques
for chemically synthesizing oligonucleotides such as solid phase
phosphoramidite chemical synthesis.
Alternatively, RNA molecules may be generated by in vitro and in vivo
transcription of DNA
sequences encoding GCREC. Such DNA sequences may be incorporated into a wide
variety of
vectors with suitable RNA polymerase promoters such as T7 or SP6.
Alternatively, these cDNA
constructs that synthesize complementary RNA, constitutively or inducibly, can
be introduced into
cell lines, cells, or tissues.
RNA molecules may be modified to increase intracellular stability and half
life. Possible
modifications include, but are not limited to, the addition of flanking
sequences at the 5' and/or 3'
ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather
than phosphodiesterase
linkages within the backbone of the molecule. This concept is inherent in the
production of PNAs
and can be extended in all of these molecules by the inclusion of
nontraditional bases such as inosine,
queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly
modified forms of adenine,
cytidine, guanine, thymine, and uridine which are not as easily recognized by
endogenous
endonucleases.
48
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
An additional embodiment of the invention encompasses a method for screening
for a
compound which is effective in altering expression of a polynucleotide
encoding GCREC.
Compounds which may be effective in altering expression of a specific
polynucleotide may include,
but are not limited to, oligonucleotides, antisense oligonucleotides, triple
helix-forming
oligonucleotides, transcription factors and other polypeptide transcriptional
regulators, and non-
macromolecular chemical entities which are capable of interacting with
specific polynucleotide
sequences. Effective compounds may alter polynucleotide expression by acting
as either inhibitors or
promoters of polynucleotide expression. Thus, in the treatment of disorders
associated with increased
GCREC expression or activity, a compound which specifically inhibits
expression of the
polynucleotide encoding GCREC may be therapeutically useful, and in the
treatment of disorders
associated with decreased GCREC expression or activity, a compound which
specifically promotes
expression of the polynucleotide encoding GCREC may be therapeutically useful.
At least one, and up to a plurality, of test compounds may be screened for
effectiveness in
altering expression of a specific polynucleotide. A test compound may be
obtained by any method
commonly known in the art, including chemical modification of a compound known
to be effective in
altering polynucleotide expression; selection from an existing, commercially-
available or proprietary
library of naturally-occurnng or non-natural chemical compounds; rational
design of a compound
based on chemical and/or structural properties of the target polynucleotide;
and selection from a
library of chemical compounds created combinatorially or randomly. A sample
comprising a
polynucleotide encoding GCREC is exposed to at least one test compound thus
obtained. The sample
may comprise, for example, an intact or permeabilized cell, or an in vitro
cell-free or reconstituted
biochemical system. Alterations in the expression of a polynucleotide encoding
GCREC are assayed
by any method commonly known in the art. Typically, the expression of a
specific nucleotide is
detected by hybridization with a probe having a nucleotide sequence
complementary to the sequence
of the polynucleotide encoding GCREC. The amount of hybridization may be
quantified, thus
forming the basis for a comparison of the expression of the polynucleotide
both with and without
exposure to one or more test compounds. Detection of a change in the
expression of a polynucleotide
exposed to a test compound indicates that the test compound is effective in
altering the expression of
the polynucleotide. A screen for a compound effective in altering expression
of a specific
polynucleotide can be carried out, for example, using a Schizosaccharomyces op
mbe gene expression
system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al.
(2000) Nucleic Acids
Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al.
(2000) Biochem. Biophys.
Res. Commun. 268:8-13). A particular embodiment of the present invention
involves screening a
combinatorial library of oligonucleotides (such as deoxyribonucleotides,
ribonucleotides, peptide
nucleic acids, and modified oligonucleotides) for antisense activity against a
specific polynucleotide
49
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W.
et al. (2000) U.S.
Patent No. 6,022,691).
Many methods for introducing vectors into cells or tissues are available and
equally suitable
for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be
introduced into stem cells
S taken from the patient and clonally propagated for autologous transplant
back into that same patient.
Delivery by transfection, by liposome injections, or by polycationic amino
polymers may be achieved
using methods which are well known in the art. (See, e.g., Goldman, C.K. et
al. (1997) Nat.
Biotechnol. 15:462-466.)
Any of the therapeutic methods described above may be applied to any subject
in need of
such therapy, including, for example, mammals such as humans, dogs, cats,
cows, horses, rabbits, and
monkeys.
An additional embodiment of the invention relates to the administration of a
composition
which generally comprises an active ingredient formulated with a
pharmaceutically acceptable
excipient. Excipients may include, for example, sugars, starches, celluloses,
gums, and proteins.
Various formulations are commonly known and are thoroughly discussed in the
latest edition of
Remin~ton's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such
compositions may
consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or
inhibitors of
GCREC.
The compositions utilized in this invention may be administered by any number
of routes
including, but not limited to, oral, intravenous, intramuscular, intra-
arterial, intramedullary,
intrathecal, intraventricular, pulmonary, transdermal, subcutaneous,
intraperitoneal, intranasal,
enteral, topical, sublingual, or rectal means.
Compositions for pulmonary administration may be prepared in liquid or dry
powder form.
These compositions are generally aerosolized immediately prior to inhalation
by the patient. In the
case of small molecules (e.g. traditional low molecular weight organic drugs),
aerosol delivery of
fast-acting formulations is well-known in the art. In the case of
macromolecules (e.g. larger peptides
and proteins), recent developments in the field of pulmonary delivery via the
alveolar region of the
lung have enabled the practical delivery of drugs such as insulin to blood
circulation (see, e.g., Patton,
J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage
of administration
without needle injection, and obviates the need for potentially toxic
penetration enhancers.
Compositions suitable for use in the invention include compositions wherein
the active
ingredients are contained in an effective amount to achieve the intended
purpose. The determination
of an effective dose is well within the capability of those skilled in the
art.
Specialized forms of compositions may be prepared for direct intracellular
delivery of
macromolecules comprising GCREC or fragments thereof. For example, liposome
preparations
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
containing a cell-impermeable macromolecule may promote cell fusion and
intracellular delivery of
the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to
a short cationic N-
terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated
have been found to
transduce into the cells of all tissues, including the brain, in a mouse model
system (Schwarze, S.R. et
al. (1999) Science 285:1569-1572).
For any compound, the therapeutically effective dose can be estimated
initially either in cell
culture assays, e.g., of neoplastic cells, or in animal models such as mice,
rats, rabbits, dogs,
monkeys, or pigs. An animal model may also be used to determine the
appropriate concentration
range and route of administration. Such information can then be used to
determine useful doses and
routes for administration in humans.
A therapeutically effective dose refers to that amount of active ingredient,
for example
GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or
inhibitors of
GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and
toxicity may be
determined by standard pharmaceutical procedures in cell cultures or with
experimental animals, such
as by calculating the EDSO (the dose therapeutically effective in 50% of the
population) or LDSO (the
dose lethal to 50% of the population) statistics. The dose ratio of toxic to
therapeutic effects is the
therapeutic index, which can be expressed as the LDSOIEDso ratio. Compositions
which exhibit large
therapeutic indices are preferred. The data obtained from cell culture assays
and animal studies are
used to formulate a range of dosage for human use. The dosage contained in
such compositions is
preferably within a range of circulating concentrations that includes the EDSO
with little or no toxicity.
The dosage varies within this range depending upon the dosage form employed,
the sensitivity of the
patient, and the route of administration.
The exact dosage will be determined by the practitioner, in light of factors
related to the
subject requiring treatment. Dosage and administration are adjusted to provide
sufficient levels of the
active moiety or to maintain the desired effect. Factors which may be taken
into account include the
severity of the disease state, the general health of the subject, the age,
weight, and gender of the
subject, time and frequency of administration, drug combination(s), reaction
sensitivities, and
response to therapy. Long-acting compositions may be administered every 3 to 4
days, every week,
or biweekly depending on the half life and clearance rate of the particular
formulation.
Normal dosage amounts may vary from about 0.1 ~g to 100,000 fig, up to a total
dose of
about 1 gram, depending upon the route of administration. Guidance as to
particular dosages and
methods of delivery is provided in the literature and generally available to
practitioners in the art.
Those skilled in the art will employ different formulations for nucleotides
than for proteins or their
inhibitors. Similarly, delivery of polynucleotides or polypeptides will be
specific to particular cells,
conditions, locations, etc.
51
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
DIAGNOSTICS
In another embodiment, antibodies which specifically bind GCREC may be used
for the
diagnosis of disorders characterized by expression of GCREC, or in assays to
monitor patients being
treated with GCREC or agonists, antagonists, or inhibitors of GCREC.
Antibodies useful for
diagnostic purposes may be prepared in the same manner as described above for
therapeutics.
Diagnostic assays for GCREC include methods which utilize the antibody and a
label to detect
GCREC in human body fluids or in extracts of cells or tissues. The antibodies
may be used with or
without modification, and may be labeled by covalent or non-covalent
attachment of a reporter
molecule. A wide variety of reporter molecules, several of which are described
above, are known in
the art and may be used.
A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS,
are
known in the art and provide a basis for diagnosing altered or abnormal levels
of GCREC expression.
Normal or standard values for GCREC expression are established by combining
body fluids or cell
extracts taken from normal mammalian subjects, for example, human subjects,
with antibodies to
GCREC under conditions suitable for complex formation. The amount of standard
complex
formation may be quantitated by various methods, such as photometric means.
Quantities of GCREC
expressed in subject, control, and disease samples from biopsied tissues are
compared with the
standard values. Deviation between standard and subject values establishes the
parameters for
diagnosing disease.
In another embodiment of the invention, the polynucleotides encoding GCREC may
be used
for diagnostic purposes. The polynucleotides which may be used include
oligonucleotide sequences,
complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used
to detect
and quantify gene expression in biopsied tissues in which expression of GCREC
may be correlated
with disease. The diagnostic assay may be used to determine absence, presence,
and excess
expression of GCREC, and to monitor regulation of GCREC levels during
therapeutic intervention.
In one aspect, hybridization with PCR probes which are capable of detecting
polynucleotide
sequences, including genomic sequences, encoding GCREC or closely related
molecules may be used
to identify nucleic acid sequences which encode GCREC. The specificity of the
probe, whether it is
made from a highly specific region, e.g., the 5'regulatory region, or from a
less specific region, e.g., a
conserved motif, and the stringency of the hybridization or amplification will
determine whether the
probe identifies only naturally occurring sequences encoding GCREC, allelic
variants, or related
sequences.
Probes may also be used for the detection of related sequences, and may have
at least 50%
sequence identity to any of the GCREC encoding sequences. The hybridization
probes of the subject
invention may be DNA or RNA and may be derived from the sequence of SEQ ID
N0:24-46 or from
52
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
genomic sequences including promoters, enhancers, and introns of the GCREC
gene.
Means for producing specific hybridization probes for DNAs encoding GCREC
include the
cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into
vectors for the
production of mRNA probes. Such vectors are known in the art, are commercially
available, and may
be used to synthesize RNA probes in vitro by means of the addition of the
appropriate RNA
polymerases and the appropriate labeled nucleotides. Hybridization probes may
be labeled by a
variety of reporter groups, for example, by radionuclides such as 32P or 35S,
or by enzymatic labels,
such as alkaline phosphatase coupled to the probe via avidin/biotin coupling
systems, and the like.
Polynucleotide sequences encoding GCREC may be used for the diagnosis of
disorders
associated with expression of GCREC. Examples of such disorders include, but
are not limited to, a
cell proliferative disorder such as actinic keratosis, arteriosclerosis,
atherosclerosis, bursitis, cirrhosis,
hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal
nocturnal
hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and
cancers including
adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,
teratocarcinoma, and, in
particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain,
breast, cervix, gall
bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle,
ovary, pancreas,
parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus,
thyroid, and uterus; a
neurological disorder such as epilepsy, ischemic cerebrovascular disease,
stroke, cerebral neoplasms,
Alzheimer's disease, Pick's disease, Huntington's disease, dementia,
Parkinson's disease and other
extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron
disorders, progressive
neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple
sclerosis and other
demyelinating diseases, bacterial and viral meningitis, brain abscess,
subdural empyema, epidural
abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis,
viral central nervous
system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and
Gerstmann-
Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and
metabolic diseases of the
nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal
hemangioblastomatosis,
encephalotrigeminal syndrome, mental retardation and other developmental
disorders of the central
nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous
system disorders, cranial
nerve disorders, spinal cord diseases, muscular dystrophy and other
neuromuscular disorders,
peripheral nervous system disorders, dermatomyositis and polymyositis,
inherited, metabolic,
endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental
disorders including
mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD),
akathesia, amnesia,
catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid
psychoses, postherpetic
neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal
degeneration, and familial
frontotemporal dementia; a cardiovascular disorder such as arteriovenous
fistula, atherosclerosis,
53
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections,
varicose veins,
thrombophlebitis and phlebothrombosis, vascular tumors, complications of
thrombolysis, balloon
angioplasty, vascular replacement, and coronary artery bypass graft surgery,
congestive heart failure,
ischemic heart disease, angina pectoris, myocardial infarction, hypertensive
heart disease,
degenerative valvular heart disease, calcific aortic valve stenosis,
congenitally bicuspid aortic valve,
mitral annular calcification, mitral valve prolapse, rheumatic fever and
rheumatic heart disease,
infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of
systemic lupus
erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis,
pericarditis, neoplastic heart
disease, congenital heart disease, and complications of cardiac
transplantation; a gastrointestinal
disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal
stricture, esophageal
carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia,
nausea, emesis,
gastroparesis, antral or pyloric edema, abdominal angina, pyrosis,
gastroenteritis, intestinal
obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis,
cholecystitis, cholestasis,
pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis,
hyperbilirubinemia, cirrhosis,
passive congestion of the liver, hepatoma, infectious colitis, ulcerative
colitis, ulcerative proctitis,
Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma,
colonic
obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea,
constipation, gastrointestinal
hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice,
hepatic
encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis,
Wilson's disease, alpha 1-
antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver
infarction, portal vein
obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic
vein thrombosis, veno-
occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy,
intrahepatic cholestasis of
pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and
carcinomas; an
autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome
(AIDS),
Addison's disease, adult respiratory distress syndrome, allergies, ankylosing
spondylitis, amyloidosis,
anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune
thyroiditis,
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED),
bronchitis,
cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis,
dermatomyositis, diabetes
mellitus, emphysema, episodic lymphopenia with lymphocytotoxins,
erythroblastosis fetalis,
erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's
syndrome, gout, Graves'
disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome,
multiple sclerosis,
myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis,
osteoporosis, pancreatitis,
polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma,
Sjogren's syndrome,
systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis,
thrombocytopenic purpura,
ulcerative colitis, uveitis, Werner syndrome, complications of cancer,
hemodialysis, and
54
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal,
and helminthic infections, and
trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and
an infection by a viral
agent classified as adenovirus, arenavirus, bunyavirus, calicivirus,
coronavirus, filovirus,
hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus,
papovavirus, paramyxovirus,
picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus .
The polynucleotide
sequences encoding GCREC may be used in Southern or northern analysis, dot
blot, or other
membrane-based technologies; in PCR technologies; in dipstick, pin, and
multiformat ELISA-like
assays; and in microarrays utilizing fluids or tissues from patients to detect
altered GCREC
expression. Such qualitative or quantitative methods are well known in the
art.
In a particular aspect, the nucleotide sequences encoding GCREC may be useful
in assays
that detect the presence of associated disorders, particularly those mentioned
above. The nucleotide
sequences encoding GCREC may be labeled by standard methods and added to a
fluid or tissue
sample from a patient under conditions suitable for the formation of
hybridization complexes. After a
suitable incubation period, the sample is washed and the signal is quantified
and compared with a
standard value. If the amount of signal in the patient sample is significantly
altered in comparison to
a control sample then the presence of altered levels of nucleotide sequences
encoding GCREC in the
sample indicates the presence of the associated disorder. Such assays may also
be used to evaluate
the efficacy of a particular therapeutic treatment regimen in animal studies,
in clinical trials, or to
monitor the treatment of an individual patient.
In order to provide a basis for the diagnosis of a disorder associated with
expression of
GCREC, a normal or standard profile for expression is established. This may be
accomplished by
combining body fluids or cell extracts taken from normal subjects, either
animal or human, with a
sequence, or a fragment thereof, encoding GCREC, under conditions suitable for
hybridization or
amplification. Standard hybridization may be quantified by comparing the
values obtained from
normal subjects with values from an experiment in which a known amount of a
substantially purified
polynucleotide is used. Standard values obtained in this manner may be
compared with values
obtained from samples from patients who are symptomatic for a disorder.
Deviation from standard
values is used to establish the presence of a disorder.
Once the presence of a disorder is established and a treatment protocol is
initiated,
hybridization assays may be repeated on a regular basis to determine if the
level of expression in the
patient begins to approximate that which is observed in the normal subject.
The results obtained from
successive assays may be used to show the efficacy of treatment over a period
ranging from several
days to months.
With respect to cancer, the presence of an abnormal amount of transcript
(either under- or
overexpressed) in biopsied tissue from an individual may indicate a
predisposition for the
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
development of the disease, or may provide a means for detecting the disease
prior to the appearance
of actual clinical symptoms. A more definitive diagnosis of this type may
allow health professionals
to employ preventative measures or aggressive treatment earlier thereby
preventing the development
or further progression of the cancer.
Additional diagnostic uses for oligonucleotides designed from the sequences
encoding
GCREC may involve the use of PCR. These oligomers may be chemically
synthesized, generated
enzymatically, or produced in vitro. Oligomers will preferably contain a
fragment of a polynucleotide
encoding GCREC, or a fragment of a polynucleotide complementary to the
polynucleotide encoding
GCREC, and will be employed under optimized conditions for identification of a
specific gene or
condition. Oligomers may also be employed under less stringent conditions for
detection or
quantification of closely related DNA or RNA sequences.
In a particular aspect, oligonucleotide primers derived from the
polynucleotide sequences
encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs).
SNPs are
substitutions, insertions and deletions that are a frequent cause of inherited
or acquired genetic
disease in humans. Methods of SNP detection include, but are not limited to,
single-stranded
conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In
SSCP,
oligonucleotide primers derived from the polynucleotide sequences encoding
GCREC are used to
amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived,
for example,
from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
SNPs in the DNA cause
differences in the secondary and tertiary structures of PCR products in single-
stranded form, and
these differences are detectable using gel electrophoresis in non-denaturing
gels. In fSCCP, the
oligonucleotide primers are fluorescently labeled, which allows detection of
the amplimers in high-
throughput equipment, such as DNA sequencing machines. Additionally, sequence
database analysis
methods, termed in silico SNP (isSNP), are capable of identifying
polymorphisms by comparing the '
sequence of individual overlapping DNA fragments which assemble into a common
consensus
sequence. These computer-based methods filter out sequence variations due to
laboratory preparation
of DNA and sequencing errors using statistical models and automated analyses
of DNA sequence
chromatograms. In the alternative, SNPs may be detected and characterized by
mass spectrometry
using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San
Diego CA).
Methods which may also be used to quantify the expression of GCREC include
radiolabeling
or biotinylating nucleotides, coamplification of a control nucleic acid, and
interpolating results from
standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods
159:235-244; Duplaa, C.
et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of
multiple samples may be
accelerated by running the assay in a high-throughput format where the
oligomer or polynucleotide of
interest is presented in various dilutions and a spectrophotometric or
colorimetric response gives
56
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
rapid quantitation.
In further embodiments, oligonucleotides or longer fragments derived from any
of the
polynucleotide sequences described herein may be used as elements on a
microarray. The microarray
can be used in transcript imaging techniques which monitor the relative
expression levels of large
numbers of genes simultaneously as described below. The microarray may also be
used to identify
genetic variants, mutations, and polymorphisms. This information may be used
to determine gene
function, to understand the genetic basis of a disorder, to diagnose a
disorder, to monitor
progression/regression of disease as a function of gene expression, and to
develop and monitor the
activities of therapeutic agents in the treatment of disease. In particular,
this information may be used
to develop a pharmacogenomic profile of a patient in order to select the most
appropriate and
effective treatment regimen for that patient. For example, therapeutic agents
which are highly
effective and display the fewest side effects may be selected for a patient
based on his/her
pharmacogenomic profile.
In another embodiment, GCREC, fragments of GCREC, or antibodies specific for
GCREC
may be used as elements on a microarray. The microarray may be used to monitor
or measure
protein-protein interactions, drug-target interactions, and gene expression
profiles, as described
above.
A particular embodiment relates to the use of the polynucleotides of the
present invention to
generate a transcript image of a tissue or cell type. A transcript image
represents the global pattern of
gene expression by a particular tissue or cell type. Global gene expression
patterns are analyzed by
quantifying the number of expressed genes and their relative abundance under
given conditions and at
a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis,"
U.S. Patent Number
5,840,484, expressly incorporated by reference herein.) Thus a transcript
image may be generated by
hybridizing the polynucleotides of the present invention or their complements
to the totality of
transcripts or reverse transcripts of a particular tissue or cell type. In one
embodiment, the
hybridization takes place in high-throughput format, wherein the
polynucleotides of the present
invention or their complements comprise a subset of a plurality of elements on
a microarray. The
resultant transcript image would provide a profile of gene activity.
Transcript images may be generated using transcripts isolated from tissues,
cell lines,
biopsies, or other biological samples. The transcript image may thus reflect
gene expression in vivo,
as in the case of a tissue or biopsy sample, or in vitro, as in the case of a
cell line.
Transcript images which profile the expression of the polynucleotides of the
present
invention may also be used in conjunction with in vitro model systems and
preclinical evaluation of
pharmaceuticals, as well as toxicological testing of industrial and naturally-
occurring environmental
compounds. All compounds induce characteristic gene expression patterns,
frequently termed
I
57
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
molecular fingerprints or toxicant signatures, which are indicative of
mechanisms of action and
toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S.
and N.L. Anderson
(2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference
herein). If a test
compound has a signature similar to that of a compound with known toxicity, it
is likely to share
those toxic properties. These fingerprints or signatures are most useful and
refined when they contain
expression information from a large number of genes and gene families.
Ideally, a genome-wide
measurement of expression provides the highest quality signature. Even genes
whose expression is
not altered by any tested compounds are important as well, as the levels of
expression of these genes
are used to normalize the rest of the expression data. The normalization
procedure is useful for
comparison of expression data after treatment with different compounds. While
the assignment of
gene function to elements of a toxicant signature aids in interpretation of
toxicity mechanisms,
knowledge of gene function is not necessary for the statistical matching of
signatures which leads to
prediction of toxicity. (See, for example, Press Release 00-02 from the
National Institute of
Environmental Health Sciences, released February 29, 2000, available at
http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and
desirable in
toxicological screening using toxicant signatures to include all expressed
gene sequences.
In one embodiment, the toxicity of a test compound is assessed by treating a
biological
sample containing nucleic acids with the test compound. Nucleic acids that are
expressed in the
treated biological sample are hybridized with one or more probes specific to
the polynucleotides of
the present invention, so that transcript levels corresponding to the
polynucleotides of the present
invention may be quantified. The transcript levels in the treated biological
sample are compared with
levels in an untreated biological sample. Differences in the transcript levels
between the two samples
are indicative of a toxic response caused by the test compound in the treated
sample.
Another particular embodiment relates to the use of the polypeptide sequences
of the present
invention to analyze the proteome of a tissue or cell type. The term proteome
refers to the global
pattern of protein expression in a particular tissue or cell type. Each
protein component of a
proteome can be subjected individually to further analysis. Proteome
expression patterns, or profiles,
are analyzed by quantifying the number of expressed proteins and their
relative abundance under
given conditions and at a given time. A profile of a cell's proteome may thus
be generated by
separating and analyzing the polypeptides of a particular tissue or cell type.
In one embodiment, the
separation is achieved using two-dimensional gel electrophoresis, in which
proteins from a sample are
separated by isoelectric focusing in the first dimension, and then according
to molecular weight by
sodium dodecyl sulfate slab gel electrophoresis in the second dimension
(Steiner and Anderson,
sera). The proteins are visualized in the gel as discrete and uniquely
positioned spots, typically by
staining the gel with an agent such as Coomassie Blue or silver or fluorescent
stains. The optical
58
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
density of each protein spot is generally proportional to the level of the
protein in the sample. The
optical densities of equivalently positioned protein spots from different
samples, for example, from
biological samples either treated or untreated with a test compound or
therapeutic agent, are
compared to identify any changes in protein spot density related to the
treatment. The proteins in the
spots are partially sequenced using, for example, standard methods employing
chemical or enzymatic
cleavage followed by mass spectrometry. The identity of the protein in a spot
may be determined by
comparing its partial sequence, preferably of at least 5 contiguous amino acid
residues, to the
polypeptide sequences of the present invention. In some cases, further
sequence data may be
obtained for definitive protein identification.
A proteomic profile may also be generated using antibodies specific for GCREC
to quantify
the levels of GCREC expression. In one embodiment, the antibodies are used as
elements on a
microarray, and protein expression levels are quantified by exposing the
microarray to the sample and
detecting the levels of protein bound to each array element (Lueking, A. et
al. (1999) Anal. Biochem.
270:103-111; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788). Detection
may be performed
by a variety of methods known in the art, for example, by reacting the
proteins in the sample with a
thiol- or amino-reactive fluorescent compound and detecting the amount of
fluorescence bound at
each array element.
Toxicant signatures at the proteome level are also useful for toxicological
screening, and
should be analyzed in parallel with toxicant signatures at the transcript
level. There is a poor
correlation between transcript and protein abundances for some proteins in
some tissues (Anderson,
N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant
signatures may be
useful in the analysis of compounds which do not significantly affect the
transcript image, but which
alter the proteomic profile. In addition, the analysis of transcripts in body
fluids is difficult, due to
rapid degradation of mRNA, so proteomic profiling may be more reliable and
informative in such
cases.
In another embodiment, the toxicity of a test compound is assessed by treating
a biological
sample containing proteins with the test compound. Proteins that are expressed
in the treated
biological sample are separated so that the amount of each protein can be
quantified. The amount of
each protein is compared to the amount of the corresponding protein in an
untreated biological
sample. A difference in the amount of protein between the two samples is
indicative of a toxic
response to the test compound in the treated sample. Individual proteins are
identified by sequencing
the amino acid residues of the individual proteins and comparing these partial
sequences to the
polypeptides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating
a biological
sample containing proteins with the test compound. Proteins from the
biological sample are
59
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
incubated with antibodies specific to the polypeptides of the present
invention. The amount of
protein recognized by the antibodies is quantified. The amount of protein in
the treated biological
sample is compared with the amount in an untreated biological sample. A
difference in the amount of
protein between the two samples is indicative of a toxic response to the test
compound in the treated
sample.
Microarrays may be prepared, used, and analyzed using methods known in the
art. (See, e.g.,
Birennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al.
(1996) Proc. Natl. Acad. Sci.
USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116;
Shalom D. et al.
(1995) PCT application W095/35505; Heller, R.A. et al. (1997) Proc. Natl.
Acad. Sci. USA 94:2150-
2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types
of microarrays are
well known and thoroughly described in DNA Microarrays: A Practical Approach,
M. Schena, ed.
(1999) Oxford University Press, London, hereby expressly incorporated by
reference.
In another embodiment of the invention, nucleic acid sequences encoding GCREC
may be
used to generate hybridization probes useful in mapping the naturally
occurring genomic sequence.
Either coding or noncoding sequences may be used, and in some instances,
noncoding sequences may
be preferable over coding sequences. For example, conservation of a coding
sequence among
members of a mufti-gene family may potentially cause undesired cross
hybridization during
chromosomal mapping. The sequences may be mapped to a particular chromosome,
to a specific
region of a chromosome, or to artificial chromosome constructions, e.g., human
artificial
chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial
chromosomes
(BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See,
e.g., Harrington, J.J.
et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134;
and Trask, B.J.
(1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of
the invention may be
used to develop genetic linkage maps, for example, which correlate the
inheritance of a disease state
with the inheritance of a particular chromosome region or restriction fragment
length polymorphism
(RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl.
Acad. Sci. USA 83:7353-
7357.)
Fluorescent in situ hybridization (FISH) may be correlated with other physical
and genetic
map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-
968.) Examples of genetic
map data can be found in various scientific journals or at the Online
Mendelian Inheritance in Man
(OMIM) World Wide Web site. Correlation between the location of the gene
encoding GCREC on a
physical map and a specific disorder, or a predisposition to a specific
disorder, may help define the
region of DNA associated with that disorder and thus may further positional
cloning efforts.
In situ hybridization of chromosomal preparations and physical mapping
techniques, such as
linkage analysis using established chromosomal markers, may be used for
extending genetic maps.
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Often the placement of a gene on the chromosome of another mammalian species,
such as mouse,
may reveal associated markers even if the exact chromosomal locus is not
known. This information is
valuable to investigators searching for disease genes using positional cloning
or other gene discovery
techniques. Once the gene or genes responsible for a disease or syndrome have
been crudely '
localized by genetic linkage to a particular genomic region, e.g., ataxia-
telangiectasia to l 1q22-23,
any sequences mapping to that area may represent associated or regulatory
genes for further
investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The
nucleotide sequence of
the instant invention may also be used to detect differences in the
chromosomal location due to
translocation, inversion, etc., among normal, carrier, or affected
individuals.
In another embodiment of the invention, GCREC, its catalytic or immunogenic
fragments, or
oligopeptides thereof can be used for screening libraries of compounds in any
of a variety of drug
screening techniques. The fragment employed in such screening may be free in
solution, affixed to a
solid support, borne on a cell surface, or located intracellularly. The
formation of binding complexes
between GCREC and the agent being tested may be measured.
Another technique for drug screening provides for high throughput screening of
compounds
having suitable binding affinity to the protein of interest. (See, e.g.,
Geysen, et al. (1984) PCT
application W084/03564.) In this method, large numbers of different small test
compounds are
synthesized on a solid substrate. The test compounds are reacted with GCREC,
or fragments thereof,
and washed. Bound GCREC is then detected by methods well known in the art.
Purified GCREC
can also be coated directly onto plates for use in the aforementioned drug
screening techniques.
Alternatively, non-neutralizing antibodies can be used to capture the peptide
and immobilize it on a
solid support.
In another embodiment, one may use competitive drug screening assays in which
neutralizing
antibodies capable of binding GCREC specifically compete with a test compound
for binding
GCREC. In this manner, antibodies can be used to detect the presence of any
peptide which shares
one or more antigenic determinants with GCREC.
In additional embodiments, the nucleotide sequences which encode GCREC may be
used in
any molecular biology techniques that have yet to be developed, provided the
new techniques rely on
properties of nucleotide sequences that are currently known, including, but
not limited to, such
properties as the triplet genetic code and specific base pair interactions.
Without further elaboration, it is believed that one skilled in the art can,
using the preceding
description, utilize the present invention to its fullest extent. The
following embodiments are,
therefore, to be construed as merely illustrative, and not limitative of the
remainder of the disclosure
in any way whatsoever.
The disclosures of all patents, applications and publications, mentioned above
and below,
61
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
including U.S. Ser. No. 60/208,834, U.S. Ser. No. 60/206,222, U.S. Ser. No.
60/207,476, U.S. Ser.
No. 601208,861, and U.S. Ser. No. 60/209,868, are expressly incorporated by
reference herein.
EXAMPLES
I. Construction of cDNA Libraries
Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD
database
(Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues
were homogenized
and lysed in guanidinium isothiocyanate, while others were homogenized and
lysed in phenol or in a
suitable mixture of denaturants, such as TRIZOL (Life Technologies), a
monophasic solution of
phenol and guanidine isothiocyanate. The resulting lysates were centrifuged
over CsCl cushions or
extracted with chloroform. RNA was precipitated from the lysates with either
isopropanol or sodium
acetate and ethanol, or by other routine methods.
Phenol extraction and precipitation of RNA were repeated as necessary to
increase RNA
purity. In some cases, RNA was treated with DNase. For most libraries,
poly(A)+ RNA was isolated
using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex
particles (QIAGEN,
Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively,
RNA was
isolated directly from tissue lysates using other RNA isolation kits, e.g.,
the POLY(A)PURE mRNA
purification kit (Ambion, Austin TX).
In some cases, Stratagene was provided with RNA and constructed the
corresponding~cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed
with the UNIZAP
vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies),
using the
recommended procedures or similar methods known in the art. (See, e.g.,
Ausubel, 1997, supra, units
5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random
primers. Synthetic
oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA
was digested with the
appropriate restriction enzyme or enzymes. For most libraries, the cDNA vas
size-selected (300-
1000 bp) using SEPHACRYL S 1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column
chromatography (Amersham Pharmacia Biotech) or preparative agarose gel
electrophoresis. cDNAs
were ligated into compatible restriction enzyme sites of the polylinker of a
suitable plasmid, e.g.,
PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies),
PCDNA2.1 plasmid
(Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte
Genomics, Palo Alto
CA), or derivatives thereof. Recombinant plasmids were transformed into
competent E. coli cells
including XL1-Blue, XL1-BIueMRF, or SOLR from Stratagene or DHSa, DH10B, or
ElectroMAX
DH10B from Life Technologies.
II. Isolation of cDNA Clones
Plasmids obtained as described in Example I were recovered from host cells by
in vivo
62
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
excision using the UNIZAP vector system (Stratagene) or by cell lysis.
Plasmids were purified using
at least one of the following: a Magic or WIZARD Minipreps DNA purification
system (Promega); an
AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL
8 Plasmid,
QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the
R.E.A.L. PREP 96
plasmid purification kit from QIAGEN. Following precipitation, plasmids were
resuspended in 0.1
ml of distilled water and stored, with or without lyophilization, at
4°C.
Alternatively, plasmid DNA was amplified from host cell lysates using direct
link PCR in a
high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell
lysis and thermal
cycling steps were carried out in a single reaction mixture. Samples were
processed and stored in
384-well plates, and the concentration of amplified plasmid DNA was quantified
fluorometrically
using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II
fluorescence
scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis
Incyte cDNA recovered in plasmids as described in Example II were sequenced as
follows.
Sequencing reactions were processed using standard methods or high-throughput
instrumentation
such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-
200 thermal
cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins
Scientific) or the
MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions
were prepared
using reagents provided by Amersham Pharmacia Biotech or supplied in ABI
sequencing kits such as
the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied
Biosystems).
Electrophoretic separation of cDNA sequencing reactions and detection of
labeled polynucleotides
were carried out using the MEGABACE 1000 DNA sequencing system (Molecular
Dynamics); the
ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction
with standard ABI
protocols and base calling software; or other sequence analysis systems known
in the art. Reading
frames within the cDNA sequences were identified using standard methods
(reviewed in Ausubel,
1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension
using the techniques
disclosed in Example VIII.
The polynucleotide sequences derived from Incyte cDNAs were validated by
removing
vector, linker, and poly(A) sequences.and by masking ambiguous bases, using
algorithms and
programs based on BLAST, dynamic programming, and dinucleotide nearest
neighbor analysis. The
Incyte cDNA sequences or translations thereof were then queried against a
selection of public
databases such as the GenBank primate, rodent, mammalian, vertebrate, and
eukaryote databases, and
BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein
family
databases such as PFAM. (HMM is a probabilistic approach which analyzes
consensus primary
structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin.
Struct. Biol. 6:361-365.)
63
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
The queries were performed using programs based on BLAST, FASTA, BLIMPS, and
HMMER. The
Incyte cDNA sequences were assembled to produce full length polynucleotide
sequences.
Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched
sequences, or
Genscan-predicted coding sequences (see Examples IV and V) were used to extend
Incyte cDNA
assemblages to full length. Assembly was performed using programs based on
Phred, Phrap, and
Consed, and cDNA assemblages were screened for open reading frames using
programs based on
GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were
translated to derive
the corresponding full length polypeptide sequences. Alternatively, a
polypeptide of the invention
may begin at any of the methionine residues of the full length translated
polypeptide. Full length
polypeptide sequences were subsequently analyzed by querying against databases
such as the
GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM,
Prosite,
and hidden Markov model (HMM)-based protein family databases such as PFAM.
Full length
polynucleotide sequences are also analyzed using MACDNASIS PRO software
(Hitachi Software
Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
Polynueleotide
and polypeptide sequence alignments are generated using default parameters
specified by the
CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment
program
(DNASTAR), which also calculates the percent identity between aligned
sequences.
Table 7 summarizes the tools, programs, and algorithms used for the analysis
and assembly of
Incyte cDNA and full length sequences and provides applicable descriptions,
references, and
threshold parameters. The first column of Table 7 shows the tools, programs,
and algorithms used,
the second column provides brief descriptions thereof, the third column
presents appropriate
references, all of which are incorporated by reference herein in their
entirety, and the fourth column
presents, where applicable, the scores, probability values, and other
parameters used to evaluate the
strength of a match between two sequences (the higher the score or the lower
tie probability value,
the greater the identity between two sequences).
The programs described above for the assembly and analysis of full length
polynucleotide
and polypeptide sequences were also used to identify polynucleotide sequence
fragments from SEQ
ll~ N0:24-46. Fragments from about 20 to about 4000 nucleotides which are
useful in hybridization
and amplification technologies are described in Table 4, column 4.
IV. Identification and Editing of Coding Sequences from Genomic DNA
Putative G-protein coupled receptors were initially identified by running the
Genscan gene
identification program against public genomic sequence databases (e.g., gbpri
and gbhtg). Genscan is
a general-purpose gene identification program which analyzes genomic DNA
sequences from a
variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-
94, and Burge, C. and
S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program
concatenates predicted exons to
64
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
form an assembled cDNA sequence extending from a methionine to a stop codon.
The output of
Genscan is a FASTA database of polynucleotide and polypeptide sequences. The
maximum range of
sequence for Genscan to analyze at once was set to 30 kb. To determine which
of these Genscan
predicted cDNA sequences encode G-protein coupled receptors, the encoded
polypeptides were
analyzed by querying against PFAM models for G-protein coupled receptors.
Potential G-protein
coupled receptors were also identified by homology to Incyte cDNA sequences
that had been
annotated as G-protein coupled receptors. These selected Genscan-predicted
sequences were then
compared by BLAST analysis to the genpept and gbpri public databases. Where
necessary, the
Genscan-predicted sequences were then edited by comparison to the top BLAST
hit from genpept to
correct errors in the sequence predicted by Genscan, such as extra or omitted
exons. BLAST analysis
was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-
predicted
sequences, thus providing evidence for transcription. When Incyte cDNA
coverage was available,
this information was used to correct or confirm the Genscan predicted
sequence. Full length
polynucleotide sequences were obtained by assembling Genscan-predicted coding
sequences with
Incyte cDNA sequences and/or public cDNA sequences using the assembly process
described in
Example III. Alternatively, full length polynucleotide sequences were derived
entirely from edited or
unedited Genscan-predicted coding sequences.
V. Assembly of Genomic Sequence Data with cDNA Sequence Data
"Stitched" Sequences
Partial cDNA sequences were extended with exons predicted by the Genscan gene
identification program described in Example IV. Partial cDNAs assembled as
described in Example
III were mapped to genomic DNA and parsed into clusters containing related
cDNAs and Genscan
exon predictions from one or more genomic sequences. Each cluster was analyzed
using an algorithm
based on graph theory and dynamic programming to integrate cDNA and genomic
information,
generating possible splice variants that were subsequently confirmed, edited,
or extended to create a
full length sequence. Sequence intervals in which the entire length of the
interval was present on
more than one sequence in the cluster were identified, and intervals thus
identified were considered to
be equivalent by transitivity. For example, if an interval was present on a
cDNA and two genomic
sequences, then all three intervals were considered to be equivalent. This
process allows unrelated
but consecutive genomic sequences to be brought together, bridged by cDNA
sequence. Intervals
thus identified were then "stitched" together by the stitching algorithm in
the order that they appear
along their parent sequences to generate the longest possible sequence, as
well as sequence variants.
Linkages between intervals which proceed along one type of parent sequence
(cDNA to cDNA or
genomic sequence to genomic sequence) were given preference over linkages
which change parent
type (cDNA to genomic sequence). The resultant stitched sequences were
translated and compared
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
by BLAST analysis to the genpept and gbpri public databases. Incorrect exons
predicted by Genscan
were corrected by comparison to the top BLAST hit from genpept. Sequences were
further extended
with additional cDNA sequences, or by inspection of genomic DNA, when
necessary.
"Stretched" Sequences
Partial DNA sequences were extended to full length with an algorithm based on
BLAST
analysis. First, partial cDNAs assembled as described in Example III were
queried against public
databases such as the GenBank primate, rodent, mammalian, vertebrate, and
eukaryote databases
using the BLAST program. The nearest GenBank protein homolog was then compared
by BLAST
analysis to either Incyte cDNA sequences or GenScan exon predicted sequences
described in
Example IV. A chimeric protein was generated by using the resultant high-
scoring segment pairs
(HSPs) to map the translated sequences onto the GenBank protein homolog.
Insertions or deletions
may occur in the chimeric protein with respect to the original GenBank protein
homolog. The
GenBank protein homolog, the chimeric protein, or both were used as probes to
search for
homologous genomic sequences from the public human genome databases. Partial
DNA sequences
were therefore "stretched" or extended by the addition of homologous genomic
sequences. The
resultant stretched sequences 'were examined to determine whether it contained
a complete gene.
~I. Chromosomal Mapping of GCREC Encoding Polynucleotides
The sequences which were used to assemble SEQ ID N0:24-46 were compared with
sequences from the Incyte LIFESEQ database and public domain databases using
BLAST and other
implementations of the Smith-Waterman algorithm. Sequences from these
databases that matched
SEQ ID N0:24-46 were assembled into clusters of contiguous and overlapping
sequences using
assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic
mapping data available
from public resources such as the Stanford Human Genome Center (SHGC),
Whitehead Institute for
Genome Research (WIGR), and Genethon were used to determine if any of the
clustered sequences
had been previously mapped. Inclusion of a mapped sequence in a cluster
resulted in the assignment
of all sequences of that cluster, including its particular SEQ ID NO:, to that
map location.
Map locations are represented by ranges, or intervals, of human chromosomes.
The map
position of an interval, in centiMorgans, is measured relative to the terminus
of the chromosome's p-
arm. (The centiMorgan (cM) is a unit of measurement based on recombination
frequencies between
chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb)
of DNA in
humans, although this can vary widely due to hot and cold spots of
recombination.) The cM
distances are based on genetic markers mapped by Genethon which provide
boundaries for radiation
hybrid markers whose sequences were included in each of the clusters. Human
genome maps and
other resources available to the public, such as the NCBI "GeneMap'99" World
Wide Web site
(http://www.ncbi.nlm.nih.gov/genemapn, can be employed to determine if
previously identified
66
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
disease genes map within or in proximity to the intervals indicated above.
VII. Analysis of Polynucleotide Expression
Northern analysis is a laboratory technique used to detect the presence of a
transcript of a
gene and involves the hybridization of a labeled nucleotide sequence to a
membrane on which RNAs
from a particular cell type or tissue have been bound. (See, e.g., Sambrook,
supra, ch. 7; Ausubel
(1995) supra, ch. 4 and 16.)
Analogous computer techniques applying BLAST were used to search for identical
or related
molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This
analysis is
much faster than multiple membrane-based hybridizations. In addition, the
sensitivity of the
computer search can be modified to determine whether any particular match is
categorized as exact or
similar. The basis of the search is the product score, which is defined as:
BLAST Score x Percent Identity
5 x minimum {length(Seq. 1), length(Seq. 2)}
The product score takes into account both the degree of similarity between two
sequences and the
length of the sequence match. The product score is a normalized value between
0 and 100, and is
calculated as follows: the BLAST score is multiplied by the percent nucleotide
identity and the
product is divided by (5 times the length of the shorter of the two
sequences). The BLAST score is
calculated by assigning a score of +5 for every base that matches in a high-
scoring segment pair
(HSP), and -4 for every mismatch. Two sequences may share more than one HSP
(separated by
gaps). If there is more than one HSP, then the pair with the highest BLAST
score is used to calculate
the product score. The product score represents a balance between fractional
overlap and quality in a
BLAST alignment. For example, a product score of 100 is produced only for 100%
identity over the
entire length of the shorter of the two sequences being compared. A product
score of 70 is produced
either by 100% identity and 70% overlap at one end, or by 88% identity and
100% overlap at the
other. A product score of 50 is produced either by 100% identity and 50%
overlap at one end, or 79%
identity and 100% overlap.
Alternatively, polynucleotide sequences encoding GCREC are analyzed with
respect to the
tissue sources from which they were derived. For example, some full length
sequences are
assembled, at least in part, with overlapping Incyte cDNA sequences (see
Example )I~. Each cDNA
sequence is derived from a cDNA library constructed from a human tissue. Each
human tissue is
classified into one of the following organ/tissue categories: cardiovascular
system; connective tissue;
digestive system; embryonic structures; endocrine system; exocrine glands;
genitalia, female;
genitalia, male; germ cells; heroic and immune system; liver; musculoskeletal
system; nervous
67
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
system; pancreas; respiratory system; sense organs; skin; stomatognathic
system; unclassified/mixed;
or urinary tract. The number of libraries in each category is counted and
divided by the total number
of libraries across all categories. Similarly, each human tissue is classified
into one of the following
disease/condition categories: cancer, cell line, developmental, inflammation,
neurological, trauma,
cardiovascular, pooled, and other, and the number of libraries in each
category is counted and divided
by the total number of libraries across all categories. The resulting
percentages reflect the tissue- and
disease-specific expression of cDNA encoding GCREC. cDNA sequences and cDNA
libraryltissue
information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto
CA).
VIII. Extension of GCREC Encoding Polynucleotides
Full length polynucleotide sequences were also produced by extension of an
appropriate
fragment of the full length molecule using oligonucleotide primers designed
from this fragment. One
primer was synthesized to initiate 5' extension of the known fragment, and the
other primer was
synthesized to initiate 3' extension of the known fragment. The initial
primers were designed using
OLIGO 4.06 software (National Biosciences), or another appropriate program, to
be about 22 to 30
nucleotides in length, to have a GC content of about 50% or more, and to
anneal to the target
sequence at temperatures of about 68°C to about 72°C. Any
stretch of nucleotides which would
result in hairpin structures and primer-primer dimerizations was avoided.
Selected human cDNA libraries were used to extend the sequence. If more than
one
extension was necessary or desired, additional or nested sets of primers were
designed.
High fidelity amplification was obtained by PCR using methods well known in
the art. PCR
was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research,
Inc.). The reaction
mix contained DNA template, 200 nmol of each primer, reaction buffer
containing Mg2+, (NH4)ZS04,
and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech),
ELONGASE enzyme
(Life Technologies), and Pfu DNA polymerase (Stratagene), with the following
parameters fox primer
pair PCI A and PCI B: Step l: 94°C, 3 min; Step 2: 94°C, 15 sec;
Step 3: 60°C, 1 min; Step 4: 68°C,
2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5
min; Step 7: storage at 4°C. In the
alternative, the parameters for primer pair T7 and SK+ were as follows: Step
1: 94°C, 3 min; Step 2:
94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min;
Step 5: Steps 2, 3, and 4 repeated 20 times;
Step 6: 68°C, 5 min; Step 7: storage at 4°C.
The concentration of DNA in each well was determined by dispensing 100 ~l
PICOGREEN
quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR)
dissolved in 1X TE
and 0.5 p1 of undiluted PCR product into each well of an opaque fluorimeter
plate (Corning Costar,
Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a
Fluoroskan II
(Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample
and to quantify the
concentration of DNA. A 5 ,u1 to 10 ,u1 aliquot of the reaction mixture was
analyzed by
68
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
electrophoresis on a 1 % agarose gel to determine which reactions were
successful in extending the
sequence.
The extended nucleotides were desalted and concentrated, transferred to 384-
well plates,
digested with CviJI cholera virus endonuclease (Molecular Biology Research,
Madison Wn, and
sonicated or sheared prior to religation into pUC 18 vector (Amersham
Pharmacia Biotech). For
shotgun sequencing, the digested nucleotides were separated on low
concentration (0.6 to 0.8%)
agarose gels, fragments were excised, and agar digested with Agar ACE
(Promega). Extended clones
were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18
vector (Amersham
Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in
restriction site
overhangs, and transfected into competent E. coli cells. Transformed cells
were selected on
antibiotic-containing media, and individual colonies were picked and cultured
overnight at 37°C in
384-well plates in LB/2x carb liquid media.
The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase
(Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the
following
parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3:
60°C, 1 min; Step 4: 72°C, 2 min;
Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step
7: storage at 4°C. DNA was
quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples
with low DNA
recoveries were reamplified using the same conditions as described above.
Samples were diluted
with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy
transfer sequencing
primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI
PRISM
BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, full length polynucleotide sequences are verified using the
above procedure or
are used to obtain 5'regulatory sequences using the above procedure along with
oligonucleotides
designed for such extension, and an appropriate genomic library.
IX. Labeling and Use of Individual Hybridization Probes
Hybridization probes derived from SEQ ID N0:24-46 are employed to screen
cDNAs,
genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting
of about 20 base
pairs, is specifically described, essentially the same procedure is used with
larger nucleotide
fragments. Oligonucleotides are designed using state-of the-art software such
as OLIGO 4.06
software (National Biosciences) and labeled by combining 50 pmol of each
oligomer, 250 ~Ci of
~,~ 32P, adenosine triphosphate (Amersham Pharmacia Biotech), and T4
polynucleotide kinase
(DuPont NEN, Boston MA). The labeled oligonucleotides are substantially
purified using a
SEPI~ADEX G-25 superfine size exclusion dextran bead column (Amersham
Pharmacia Biotech).
An aliquot containing 10' counts per minute of the labeled probe is used in a
typical membrane-based
hybridization analysis of human genomic DNA digested with one of the following
endonucleases:
69
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).
The DNA from each digest is fractionated on a 0.7% agarose gel and transferred
to nylon
membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is
carned out for 16
hours at 40°C. To remove nonspecific signals, blots are sequentially
washed at room temperature
under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5%
sodium dodecyl sulfate.
Hybridization patterns are visualized using autoradiography or an alternative
imaging means and
compared.
X. Microarrays
The linkage or synthesis of array elements upon a microarray can be achieved
utilizing
photolithography, piezoelectric printing (ink jet printing, See, e.g.,
Baldeschweiler, supra.); ,
mechanical microspotting technologies, and derivatives thereof. The substrate
in each of the
aforementioned technologies should be uniform and solid with a non-porous
surface (Schena ( 1999),
supra). Suggested substrates include silicon, silica, glass slides, glass
chips, and silicon wafers.
Alternatively, a procedure analogous to a dot or slot blot may also be used to
arrange and link
elements to the surface of a substrate using thermal, UV, chemical, or
mechanical bonding
procedures. A typical array may be produced using available methods and
machines well known to
those of ordinary skill in the art and may contain any appropriate number of
elements. (See, e.g.,
Schena, M. et al. (1995) Science 270:467-470; Shalom D. et al. (1996) Genome
Res. 6:639-645;
Marshall, A. and J. Hodgson (1995) Nat. Biotechnol. 16:27-31.)
Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers
thereof may
comprise the elements of the microarray. Fragments or oligomers suitable for
hybridization can be
selected using software well known in the art such as LASERGENE software
(DNASTAR). The
array elements are hybridized with polynucleotides in a biological sample. The
polynucleotides in the
biological sample are conjugated to a fluorescent label or other molecular tag
for ease of detection.
After hybridization, nonhybridized nucleotides from the biological sample are
removed, and a
fluorescence scanner is used to detect hybridization at each array element.
Alternatively, laser
desorbtion and mass spectrometry may be used for detection of hybridization.
The degree of
complementarity and the relative abundance of each polynucleotide which
hybridizes to an element
on the microarray may be assessed. In one embodiment, microarray preparation
and usage is
described in detail below.
Tissue or Cell Sample Preuaration
Total RNA is isolated from tissue samples using the guanidinium thiocyanate
method and
poly(A)+ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)+
RNA sample is
reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/pl oligo-(dT)
primer (2lmer), 1X
first strand buffer, 0.03 units/~.1 RNase inhibitor, 500 E.iM dATP, 500 pM
dGTP, 500 pM dTTP, 40
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~M dCTP, 40 E.~M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The
reverse
transcription reaction is performed in a 25 ml volume containing 200 ng
poly(A) + RNA with
GEMBRIGHT kits (Incyte). Specific control poly(A)+ RNAs are synthesized by in
vitro transcription
from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr,
each reaction sample (one
with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of O.SM sodium
hydroxide and
incubated for 20 minutes at 85°C to the stop the reaction and degrade
the RNA. Samples are purified
using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH
Laboratories, Inc.
(CLONTECH), Palo Alto CA) and after combining, both reaction samples are
ethanol precipitated
using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100%
ethanol. The sample is
then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook
NY) and
resuspended in 14 ~l 5X SSC/0.2% SDS.
Microarra~paration
Sequences of the present invention are used to generate array elements. Each
array element
is amplified from bacterial cells containing vectors with cloned cDNA inserts.
PCR amplification
uses primers complementary to the vector sequences flanking the cDNA insert.
Array elements are
amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a
final quantity greater than 5
~g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham
Pharmacia
Biotech).
Purified array elements are immobilized on polymer-coated glass slides. Glass
microscope
slides (Corning) are cleaned by ultrasound in 0.1 % SDS and acetone, with
extensive distilled water
washes between and after treatments. Glass slides are etched in 4%
hydrofluoric acid (VWR
Scientific Products Corporation (VWR), West Chester PA), washed extensively in
distilled water,
and coated with 0.05% amiriopropyl silane (Sigma) in 95% ethanol. Coated
slides are cured in a
110°C oven.
Array elements are applied to the coated glass substrate using a procedure
described in US
Patent No. 5,807,522, incorporated herein by reference. 1 ~l of the array
element DNA, at an average
concentration of 100 ng/~1, is loaded into the open capillary printing element
by a high-speed robotic
apparatus. The apparatus then deposits about 5 n1 of array element sample per
slide.
Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker
(Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in
distilled water.
Non-specific binding sites are blocked by incubation of microarrays in 0.2%
casein in phosphate
buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C
followed by washes in
0.2% SDS and distilled water as before.
Hybridization
71
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Hybridization reactions contain 9 ~l of sample mixture consisting of 0.2 ~g
each of Cy3 and
Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer.
The sample
mixture is heated to 65°C for 5 minutes and is aliquoted onto the
microarray surface and covered
with an 1.8 cm2 coverslip. The arrays are transferred to a waterproof chamber
having a cavity just
slightly larger than a microscope slide. The chamber is kept at 100% humidity
internally by the
addition of 140 ~l of SX SSC in a corner of the chamber. The chamber
containing the arrays is
incubated for about 6.5 hours at 60° C. The arrays are washed for 10
min at 45° C in a first wash
buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a
second wash buffer (0.1X
SSC), and dried.
Detection
Reporter-labeled hybridization complexes are detected with a microscope
equipped with an
Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of
generating spectral lines
at 488 nm for excitation of Cy3 and at 632 nm for excitation of CyS. The
excitation laser light is
focused on the array using a 20X microscope objective (Nikon, Inc., Melville
NY). The slide
containing the array is placed on a computer-controlled X-Y stage on the
microscope and raster-
scanned past the objective. The 1.8 cm x 1.8 cm array used in the present
example is scanned with a
resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excites the two
fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube
detectors (PMT 81477,
Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two
fluorophores. Appropriate
filters positioned between the array and the photomultiplier tubes are used to
filter the signals. The
emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for
CyS. Each array is
typically scanned twice, one scan per fluorophore using the appropriate
filters at the laser source,
although the apparatus is capable of recording the spectra from both
fluorophores simultaneously.
The sensitivity of the scans is typically calibrated using the signal
intensity generated by a
cDNA control species added to the sample mixture at a known concentration. A
specific~location on
the array contains a complementary DNA sequence, allowing the intensity of the
signal at that
location to be correlated with a weight ratio of hybridizing species of
1:100,000. When two samples
from different sources (e.g., representing test and control cells), each
labeled with a different
fluorophore, are hybridized to a single array for the purpose of identifying
genes that are
differentially expressed, the calibration is done by labeling samples of the
calibrating cDNA with the
two fluorophores and adding identical amounts of each to the hybridization
mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H
analog-to-digital
(A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-
compatible PC
computer. The digitized data are displayed as an image where the signal
intensity is mapped using a
72
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
linear 20-color transformation to a pseudocolor scale ranging from blue (low
signal) to red (high
signal). The data is also analyzed quantitatively. Where two different
fluorophores are excited and
measured simultaneously, the data are first corrected for optical crosstalk
(due to overlapping
emission spectra) between the. fluorophores using each fluorophore's emission
spectrum.
A grid is superimposed over the fluorescence signal image such that the signal
from each
spot is centered in each element of the grid. The fluorescence signal within
each element is then
integrated to obtain a numerical value corresponding to the average intensity
of the signal. The
software used for signal analysis is the GEMTOOLS gene expression analysis
program (Incyte).
XI. Complementary Polynucleotides
Sequences complementary to the GCREC-encoding sequences, or any parts thereof,
are used
to detect, decrease; or inhibit expression of naturally occurring GCREC.
Although use of
oligonucleotides comprising from about 15 to 30 base pairs is described,
essentially the same
procedure is used with smaller or with larger sequence fragments. Appropriate
oligonucleotides are
designed using OLIGO 4.06 software (National Biosciences) and the coding
sequence of GCREC.
To inhibit transcription, a complementary oligonucleotide is designed from the
most unique 5'
sequence and used to prevent promoter binding to the coding sequence. To
inhibit translation, a
complementary oligonucleotide is designed to prevent ribosomal binding to the
GCREC-encoding
transcript.
XII. Expression of GCREC
Expression and purification of GCREC is achieved using bacterial or virus-
based expression
systems. For expression of GCREC in bacteria, cDNA is subcloned into an
appropriate vector
containing an antibiotic resistance gene and an inducible promoter that
directs high levels of cDNA
transcription. Examples of such promoters include, but are not limited to, the
trp-lac (tac) hybrid
promoter and the TS or T7 bacteriophage promoter in conjunction with the lac
operator regulatory
element. Recombinant vectors are transformed into suitable bacterial hosts,
e.g., BL21(DE3).
Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-
D-
thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is
achieved by infecting
insect or mammalian cell lines with recombinant Autographica californica
nuclear polyhedrosis virus
(AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of
baculovirus is
replaced with cDNA encoding GCREC by either homologous recombination or
bacterial-mediated
transposition involving transfer plasmid intermediates. Viral infectivity is
maintained and the strong
polyhedrin promoter drives high levels of cDNA transcription. Recombinant
baculovirus is used to
infect Spodoptera fru~perda (Sf9) insect cells in most cases, or human
hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to
baculovirus. (See Engelhard, E.K.
et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al.
(1996) Hum. Gene Ther.
73
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
7:1937-1945.)
In most expression systems, GCREC is synthesized as a fusion protein with,
e,g., glutathione
S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His,
permitting rapid, single-step,
affinity-based purification of recombinant fusion protein from crude cell
lysates. GST, a 26-
kilodalton enzyme from Schistosoma iaRonicum, enables the purification of
fusion proteins on
immobilized glutathione under conditions that maintain protein activity and
antigenicity (Amersham
Pharmacia Biotech). Following purification, the GST moiety can be
proteolytically cleaved from
GCREC at specifically engineered sites. FLAG, an 8-amino acid peptide, enables
immunoaffinity
purification using commercially available monoclonal and polyclonal anti-FLAG
antibodies (Eastman
Kodak). 6-His, a stretch of six consecutive histidine residues, enables
purification on metal-chelate
resins (QIAGEN). Methods for protein expression and purification are discussed
in Ausubel (1995,
supra, ch. 10 and 16). Purified GCREC obtained by these methods can be used
directly in the assays
shown in Examples XVI, XVII, and XVIII, where applicable.
XIII. Functional Assays
GCREC function is assessed by expressing the sequences encoding GCREC at
physiologically elevated levels in mammalian cell culture systems. cDNA is
subcloned into a
mammalian expression vector containing a strong promoter that drives high
levels of cDNA
expression. Vectors of choice include PCMV SPORT (Life Technologies) and
PCR3.1 (Invitrogen,
Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 ,ug of
recombinant vector
are transiently transfected into a human cell line, for example, an
endothelial or hematopoietic cell
line, using either liposome formulations or electroporation. 1-2 ,ug of an
additional plasmid
containing sequences encoding a marker protein are co-transfected. Expression
of a marker protein
provides a means to distinguish transfected cells from nontransfected cells
and is a reliable predictor
of cDNA expression from the recombinant vector. Marker proteins of choice
include, e.g., Green
Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow
cytometry (FCM),
an automated, laser optics-based technique, is used to identify transfected
cells expressing GFP or
CD64-GFP and to evaluate the apoptotic state of the cells and other cellular
properties. FCM detects
and quantifies the uptake of fluorescent molecules that diagnose events
preceding or coincident with
cell death. These events include changes in nuclear DNA content as measured by
staining of DNA
with propidium iodide; changes in cell size and granularity as measured by
forward light scatter and
90 degree side light scatter; down-regulation of DNA synthesis as measured by
decrease in
bromodeoxyuridine uptake; alterations in expression of cell surface and
intracellular proteins as
measured by reactivity with specific antibodies; and alterations in plasma
membrane composition as
measured by the binding of fluorescein-conjugated Annexin V protein to the
cell surface. Methods in
flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometr~, Oxford,
New York NY.
74
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
The influence of GCREC on gene expression can be assessed using highly
purified
populations of cells transfected with sequences encoding GCREC and either CD64
or CD64-GFP.
CD64 and CD64-GFP are expressed on the surface of transfected cells and bind
to conserved regions
of human immunoglobulin G (IgG). Transfected cells are efficiently separated
from nontransfected
cells using magnetic beads coated with either human IgG or antibody against
CD64 (DYNAL, Lake
Success NY). mRNA can be purified from the cells using methods well known by
those of skill in
the art. Expression of mRNA encoding GCREC and other genes of interest can be
analyzed by
northern analysis or microarray techniques.
XIV. Production of GCREC Specific Antibodies
GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE;
see, e.g.,
Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification
techniques, is used to
immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE
software
(DNASTAR) to determine regions of high immunogenicity, and a corresponding
oligopeptide is
synthesized and used to raise antibodies by means known to those of skill in
the art. Methods for
selection of appropriate epitopes, such as those near the C-terminus or in
hydrophilic regions are well
described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)
Typically, oligopeptides of about 15 residues in length are synthesized using
an ABI 431A
peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to
KL,H (Sigma-
Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS) to
increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are
immunized with the
oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are
tested for
antipeptide and anti-GCREC activity by, for example, binding the peptide or
GCREC to a substrate,
blocking with 1°Io BSA, reacting with rabbit antisera, washing, and
reacting with radio-iodinated goat
anti-rabbit IgG.
XV. Purification of Naturally Occurring GCREC Using Specific Antibodies
Naturally occurring or recombinant GCREC is substantially purified by
immunoaffinity
chromatography using antibodies specific for GCREC. An immunoaffinity column
is constructed by
covalently coupling anti-GCREC antibody to an activated chromatographic resin,
such as
CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the
resin is
blocked and washed according to the manufacturer's instructions.
Media containing GCREC are passed over the immunoaffinity column, and the
column is
washed under conditions that allow the preferential absorbance of GCREC (e.g.,
high ionic strength
buffers in the presence of detergent). The column is eluted under conditions
that disrupt
antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high
concentration of a chaotrope, such
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
as urea or thiocyanate ion), and GCREC is collected.
XVI. Identification of Molecules Which Interact with GCREC ,
Molecules which interact with GCREC may include agonists and antagonists, as
well as
molecules involved in signal transduction, such as G proteins. GCREC, or a
fragment thereof, is
labeled with'ZSI Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M.
Hunter (1973) Biochem. J.
133:529-539.) A fragment of GCREC includes, for example, a fragment comprising
one or more of
the three extracellular loops, the extracellular N-terminal region, or the
third intracellular loop.
Candidate molecules previously arrayed in the wells of a multi-well plate are
incubated with the
labeled~GCREC, washed, and any wells with labeled GCREC complex are assayed.
Data obtained
using different concentrations of GCREC are used to calculate values for the
number, affinity, and
association of GCREC with the candidate ligand molecules.
Alternatively, molecules interacting with GCREC are analyzed using the yeast
two-hybrid
system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or
using commercially
available kits based on the two-hybrid system, such as the MATCHMAKER system
(Clontech).
GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven
CT) which
employs the yeast two-hybrid system in a high-throughput manner to determine
all interactions
between the proteins encoded by two large libraries of genes (Nandabalan, K.
et al. (2000) U.S.
Patent No. 6,057,101).
Potential GCREC agonists or antagonists may be tested for activation or
inhibition of
GCREC receptor activity using the assays described in sections XVII and XVIII.
Candidate
molecules may be selected from known GPCR agonists or antagonists, peptide
libraries, or
combinatorial chemical libraries.
Methods for detecting interactions of GCREC with intracellular signal
transduction
molecules such as G proteins are based on the premise that internal segments
or cytoplasmic domains
from an orphan G protein-coupled seven transmembrane receptor may be exchanged
with the
analogous domains of a known G protein-coupled seven transmembrane receptor
and used to identify
the G-proteins and downstream signaling pathways activated by the orphan
receptor domains
(Kobilka, B.K. et al. (1988) Science 240:1310-1316). In an analogous fashion,
domains of the orphan
receptor may be cloned as a portion of a fusion protein and used in binding
assays to demonstrate
interactions with specific G proteins. Studies have shown that the third
intracellular loop of G
protein-coupled seven transmembrane receptors is important for G protein
interaction and signal
transduction (Conklin, B.R. et al. (1993) Cell 73:631-641). For example, the
DNA fragment
corresponding to the third intracellular loop of GCREC may be amplified by the
polymerase chain
reaction (PCR) and subcloned into a fusion vector such as pGEX (Pharmacia
Biotech). The construct
is transformed into an appropriate bacterial host, induced, and the fusion
protein is purified from the
76
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
cell lysate by glutathione-Sepharose 4B (Pharmacia Biotech) affinity
chromatography.
For in vitro binding assays, cell extracts containing G proteins are prepared
by extraction
with 50 mM Tris, pH 7.8, 1 mM EGTA, 5 mM MgClz, 20 mM CHAPS, 20% glycerol, 10
pg of both
aprotinin and leupeptin, and 20 ~1 of 50 mM phenylmethylsulfonyl fluoride. The
lysate is incubated
on ice for 45 min with constant stirring, centrifuged at 23,000 g for 15 min
at 4°C, and the
supernatant is collected. 750 ~tg of cell extract is incubated with
glutathione S-transferase (GST)
fusion protein beads for 2 h at 4°C. The GST beads are washed five
times with phosphate-buffered
saline. Bound G subunits are detected by [32P]ADP-ribosylation with pertussis
or cholera toxins. The
reactions are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS,
10% (v/v)
(3-mercaptoethanol, 20% (w/v) glycerol, 95.2 mM Tris-HCI, pH 6.8, 0.01 % (w/v)
bromphenol blue).
The [32P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and
autoradiographed. The
separated proteins in these gels are transferred to nitrocellulose paper,
blocked with blotto (5% nonfat
dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM CaCl2, 80 mM NaCI, 0.02% NaN3, and
0.2% Nonidet
P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours
with G a subtype selective
antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are
incubated with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin
(1:2000, Cappel,
Westchester PA) and visualized by the chemiluminescence-based ECL method
(Amersham Corp.).
XVII. Demonstration of GCREC Activity
An assay for GCREC activity measures the expression of GCREC on the cell
surface. cDNA
encoding GCREC is transfected into an appropriate mammalian cell line. Cell
surface proteins are
labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood
90:2398-2405).
Immunoprecipitations are performed using GCREC-specific antibodies, and
immunoprecipitated
samples are analyzed using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)
and immunoblotting techniques. The ratio of labeled immunoprecipitant to
unlabeled
immunoprecipitant is proportional to the amount of GCREC expressed on the cell
surface.
In the alternative, an assay for GCREC activity is based on a.prototypical
assay for
ligand/receptor-mediated modulation of cell proliferation. This assay measures
the rate of DNA
synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides
encoding GCREC is
added to quiescent 3T3 cultured cells using transfection methods well known in
the art. The
transiently transfected cells are then incubated in the presence of
[3H]thymidine, a radioactive DNA
precursor molecule. Varying amounts of GCREC ligand are then added to the
cultured cells.
Incorporation of [3H]thymidine into acid-precipitable DNA is measured over an
appropriate time
interval using a radioisotope counter, and the amount incorporated is directly
proportional to the
amount of newly synthesized DNA. A linear dose-response curve over at least a
hundred-fold
GCREC ligand concentration range is indicative of receptor activity. One unit
of activity per
77
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
milliliter is defined as the concentration of GCREC producing a 50% response
level, where 100%
represents maximal incorporation of [3H]thymidine into acid-precipitable DNA
(McKay, I. and I.
Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University
Press, New York NY, p.
73.)
In a further alternative, the assay for GCREC activity is based upon the
ability of GPCR
family proteins to modulate G protein-activated second messenger signal
transduction pathways (e.g.,
cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid
encoding full length
GCREC is transfected into a mammalian cell line (e.g., Chinese hamster ovary
(CHO) or human
embryonic kidney (HEK 293) cell lines) using methods well-known in the art.
Transfected cells are
grown in 12-well trays in culture medium for 48 hours, then the culture medium
is discarded, and the
attached cells are gently washed with PBS. The cells are then incubated in
culture medium with or
without ligand for 30 minutes, then the medium is removed and cells lysed by
treatment with 1 M
perchloric acid. The cAMP levels in the lysate are measured by
radioimmunoassay using methods
well-known in the art. Changes in the levels of cAMP in the lysate from cells
exposed to ligand
compared to those without ligand are proportional to the amount of GCREC
present in the transfected
cells.
To measure changes in inositol phosphate levels, the cells are grown in 24-
well plates
containing 1x105 cells/well and incubated with inositol-free media and
[3H]myoinositol, 2 ~,Cilwell,
for 48 hr. The culture medium is removed, and the cells washed with buffer
containing 10 mM LiCI
followed by addition of ligand. The reaction is stopped by addition of
perchloric acid. Inositol
phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion
exchange resin, and the
total labeled inositol phosphates counted by liquid scintillation. Changes in
the levels of labeled
inositol phosphate from cells exposed to ligand compared to those without
ligand are proportional to
the amount of GCREC present in the transfected cells.
XVIII. Identification of GCREC Ligands
GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster
Ovary) or HEK
(Human Embryonic Kidney) 293 which have a good history of GPCR expression and
which contain a
wide range of G-proteins allowing for functional coupling of the expressed
GCREC to downstream
effectors. The transformed cells are assayed for activation of the expressed
receptors in the presence
of candidate ligands. Activity is measured by changes in intracellular second
messengers, such as
cyclic AMP or Ca2+. These may be measured directly using standard methods well
known in the art,
or by the use of reporter gene assays in which a luminescent protein (e.g.
firefly luciferase or green
fluorescent protein) is under the transcriptional control of a promoter
responsive to the stimulation of
protein kinase C by the activated receptor (Milligan, G. et al. ( 1996) Trends
Pharmacol. Sci. 17:235-
237). Assay technologies are available for both of these second messenger
systems to allow high
78
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
throughput readout in mufti-well plate format, such as the adenylyl cyclase
activation FlashPlate
Assay (NEN Life Sciences Products), or fluorescent Ca2+ indicators such as
Fluo-4 AM (Molecular
Probes) in combination with the FLIPR fluorimetric plate reading system
(Molecular Devices). In
cases where the physiologically relevant second messenger pathway is not
known, GCREC may be
coexpressed with the G-proteins Gaisn6 which have been demonstrated to couple
to a wide range of G-
proteins (Offermanns, S. and M.I. Simon (1995) J. Biol.. Chem. 270:15175-
15180), in order to funnel
the signal transduction of the GCREC through a pathway involving phospholipase
C and Ca2+
mobilization. Alternatively, GCREC may be expressed in engineered yeast
systems which lack
endogenous GPCRs, thus providing the advantage of a null background for GCREC
activation
screening. These yeast systems substitute a human GPCR and Ga protein for the
corresponding
components of the endogenous yeast pheromone receptor pathway. Downstream
signaling pathways
are also modified so that the normal yeast response to the signal is converted
to positive growth on
selective media or to reporter gene expression (Broach, J.R. and J. Thorner
(1996) Nature 384
(supp.):14-16). The receptors are screened against putative ligands including
known GPCR ligands
and other naturally occurring bioactive molecules. Biological extracts from
tissues, biological fluids
and cell supernatants are also screened.
Various modifications and variations of the described methods and systems of
the invention
will be apparent to those skilled in the art without departing from the scope
and spirit of the
invention. Although the invention has been described in connection with
certain embodiments, it
should be understood that the invention as claimed should not be unduly
limited to such specific
embodiments. Indeed, various modifications of the described modes for carrying
out the invention
which are obvious to those skilled in molecular biology or related fields are
intended to be within the
scope of the following claims.
79
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
a
H
y -Ic-~Ic-Iw-Iv-Ir1c-I-Ir-1r-W-iw-I-Ir-1r-ic~c-Iu-1c--1v-iv-1c-W-I
, W 0.1f~GAPa~APawPa(~1f~)Pav PaPaW t~~ a1~1Paf~lf~l
_~ W P~
N U U UU U UU UU U UU U UU U UU U UU UU
y~
U Opr-1NdlO rO c-IdlM rM M NO u-ILnM r Mr OlN
O O L17l0r O1c-1Ndl010101w-IrO N lOr r v-Ic-Irc-I
U N r1v-Ie--Ic-1c-IN NN N Nr-1N NN c-Iv-1N O w--iu-)Oc~
~
~.,'L17LC7Lf~117L<7U7Lr7U7tnInt17Il'711~InLl~In111II7l0l0l0lfll0
U
H r r rr r rr rr r rr r rr r rr r rr rr
~
d~~rdldicrdi~ dld~~ dldid~dl~rdl~rd~~rWr dldl
r r rr r rr rr r rr r rr r rr r rr rr
r-I
O
Pa
N
~
O
O
'Z,
N
r-1dlt17l0r 0001O c-1N M dlLnl0rCO01Os-IN MdlLnl0
(~
U N N NN N NM MM M MM M MM M dl~N'd~dldld'dl
H
Ot
W
r-1
CIl
O
W
q
H
a-I~--I~-1u-Ir-ir1~ ~-ia-Ic-Ir-1r-Iw-1a-iw-Ic-IwH~-Iw-1e-IwI~r-1
e--iN Ca~1faG~Cafaf.~~1~1GafaG7CaC~f~C.~f~GaA CaA f~Ca
N U U UU U UU UU U UU U UU U UU U UU UU
Ci
-I~N c~Nd~O rO c-1d~M rM M NO r-I111M r Mr OlN
r-I
~y O O Lf1l0r d'1v-INdlO10101c-lrO N ~Or r c--ic-Irv-1
.r.J
U N v-1c-Iv-Iv-I~-IN NN N Nr-1N NN ~-I~N O r-Ic-IOr-I
N tt7LnInLC7L17Lf7Lf7tf7L11N LOL(1117Lt7L17Ll7LnLC7l0l0l01.0l0
C~ H r r rr r rr rr r rr r rr r rr r rr rr
did~~dldtdtd~didi~ ~Hdl~ dW d~d~d~V~d~did~~
H
~ r r rr r rr rr r-rr r rr r rr r rr rr
O
W
N
~
O
1~
N -IN MdiL1~l0r 0001O ''~N M dl1.17l0r~ d1O~ NM
W l l l I
H
r w-Ir c-irw-Ir~v-Ir1-INN NN
r~1
W
O
CIA
W
H CO.-INdlO rO c-1dlM rM M NO c-!LC1M r Mr 01N
U O O tf7lDr 01v-1Ndla1dlO1v-1rO N l0r r r-1~-Irv-I
'~
N .-Ic-Iv-Iv-Ic-1N NN N Ns-IN NN c-Ir1N O ric-IOu-I
U ~ ~ 1.c1Lf7Lf7111InLOLf71.1)LnLnLf7LL7t11L(7Ll7Lntolfltol0to
N
r r rr r rr rr r rr r rr r rr r rr rr
H ~ dldldldlct'dldldldldlcf'd Wdldldldldldldldldl
O N
~ r r rr r rr rr r rr r rr r rr r rr rr
W
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~ r-i r-ir- m n
ro
inm r~ ~n ~ .N .N .s,o,
>~~ ~ ~ ~ ~ ~ a~
N U cd U N -~i
.
~ ~ ~ ~ ~C
N s~ ~ a
~ ~
N r1 -r-I-r-i P;
UO O Pa d, O O ~.,''O O .!-~_
~ ' N ~ '~ ~ ~
~ h r-
Lf1
~x ~ r, .~ ~ ~ s~ ~
~. ~
~ m o W Ea .u ,~ Ei E-~x c0
~n n N M
m .~ .j -~",.t~-- .i.~Ll~ I r~
1 ~-n I c-t
~-I.i-1N ~I .l~ N ~ I
r-I r1 O
~iO aS .,..I O (0 r-,~ r, r~ -r-1Ul
.. .. d~
'-'.!-1P: i W [Y.,(R lYl Ul Ul (d N
CO O N M
i '-'QS ~ ~-'~ v U1 ~ ~ U1 .1.~
L~ L~ M
r-1N v-IUl Ul v-Ir-I N r-1r-IF(',N
r-1r1
R',U d~ ~ ~-,~ d' ~ ~ .L~ ~ ~ ~ ,~
~ ' ~ ~ N
r-IN M O r1W U1 M U U1 ~y U U N O
N ~ tU O ~ 00
H'4M .~.,;j5=,'~,'M U7 ~i '~ Ul U2 ~ r1
~,'v-1 C,'v-I c-Ic-1
Pa N O U O O N ~ N O ~ ~ tfi~,
O M d~ d~ cN
~I>sw x ~n-~I~I m ~ -~ ~ ~ ~ ~ x
c~ I ~ ~ ~ ~o ~ .~
~ ~ H " ~ f.~~ H I C~ b~ I I .-I~
C LJ1 Ln ~ 'fd a j O U~ t!?~ N
C 01 01
'J .-r~ N . (t( ,.,U7 tt
~ ' ' ., ~ ' 1
C
iU1lfl~, U7tf7, ~ U7 ~-1 ~ ~ U ,.q
~, O to O O O N
~
N>~-r-I-r-1u7 ~ r1 ~ ~ .N ~ ~ m -~i
of ~ ~ d~ ~ cftd~ O U'
UN O N ~ O O N ~ O Wo ~ ~ ~ C7
a~ .-i r-Io~ oo oo ~ U
NUlJ-1.!-)~i~.-~,~ ~.,('',.. .. ~ M
c-I I r-I lD M
S-II O O '-'O O O 00 O (~ OJ M O1
v L~ v 01 I I 41 01 r1
x x ~I ~I x w ~I ~o ~n Ix
~r r-,~ ~r ~I ,~ m o
N C~ ~ N ~ ~ i h,''-''J p.,'fx ~ O
N c-I In N N '~i
.1-1r1r-I~,'.H r-IO .. .. O O ~''
. P;
U1U ~1 ~1 'n-Li~1~I ,~I,~,'~I ~-1 ,~',~', ~I
((SN O fISr1 M c-1 r-iri
cW-IO O O O O U O O U U O
U' u1 1~1~o
1~ctS1~ .1-~~IJ~.1-I.1-~~I 1~ J--~~I S-I~1 .1.1
1~ -I~tn U~ U7 Ul
U ~ ~ N ~ ~ ~ ~ x
O O
.1-1 .l~.!-~ U .1~U U 1~ .1-1.I->a1
~I ~I f-1.ti
N?-IU U i U U U qa U U (2,, C1~U
(ti -r-1 ~ r1 r1 ~ ~ q~ ~
NofN O N N O N N N tv N N N U
G'9.'~., ~ P~lN ~ i~ N N O N
3 ~ ~ ~ ~ ~ Z ~ ~ ~ Z ~
U~ ~i ~ O ~" ,~iN 5~ S~ N N N ov
1r-1C5 ~r ~-I N '~ ~I O N ~I ~I P~la-I
L~ ~-I
~ O ~ C7 U' h I'7
e5N ,-qO .I-1 ~ .!-~ ~
U7 o1 Ul
r1U (is.1-1>_,'-1~.1J(d G' .1~.h ~,'~,'~-',.h
c-I ~ ~ ~ -~ .-.~ N
J-1N N U cdU U O rtiU U ccSdi ctiU
~ v N ~ o1 eo o1 o1 a1 ~..~'r-i
td~I.U cd ~1ctica !~ ~4 cd ~ti f-1W-1S-Icd
O o1 O 0~ rn o~ a ~ U cti
.!~.l.)Ui 4-IO 4-I4-IUA O 4-I4-I O O O 4-I
' ,L,' o1 .s;dl o1 o1 o1 o1 O
' ' ' '
dS(d ~ Zir--1r1 (~ ZS .-1.-I ~ W d .-I
WW H ~--IO O a-iEn r-I-I rI r1 -I .-I.t~
E-~O O H O O O O O O O
~- c~ v v ~- ~- ~- v ~- W N
M ~7 N ~ p O ~ ~ N
~L~o~ m , ~ M O ~ O O ~ M t~
N II I 1 ~ ~ I ~-I~-II W -I I '-II
~ WW W W I I W I I W I I W I W
OO O O ~ p O O o O o O O o O
U OO L~ M ~
~ O O 01 r1 ~ c-1 l0 ~ L~
L~d~t17N ~ ~ '"'I N M ~ 41
W M N N
O 01 Lf7~ ~ ~ O1 CO ~ L' CO l0 lflO
N~ O d~ ~ O O O O O -1 ~
~ M -I ~ ~ Ln N O 1 00 O O r d
l0 M L L~ O d~
f~
(d LilL~~ ~ N ~ ap l0 N . O 00 O 01 l0
O v-I
M ~ ~ ~ ~ p IllL~ M 01 L~ L~ l d~
q N M 00 N v-I0~ O r1 r1 r L~
di
H NlDv-IN ~ N N -I l0 M ~O l0 lO -1 M
O ~ c v
~ ~ b1 ~ ~ X31~ b1 ~7 X71>,TZ~ ~Sl
W -I r-Iw-Ir-I~ c-it-Iv-1c-Ir-1 v-Ir-Ir-Ic--I
q q q q q q q q q q q q q q
N U U
~
U U U U U U U U U U U U
.1l 00 v-IN d~O h O s-Id~ M t~ M M N
q
~ o o m o ~ o~ ~-IN d~ o~ o~ o~ r1 ~
~., -! -1 I -I1 -1
O
q
U
H
N ~ r w-a i- N N N N N v N N
Lf7 Lf1Ln LnN Ln II7Il)lf~Lf~ LI~Lf~LO II)
~
H I~ L~ t~ h t~L L~ L~ t~ l~ l L h L~
~
O d~ d~ d~ d~d~d~ di d~ cH d~ d~ d~ d~ d~
L~ L~ L~ C~L~L~ t~ L~ L~ L~ t~ t~ l~ L~
..
.ri
'~
-~
A r1 N M d~1f7l0 L~ 00 01 y
-I c-1r1 c-1
r-i
W
O
CI~
W
81
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~I .u as m .u
to ~ >~
.u -,
o x
U A fl
r~ r-~
~
~(',.L.) N J-~
tn ~ 'Z$ U1
O
~-IS-1~', ~-I
d~ 01
-rl N 2S
l~ O
O -r1c-I
00
N
a~
U1 (!j~ L~ Iii
O
~-1O ~ ~-1
L~ 00
x x~ ~Ip x
v W
N --1
U1 r-.?-1 U7
C~ M
Ul (~ (a r, ~in
01 01
~ ~ Ci ~
~ r ~; ry ~ ~r
-I i
U U UU
1 ~-IN ~ U
~-i '~ ',O 1
u
d~ U1 O U~ U ~U7
o ~
f ~ i ~
l H
-
c~ r r --
x v ~
O Ul r-IUl ~U7
to U7 ~ to
~
00 ~,'-rlU7 ~- ~,'
01 01
I ~I -r-I~i '-'
''OC5 I
-1 ~o C7 cI3 ~ ~-,oo~
r-Ir-IU U ,~-I
p'.,fs.~~ -r1 a1U1U1Ll~LTa
a1 F(,'ry' d1
O N ~
~ ~I ~I -r-IUl ~-1~I
', tn 111
r-1
U O O r1 ri-riOO
O1 r-i o1
~I 1~ .1~h ~1a S~1~.4.1
N .t~
O , , 4-I OcdcISf.~~
O r-Itd tit r-I
.!-1O (U '~-~.1~IAff7N
~I r-i"~,
, U U tR , UU
~ N N
N N N -rl NO O N~
N U U
~ ~ o o ~~.I
o o ~
~' ~ ~'w~'~ ~x x ~~
h ~ ~
0 o .u o0
0, 0,
~ -I-1.1JN ~,''c-1.-I.l-~.4W
r1 .-.~ -I
ca U U f=, rdfi.,fi,UU
~ -- o ~ ~-
V ~ to to a ~Ia a ~~
~, o ~
0 ~u a-Io 00 0 4-I~u
0, o ~
''Wr-Ir1 4-1 '~UIU7r1r-1
-I r-IN c-i r1
o--o o--U-- ox x oo
to to
In ~ N 00N N N
O
O ~~ O
'-I
-r-i ~ W ~ W WW (s1W
~I
O ~ O OO O ~O
,.Q lfl~ N '~ d~M L(7OO
Ul
~-I di N ~ ~ c-I01N ~d~
W
t~ ~ N L~ M c-Iu-Ir1~N
O a1 117l0 O~ cH O1
O l0 O
M N O O ~M
~Z 00 M -I d~ N~Ol0 M
W v O
,
.~
L~ N v-Iv-1 MM M O
a -1 01 LC
c N M )M M N01
H l0 M L~ -I l0-1--I ~
~ v i M
I
b7 b7 tS7YS7 b7~1~1~~7
N
'~ ~ a q a RA q Aa
N U
~
U U U UU U UU
J-1 O s-IIn M L~M L~OlN
~
~y O N l0 L~ L~~-Ir-IIW-1
O -I -I O
(~
U
H
N ~ ~ N ~-I~-Ior-I
tn ~n tn tt~ ~o~o~oio~o
H L L~ t~ L~ Gl~l~l1t~
~
O di d~ d~ d~ did~d~c1'd~
l~ C~ L~ L~ L~l'l~I~l~
N
~
O
_
ri
,Z
~ Lf1l0 L~ ~ 01O v-INM
H I l -1 -1 l
w- r ~ ~ rN N NN
~
r-I
W
O
U7
W
82
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~ U
U O O
U1 ~1 1 C
-~ /1
U1
(d
1 W I W I I
I rn u t u u
u1 ~n c
1 cn I n a ~ n , m n
~ N w w H r~ w x x m H w 1 ~ H w
o x w w w H H
r~ x H o
V ~ H H H W i W W H O H H H '
ca r O O H
~
. . [- r.~ Ft,H
a~a a a a x ~ o ~ ~ as x ax ax O a o
a ax
as r~ w w x ~ x x w w w m w r~ r~
m as w w
>~
a ~' m
,-I r ~-I4.i
-I
~I d W ~ O l17 N ',~y x M .I-~
-I ~
W O LW -I c6 ''(~c-I N r1 H t-lO
c-I W
w .L.) [~ tl..lM O M ' r1 a 1
I N M 00 ~
M
rl (~, d~ a M ,.r_,x N ~, P;
L~ w ~ ' a
w l~
x
Cl~ N d~ I U1 N ~I U1 U1 ~I (~ O Cl~Ul
r1 l0 I N I O LW H M
I -I
I
N I~ ~-I U CJ N S-1w '-'~-I S-I~ 4-1 E-~ F'n~-1
4-I d~ w-I 11~ 01 N l0 LY1 a
t~ 00 a
01
U O O N I W o~ O I ~ O O .I-~~1 W O O
-rl ~ M m o~ f~ v7 ~
o 1 ~
m
E-~.t, ~1 N l0 l~ d~ ~-i.U .1~(d N I W L-~J-1
I N U O N 1 l~ W
M N w
<U W i M r-I ~(,'i r1 O ~ ~ >_',fir U W
,'~ I M H di M ',~',
Cf~ tn
U1
~ W N N x d~ N N .1~4J N b~ ~ d~ W W N
M ~o oo ~ d~ o~ r1 u~
W
U U J-1 r-I . U tn ~ U U r1 U7 f~' U U
o1 N N a I to ,-I a 'Z, ~o
a N
' '
W N (IS 'J >=iN ~i N ~ N Ul 00 W W N
00 i.n ~ Ln LC7 00 In c-iGi.~ l0 O
N ~
tl~ Q',~I ~, M r1 S-Ir1 U ~I ~1 O (Y, C7 P.'~i
~'.,I '~ M U ~ IfsM ,5 . N M
L~
y -I I cf'S (O NLnNCJN 1 ~-1 U wMN 'JiHHaI
07 'N l0 M
N f~ CS J-1 d1 ~, ''~~, S-I'~ ''dO W l P; ~1 C3
~0 M ,'~ w M L o1 L~ dW E-~ L
,5-~ a -l I
,~.1W N ~ N O O N O N N .!-~t] O W N
Ul N O I I c-I M c-I01 M ~ r-1
I I c-1 M
I
a r-1 ~ O c-1 ZS ri ''(jN r1 r-I~ N H E-~ a r1
l0 In r-I L~ ~i N v-Ix d~ W
cN v-I ~
00
1.1 W ~ ~ O U ~-1i I ~,"~ i N ~ O U W ~
-rl M P-t N ~''.,O ',~iI I a LO
N 01 tl1 r-I
"~ ~ P i ( ~ ~ N (~ ~ ~ U ',-~: F(,' ,~
01 N l0 N 01 ri O l0 O W l0
N N v-I ',~
N
O O U W di ~',O !~'a.1o O a~ ~ rx w O O
Ln Ot a o ~a a ~ N ~ N
a ~ rC Z
X77 U U r1 O (iiU (If~.,U U ~1 r-I a U U
Q H N <-i Pa ~, Pml O M
H
.~I ~ ~ ~I ~I ~I ~ . . I ,-~ O N
G1 ' H O U
W
~ S-i O W -S W ~i N f=,'~''.,'JY ~'a E-~ '~-i~i
1~ L -1 ~ ~ '~ N O O tv ' W M
H -I ~ 1 lD l ~ 01 ~
M ~ O i ~ ~ ~
l ~
H
W r -1 ~ O r . ~ r1 r ~I r1 P; H r1
00 N N c l0 .1-, Ul ~I I 1 ~ ,~ W d
01 I ~ N ~. d N L M O M N
.N ~ (d di N ~ O Ul r-I c-I
d~ N W 11~ ~ O
I~ -I N L~ H
N P,'
N
En .I-IO .1 ~ .V ~ G' .1J .1~.1~ f.~ H H 1~
o L~ ~ oo w 5=',~ ~ .4J .1 d~ ~ W ~-IH
OI W W J C7 ~ W
w o~
0 0 ,~ c~ m o ~n c~ o o U o co w 0 o
0 0, ~ I I ~ a ~-I~ ~a N x E-~ 0 I
I I I 1 0
0
P-n'~-I (1j .~',5=i~.1Ci ~I ~-1 ~I (~ ~ ~'',W P; ~-I
~i O I N v-Ir1 1 r1 ~' G' O I O O L~
N L~ 11~ l0 U
O
p-it .1~ ~1 c~ i l~ .1~~I ~2t4-t O b7 U W ~
A O d1 O O fR N .~.X51 >;51O lO I1~' O N
01 O Lc~ v-1 ,~-~
O
I I N r1 ,<II ~1 (a I I r1 ,S..n"W 1 I
a l0 N Ltl d~ -r-1r1 0.',r1 Pd ,~,'v-1
l0 v-I N L~ a
N ~
o c~ ~ ~n N c7 N ~ c~ cn o x ~n rx cn c~
M oa o a a M w ~I-I~a ~n w ~ o a a
~C of w H c~
w
0 00
~,
.~,
M
-r1 M
(t$ u-I
Ul LO
.!~ O
r~l u-1
N <'
''
1~ N N
~ d~
~ ~
Z
-~,
.1~
O
U~
W ~ N
~ O
M
U
S~'
O N
l~
O
N
N
d~
l~
l~
O
L17
.-i N In
-I~ d~
1.W-1
O
Cl~ OJ
U1 N
t!1
E-~
E-~
L~ E-t
N ~
N
d~
O
'
~-I N
~-I
t0
d~
00
~ ~
~ cn~~c o
Op r~H o~
,
w
u~
O O Ln
O O
M
C~
Lf1
N N
M M
t1~
l0
v-I
rn Ea
U1 u1
u1
m
E~
N
N
Ln O
-r1 n M
U
_y
M
U
W
H
H
A
~
~ o r1
U
N
H ~ L~
~
O d'
W ~ t
L~
A
W -I N
y
83
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
U
i W O
Q I I I 1
1 u a v 1 i~ u~ 1 v a
r
~ c.~rxIx ~ H v~ ~ ~ H w P4 fx ~ H
o W m ~n m H O n
ca w w G4 W
x H H ~~-4
W W H H H W W H
H H
~ O O r.~ r.>;H O O
t0 O ~ ~
~ L4f-~ W Pa l~1~i Pa W
(Y1 W C4 W Pa
-,-i -,-1
fn cN 4.1 U7
, W O -ri ,
~ H
d'''dt~ o r- W H O '
I d
HO o1 r1 -rl a ~ I ~ O
M .
o~ Ul FI ~ ~ H U
"C t
I , Ul~-I o O l Ul ~-t IJ~ U1
U Mv n- ~-1w-I W H W v-1~-I S-1 f-I
t1..1 01 S-I ~ N !x v
I U1 a
O
U a~ O O .!~ ~-1 W '~; O O O O
-rl r-i 1 -1
01
~J c-1 ~I J~ .1-1ciS ~ W W H .!-1 ,l-I.l-1.t-~
.1-~ N 00 L~ H Cia
N
tv N O i ~ 5=,' i U ~,' W 5.~, O i i
'JnN l~ I
U7
~ U~ W N N b~ ~ W u1 W O . .1.~N N
I I H ~ .-I d~ W U M
-1 U U - al Y U1 U
S~ d~i o ' ~ -I
f u
w
c-1~,' N N r r1 ( U N ~i S~ U ~
N u-I~ L~ , W N O ~
d~ ~ Ul .tea O M c-i N
d~ 1 ',
W d~
~
C!~ ~',-r1U ~1 ~1- P.,' C7 p: S-I-r1U S-I ~-I
~'., U' 00 C~m fia N M 01 tn ~ Ul
o1 I
(If (aN c-I 1 ,<I U 'Jn I ((S~ M I
O H l~ M
N N H
a
U ~,~I '~ 'Z3O W W, ~1 ''d~, ~I 'i~ '~
l~ N 00 L~ H L~ N ',~-~h V7
N i-l m'-~-I [-l
O O N .!~ C7 O (~ W N O I N N
M O ,'~, M ~ r1 H M to
~ 1 O 1
I
~ ,~ ri~ N H W a ~I '~ N .-I r1
~ . N v-1I 00 ~ I N v-1
I M v-I ~ 00 Lf~
.~ ~ S~ f2, , N N U a Wo s'~,o ~ , t~,
-~ >~ o ~ o o H ~ o ~
.I ~ x M cr
~
N(d ~ ~ U .~'' ~, ~ ~ ~ ~S ~
r1 O In O P-I ~ ~ -rl O
O N I a M M
N
-.-i~~I O O N -ri f1-i O O ~ ~.i O O
td a ~', R; ',~ N N ctf a
N r.~ ~ '7-~ U1 H
G;
.!~rt~ U U ~I r-I a O U U r6 ~ U U
~ ~~ W W H M H ~ Pa
O ~ In S
I
f I ..~ ~ O U N ~ O
C/~ , U'L~>=i41~G'N~Jv . W ,~-iW~'.~~ N'dLn~,'NN~iN
N ~.~.,r1 -rlM ~'O H H r1 c-I~., r1 -r1
Oa ~-1 ~-1n-1 N Ri N l0 ~-1 S-I
O1 -r1 ,tea 01
Ln ~-1 O
~ r1
N
NN N N O IR O H W N W Ul ~ N
~ ;~ "~'1l7 ~ P.,' M c-I-1 ~ ~
N N O N N ~-I
N
r-1.~,~' .5.~ -L~.!.I S~ E-~ H .I-1.~.,~,' .1~ -t~
~r .5.~ .S~~ .!~ W r-1H u-!~?t .I-I.t~
r1 C7 ttf f~ H Pa
a a1
cdmas o o U o w H 0 0 m ca o 0
r-1ca cdN as o 0 1 a r1 c~ ~s
w 1 x 0 1 1
I
~S-1~I S-I0.S Zi W O ~ ~I ~' ~I ~I ~1
r1 I ~ o ~, U O o I -rl ~' >=,
~ OD I o d~ M
01
t7~ai.u , ~1,4-1 O U f~ W , W-i.1-I, ,
-IS~ o b1o t5~ ~ o ~-1~ o W ''
d -I -IM ~ o I I ~ n I
O 1 : o~ ~ ~' l
I 1
- -I
-r-I( r -rr-i -r w . -i -I r1 1 -rl
tnH~ 1 C7p N a f-a -n C7 Ol ~ r .
4-1U' tn, v fx C7 H H 4-1 c-1 U'
rr~ N ~ C7 fa Gv C7 C7 ~n
",~ O m C7 m I
W W w Z
f-~ ~
n
V -~1
ca
m
a~ ~
m u~
-~I
.~ N
o~
0
-''Io-I O
N
L11
ra
.h n
ai ,~.~ ~
cd o C-n
o ~
H
-~1 ~ v~
r-I u1 r1
u~
~ ~
~
0~ dy
-1
N ~ dW
O .-1 -1
-ri M ~-1
N
u1 H
u~ H
H
N ~ H
~o oo~0
0
~ o
~-o In
o d'
o
c-I M
N r-1
N c-I
N
v~ H
H u1
u1 u~
r4
U
~
~~
r N L~
i
-
N M M
N
O W -I
rv q
! t'
'
. N c
-
~
~
U .-I r1
N ,
H
In
H L L~
~
O d' d~
~ I
q M d
Z
84
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
o w o
~ vi v I ~I a' r~ m :n I
~ u~ v1
~
, ~ m ~
~ ~ ~ ~ ~ A ~ W W ~ ~ ~ ~
~ ~ U ~
~
u ~ t t
. r~
~
-1-~ H H H r.G ~(,' H H H F(,' F(,'
ai H arx O a ~ ~ O ax O a
a~a arx arx as ax
ww yaw ww m x x a~~amw ww r~
I
~ .. ~, o
x ~ u x
o; w H ~ ~o .. w a
M -rl H 'finI C7 O o~ M H ,'N I
N oo a ~ O I ~,''N N In a t-a
CJ .~., a l0
~"I
U! ~-I QS p'., CJsM f-IU7 ~I f1,' Ul
U7 I H H 00r1 i.l,N H w-I
O ~ 4.1 O Pa P-.'N '-'~I ~ [J O Pa a',
t1..1r1 I a N O I ~ I E-W Ul
O a o ~ o
r N
~', !d ~ l0 W W H ~ ~ .!-~. W W E-~
.1-> M C=.t I ~I ~ (CJ CTa
N N
f~" I?t W ~i W O O ~ FI W ~', Pa
f~ r1 '~ N M
b7 ~ f.~ U U7 w .. .1-~O b~ U Ul W
. u1 W ..o 1 E-~ N W .
W U u1 -I - W ~o
Z I C ~ o~
. ~ r-I ~ ~ N ~L U ~ ~ U
u1 ~ W ~ ~ ~ fk W
~ Ix o fsaO U u1 W o
ao W d~ ~ 1n o
o
'' Ln 11'., C7 P;-r1U ~I ~ O Ch (Y.,
l0 M M M C7 00 M M
l0
(a ~I U 'Jn t aS N .-I f-I P-', I
N d' H w ~-1 E-~
M M H M H
a ',~
0 o w~~lx rx A~~~ s~ Lit o Sa o N
znH H N I
I
.u o M o a w o a~ .u H a~ w
~ I x o, c-I~I v r, ,-m ~ ~-I
I I Nw~ a ~~I. ~ ~, ww~-' a
c~, N I N ~N A~ ~
p~ u, ~ I
,N.,..1U ~ONM N W~,'~,'~.,~oL~U I W aZiNWtl1
~L(~ Ua ~-, 01
(($ U '~ F(,' ~ O (!j~ U L~ U W ~
N O W ~ I -r1O N E-~ ~
M N a O
M
N -r1 G4 O (.,"f-IO U L~ W ~ O
O ,5-I R; ,~ M L~ (ISa Ei ~ N
U7 ~-I ~., N
',.'C,n
~ ~I ~ ~ a O U t6 ~ U ~I P4 U
~ H ~-I0~ ~ PI1 rI O M
a H
.. I ~ O U In~I O f-~ U W N
.. W U
M ~ N E-~ Z N ~ W n ~r Z
oo . u~~ Zi ~ ~ H W
~ m ' H ~
~ ~ O
d -rl f~ . ~ -rl I c-I H
d t M ~r W N Ul ~-I .. P; W
O O O M N ~ 61 00 ~ M
tIW UI r1 N O L11 O H
-i W O H ~ O P,'
M -I p'., N N N
N N
.u s~ H w H ~ ~ ~ .u E-~ H
d~ +~ w ,-Ioo .u d~ w .~
~ ,-I o, ~--Ico mo
a rte, H
U O rti W H O <n c~ O U N U E-~ O
N FC O o a r1 c>3 Ot O o
1 I o W I ~
i
(IS ''CS W O p;~.,~I SI B O Q,' (1'.,
O ~i U O I -r-I~,-'I O O
N I O I cP U
L~ N d~
4-1 O ~ U fli P-i(($.1..1i 4-I Gy W
O al ~ O 01 ~, ty7 O p'., O
N l0 O O 01 ',~i
M L~ c-I
r1 ~, W W I ~-1(ISI r1 a P-t I
(Y, -r1 a ~'-v~ -r1 p a ',~G-'
c-I 0~ q O1 ; Ca
M N t.n
N
ow~cnx mwa rxt7c7wC7AH~ ~~uc7 ow~H OC7C7wc7A
~nx
0
~
a
-
m
~
S<i N
~
J-1
M '
o
v
u
N . Z
~ ~
?
w o
r-I , ,
.-i u,
,-a
zz
c~
H s~
0
.,
M
-r1
ri c-4
Ul
N
N H
~
~ mN
w
~
d~
c
-I
~
~
'z3
.
U
.'-I
M
U
0.i
N
'~
R
4J
. O
V
'1~
~
H r-I
U
U
H l
~
O
LL
W '
q d~ tt
~ 7
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
N O
U
W 1 1 ~1 W I W I I
I u~ u~ y 1 I cn a v~ u~
r~ rrs cn u1 cn
-I Ix F.4PW,'W H O H c1 fx W H W W
0 W H ~' H H
c~
~
1~
~ U W ~ ~ u7 u1 W W ~ f-~
. U ~ f~ U
W
P ~ ~ W al ~ W Pa W
9 W ~ W W
f~l
>~
.,-I
In
H
~
' W ',~, H 'LSlb l
-I W .01
r
O M lOH ,5i I O O1 r-Iri
d1
N
.~','~, N l4~ a N ,L;N N Lf1~
LC1
,Y,
U7 ~-1U7 ~.IN H U1 ~-IUl U1 ~-IN (d
U1 I M ~'-~, 00
w-I
I
N v S-1 ~ C7O Pa P; '-'~i ~-1~ C7 4-!
4-t M Ln .'~', CO I cti
fi,
O
U o O .>,I H ~ O ~ O O .u 1 ~i
,~ o~ o C7
I
~
~'.,~ ~I -t~ (CSw-IW W H ~-14-1 -4WIS l0 N
.U M N fst N ~ I
N
N
O ~ O a ~i ~ W ~"-rW O (2~ S~ G' M ~
O ,'NH ',finN d~
M
H
,' CJ .i-1N b1 N U Ul W . .1JN N ~1 N ~
I U1 I U i f W .. I H L~ l N
O~ to U o ~ v-1
d~ W U
' U
'
~ ~ r ~ ~ U 7 a U U r f~ ~
tU v-I~,'O N U7 ~ Z W ~'.,1 O d U7 M .
'Tf L1~r1 fY, O N ~ N 1
W M r1 7
LC1 ,
01
U] ~'r1 U ~-1 . C7 f~,'r1 U S-1 ~-1 O P4
~i C~7M ~ N M U~ ~O ~--l .
1.n
(~01N N S-1diM,' I (DdbN c-1 I ,~-I01MU
HHa d~N
O ~, ~I ~ O O f1,' (~ .~.,~I 'd 'i-5O 00 W
N L~ H H L~ ~-I L~ O W L~
,'N I N N
U
,l.1 O N 11 N O q W O N N .1..1c-I(,7
(J] N M I 01 H N M O I M
I ,'N c-1
1
C~ O r1 G2~~lH W a '~ N r1 r-li (~ N
N d~l~ H N i-1 01 H
0 ~ I 111
J~ N 1 ~',~ N I U a W 1 )-'.,, ~ N I O
,-1 ~,"O O r1 lfl ~',O ',N O~ O
N LO I
M
([j 'ZSN (O ~ U O F(', ,"J!U (IS~ ~ U Lf)~'
(1j v-Ir1 O M W lO Ln r1 O N O
N a O N
N
w >~ ~1 O a~ ~,w x O ~ s~ O O a~ ~ ~I
O ~1 ~ a ~nz N ~, ~a a ra Ix
H N o
~
b7 .I-1(d o U ~ W p ~ U t '~'U U ~I r1 r-I
N 0.l . ~ ' '~ PI7 W
~ H ~' a r1
J ~
wi ~ -1 N G," . . N , , ~,' ~i W f-',
~-1 O ~ 'TSN .. N v -"~-~, N N N M O
U2 , .~.,N ..H W , ''~ r-1 .. W
~ .-1 d1 H l .~.,~ S-1 a0 O
~-1 p'., ~ ri r-1
d~ Z, ~I ~-1
O L
v-I
N
O U7 N O M O H W U Ul N O O 00 Ul
O1 ~ W-I u1 N (Y., M cN -. ~ ~ I!1N ~
N N 00
N
-Iyn ~ .u .u o,H w H ~ ~ .u .u .L~~ f~
~, u d~ H w ~-Id~ ~.,.u .N d~ a .u
w o, r1 ~
~
cdU1 !tiO U x W H O U7 cd O O U x O
H r-1cd N I O o H r-Icd rtiN I ca
I o W x
I
', S-I,<I (ISI W O 0.',~'.,~.If-I S1 fIS1 '~
1 r1 ~," O L~CJ O I r1 ~'.,~'.,O N Ci
M O I i
L~
~ ~ ~ ~ ~ ~ ~ O
v ~ ~ ~
~I (I$I r1 L~W W I ~I ciiI I r1 1.nI.()
d~ -I p.,'N a ~i N P4'N r1
~1 ~
'~
cnHa ~~-Io~nolow ~c~xc~ow r:~aHH ~~.lc~tnxcn~now ~r~~n~~
I
~
r
'~ H
~
r
a
us
s~ ~
~
~
c~ ~ z
o
a
O 'z,
U
~
r1 r1 M
S~
O M
''I 00
r1 O
.4.1N
- O l0
H
r1 t~
Ul
.1-~,~ Ul
O
~~ HH an
~
M U]
r1 01
d~
O N
O
O
M l0
N N
M
N
'~
~
-r-tN c-i
~ M M
N
P~'
O c-I c-
a Ca
~
'N ~ o
.1
~
CJ -1 N
O
WH
~ ~
.
H l~ h
O
Q<
86
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
O O
~', U ~i
O f~ ~7 O
I I ~ ~
~''O~O C- W fx~ Wx H WN ~C HO H W
~ C- ~ -~
'-I U7 (~ iI~ H WW ~,' f~ ~,' ~, u1 u7 H
,~'' U '~ '-W p
.h
cti ~ O r.~ Ei H O H H r.~ ~; N
~ ax a o ~~ O rx H H O a o
a~a as ax arx arx
mw m ~ xx realw yaw mw mw ~o
s~ o
~
O L~''~N O r- ,' M O
I l.,
01 W
N
Ga .~.,'JO M 00 r1 H
~ ,~
00
M
W 1,S,''',>C, N N .~., ~ I
00 a a
c-I
x
U7 a U1 U1 d~~-IUI U7 ~-I'J c~ P4 U] Ul
U1 I L H t17
a
I
N ~ W R; ~-It11v ~-I ~-t~ I 4-I O W P,'~I
4-I '~-n 1.~l '~,''~ d~
I
L
H ',7 O O 'Jr1 O O .1W.n ~I H ~i O O
H ~-I O I a
o0
01
W O E-i .4~ ~I .1-~.!-~(tSl0 N W W H -I-1
W N M M d~ C~
~O
N
N E-~ W C~ O ~ >~ 1~ N ~, W ~ W ,
O U H ~ H Ln
o~ r-I
x
O O W N .I~N N b~ CIr~ U u1 W N
o U I U in - ~ W U
; ' o~ U l ~ W Z
p; o U t~ U1 -I
~ U
P W N 5~~ ~ N r o ~ , N ~ N
Z o U N r1 U1 . P4 W
p., lfli.n W o
H W o t
o ~
U1 w O R-n' ~-I-r1U ~-1 ~-I 01 f1', Ch R.n'~I
~ A M CJ CO ~, M d~ N M
N
j ~HUW I cdN N I S-IrIMU ~HH,'~I
I~'~N
o xo~ A~ ~ a~~I ~~a ~o o N~ w~~lxrx Aln~
N
I
~I oxa~ w~-I a~ o a~M oM ~ z c~MH oa w~la~
m I I I ~
Nwc~aM a- ~-I~roa~ ~-IN~,~~I~, I N Nw a ~I
~ I ~
~ ~
.u U C7 W d~, :~ i~ ,f~U I_nN ~-I w ,
-~1 H d~ vo N ~ o ~-Io U a o
m N
~o
(d ~ w ,~ O W O(d ~ ~ U O x F(', ~
(d ~ N l4 -I .r1O M O W H
N M a
N
w w o M O ~~I O O U N -rl C~., o o
a N H rtfa E-iP; ',~ t
w ~-I ~,
rC
t51 a "~ U tl~U ciS~ U U S-If~ r-1 a O U U
O ~ ~T-~ M I I ~I~.,W ~ W H d1
I N oo O Ca O U N
O H I W
ct' ~
U1 fYl 'Z,LnL.," N 1=i ~i ~ ~ ~'., E-~ ~ ~,'
W t0 W O '-dN N O O Ul d~
' l~ L ' '
~ ' ~
' ' O
L
Q H .-I ~.,-rl ri a0 -r-1 .fir H -ri
, -u-I r-INm ~I , O ~-I, O W t1~
,~ W N -~ I1~ I m O I c-i M W-I
,Z, M a N rv M o0 f~,
c-i H ~ ~ t!~ O H
O O r1 u1 f~
W W ~ N
a O
N
H H E-~ .1->~S~''.u .1~.I~y-i>~ H W N a
~' .-I ?r .N .I~d a -N W r1 H
C7 W r-I o1
a
W W O O U1cd O O U x O W H O O
u7 o r1 c~ ai N I ~S O o I
H I x o
I
W W f.~ ~I ~~I ~I N ~i I ~ W O f~ ~I
H o -~I~ >~ o o~ ~ U o m
o I o
~
U U W , cd.1.~, 12,4-It~ O U V; W ,
O ~ t~ b1 O o~ b~ ~ O M
r1 ~ o
N
C7 C7 H~ C7 C7 O ~ P~'4 Pw4 C7 C7
~ 4-I~ m W ~ can C~_7 ~ FC
~ ~ Ca7
~ ~
+~
J~ o
r-1
N
>~
~
~
M o
~
~
.
u
P.I
r1 M
U
~
O ~p
- W -1
Ln
M
~
H
N
In
LO
l~
,~',
Tn
O
W in
U1 Ln
rl
O M
~-1
M
N
O
~
~
-r1 d~
-
~C M
~
R',
N c-I
U U
.~
~ H
1J
~
U N
O
H
W n
H~
O
w
~
~Z ~ o
87
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
- - -
O ~
-'~
cn
aS
P, I W s f~ Pa I W I
'-' I u a I t I u~ rn I
'~ u u c
~
1 W I ry ~ a n
~ u~ ~
,~ r~ rx w H w C-~ E-~r-~rx x w H w C~
o x r-~ o x C-~ o
ca
~
~
1
~ W W ~ f~ ~ u1 U1 H W W r~ f~~~ u~
. U ~ fa U ~ fa
.
W ~ ~ ~ ~
~ ~ W W ~ ~ ~ ~ W ~ ~ W
W W W ~ W
-,-i . -,-I
Ul <' 4-I m
f-~ o -~I C~
'~i o x ~ O zi m o x W
O W I ~ O 0 H
H '
5-~
~ , , 1 M ,
In ,-ti M a 01 ., ,s,'N N N
~ ~ u-I a a
N a W
,'~
U7 N ~-IU7 U~ ~-1 f~ U7 U7 ~-IU1 U1 ~I t~
UI 01 H r1 ~,~ 01 H
1 1
N N " ~I ~-IW O P ~-1 '-'~-I ~-1~ O Pa
4-I H H o O -I W i ' O I c-I
o~ N ~ Cl~ c--I
~
U .u N O O a~ O O .u H ~
-~I I ~ .1-~-1-Wfa W E-~J-~ S-IN .!-Wf~ W W
1 ~ W N .l~ of f~
N 0 f~ ~ ti
I 1
N N
01 O i a ~,' W W i O C~ ~ ~,' W '~,"
~ 00 ~,' ~ N l
U7 Ul
.u ~ N ~ U W U .u N N b~ U rn
t M ~ u1 I En ~ ~ W
W
U1 pa U U -rl W U U U1 , U U -r-1W ''W
r1 N a~ Ln ~-I % t~ a~ ~ ~-Ia~ d~ ri n
~ a~ a~ ~o w a~ . a~ x w
a ~ r1 x o ~r ~I ~r
m w m ~
mo ~r w
~ In
r1 U ~-I ~I ~ CJ Q',S-I-r1U ?-I ~I ~ C7
C7 01 U N M CJ OJ ,'~ N
I $-I ,5n I ttS~ v-I I ~-I 'Jn
E-~ ~O w H
~ H N H
N a a
.~.,S-I'~ 'TSO P,' (~ ~ .~.,~-I'~ '~ O R'~
O1 L~ d~ w-1 H 00 ~-I L~ N O H
N a I N a I
~-I O N ~ .J, O W N O ~ N .1-1O Ca
U1 u-IN M O CO Ga r1 r-IN N M O ~ E-~
'~ ,.~T.ir1 I L~ a '~ ,5n r1 I W
v-I r1 c-I~ E-~ H ri u-I~ l0
N 'r'~-~W N ',ln~
I tn l0 I d~
~
.u-~I~ ~~ s~oM~r~a~ ,-I mo s~,I ~~ C~o~r~~a~ Ua
I~ Ua I~ ~-I
c~ N ~ ~ ~ U r.~ W-1~ o <<S~ ~ U r~
cd I -~I0 o W o~ ~I o ~ w
00 N a o N a
~M ~t oaN o more r~,pzoM o ~~ ~t oaN o mnr~r~,~~
~a as
~ ~ ~ U U ~I a U U cd ~ U U ~I a O
O ~ ~ CO .. ~', O ~-I ~-I'~ G~ .. ~' H
~I O H . H In ~ O H p
H p 5
U
W
-rl . I . U W
A N ~ ~ ?~ N ~ ~ , O ~ ~ M (~
try z5 N N di u ~ zi N N L ..
~ . t l H . '
O l ~ O l
- ~ > ~
l '
S '
r r n r r1 ~ -r .-I ~,
N Ul -I -I .I G W N . fn I S.In O
al ~. N N O ~ M N N ~ o~ N O r1
~ ~ Ln ?-i v-Il0 N ~ L.f1fx
M N O ~ N O H
H N (Y.,
1Y, N
N
~ ~,'.t.~.u .1-I H H .1-~~ ~.,''.1~ -.I-I.1~ Ei
d' ~ 1W 1~ di W ~-I'J d~ ?i .u .J,d~ W
I C7 W e-I C7 W
a1 o1
Ul ((SO O U W O O U1 (d O O U W H
H ri (0 (d N H O I H r1 (d (D N O
W I O W I O
O
I ~I ~.t ~.t~i W ~ W-I~ ~t ~t ~t ai W O
~I ~ ~ o O o .I ~I ~ ~ o U
1 ~ U I m o
o
(a .1J~ ~ 4-I U p.1~ f~ .1~~ a 4-1 U P;
O1 W b1 O P-n' O c-IO ~ t57 ~1 O ,'N
~ -I 1 M ~ O M O
1 I ' O '
1 W
-1 -r r r1 W I I S-I I I ~-I W W
- N ~ 01 C7 p., a ~; ~-1M ~ r-1 -rlP- a
E-i4-Ic7 u1 N ~1 c7 c7 C-~4-I01 c7 , ~1
f.~ m o rx q H a c7 m N rx
rx w c7 m o C7
f.~~ c7 of w c7
w a w
.
r
o
~
-
~
ro~
~~
o
M
'
o
.u
O
U
W
C7 Z
C~
N O
01 M
~
'--Ia0 N
~ N N
N ~ ~
c~ ~ U1
u~
rl (/] v-i
r1 M
U1
~
I ~ l0
.1-1Ul 01
M
'-'Il0 00
N N
N
~ ~ t!~
C~
~ ~
~
W H~ HMm
tn
o l
0 CO
M c-1
v-I N
tn U1
U~ U1
U] U2
W
-I H
~ M M
N
R-~'
r1
1 d~
I
'u
~ M
- ~H O1
~
~1
~
y , N
U N
H
~, ~ N
H L
H
O
W
H ~ r1
r-O
~
88
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~
(d I ~ O 1
O H W ~ w H I I O H W x W
~ x W W x
~ ~ ~
- t~ H fx I ~ f C C H u1H f Ix
i W U -~ -~ v W W
~ fa
~
1
~ UW ~ ~ ~ Z 1 ~
, ~ U
.
.
H ~'~ ~ aa rx az a~ ax a o ~ ~ aa
~ a
A
~ m ~ ~x x mr~ w raw yaw oaw m ~ x x m~a
4-I U1 0 4-I m
-~I CL o .~I
.1~ O O '~y W M .1-> O
M
~ O l H w ~ ~
5-I
. 01 ~ 01 , . O
. ~ M N ~~a U .,
7 U~ l l a~~~-r H -i
~ ~~I~x
I
U1 o -1 -I Id W Ul ~-IUl
Ul 4~ ~1 N -- ~i ~-iu-I dW O f~ f~~i ~- ~I
N m I -I a o~
4-I ~ 4-t
fWo H
a
~
U O O N ~ O O .I-I~-1 ~ O O o~ O
r1 I I H ~
c0 1
~
~'.,H L~ d~a ~-1.!-1.L1c~ N d~ W W H 1-~ f-1.l~
.!-l N LC1 ~ C=a N
N N
W ~2,In1 O G~ C2,~ ~ N W ~' W , O ,
~ t~ M ~
H x
W N G4d~ -1-IN N t37 ~ H U u1 W N 1~ N
I d~ r1 r-I W I
U U IU1 ~ U U r1 U1 W U U UI , U
~ o o1 d~ C~ ',~ 'z, ~-I ~-I
N
W N v-1~,'N N N W 00 ~ W N ~i N N
O N M v-IO Q', O d~
W
d~
U] R'~ S-I~iW U ~-1 .~-I~ ~.. C7 P.,'~-I-r1U ~-1
~., M ~i W M C7 00 ~ N M C7 <'
LO
I (~ N 01 I ~.1O~NU d~N ,5-~ I c001N 01
'~ HHa
O qm ~ ~ ~I ~~N ~o o~a w~Nr~ r~ Aln~ girlLI ~~N
, H
I
S-I W N O N N -1 C] O ~1 W N O N
U1 u-I lD M O ~ M d~ c-I N M
,.y, ,'l,v-I '~'n
I I
a rl '~ ~ r1 r1 , N H H W ,~r-i''C5N .-I
- ~o ~ N r-II d~ ~o FC N
I o~ ~ I
.I-1W ~ Nf~,~i 5~.1~2tN !v ~-I W ~ I ~,'S2~
r1 M N ~i O CtlL~ O U a O ~i O
l0 L~ l0 I w-I
M
~j ,'~ y-I''dN f6 ~ ~ U ,.~ F(', ,'W~ N f~ ~
~f t!1 1 r1 O LC7 O W -I O r1 O
O L~ N N H ~
N
O O -rl~ ~1 O O N r1 Gx, O O ~ ~I O
~ H ~ t~ a ~', P; ,".~ L~ O td a
M N ~', O 'Z, N
r.(;
~ U U ~t ~ U U ~-1 r~l O O U U H O U
M o ~' O P4 ' W W N X ~ W
Z H W U f~
~Weo y-1~, N'~d~N >~O' ' H ~tr~~d~-I , >~N.
W H- l -1 ~ ~r ~N -I H l ~ N'B
tn -I i i o o ' ~ ~
-i ~ ~ I i ~ O
~ ~
~ r i~ . r r n r r -r ~ . -r1
W v N ., I I 1 I P, W N N ., ~1
M N di Ul L N O ~N ~, M N 11~U7 01
W a ~ N ~ Ln Ul O H ~-I ~ O
~ N ~ (Y., ~
N 00 N N
N
H .>,.-I~ s~ .r~ .1.s.u s2, H w H ~ ~ s~ .L~
r-I d~ ~ .u .u ~r ~ w ~-IH d~ ?, .u
~-I ~ ~ a, r1
a
00 0 ~a~n~mr-Io o UN o ~x wHO0 00o mH ~~-Io
~w ~ I I I raw
' P: ~1 G'~' ~I ~i ~I ca 'd W O (x~I ~,'~I ~I
o I -rlG' 5~ o >~, U o oo I r1 >~,
i ~ I o I
l
W , t71c6 .1y, , 4-I O b U f~ W ~2,c~ .l~~L
o 00 b1 L~ O o~ ~ o o ~ ~ t'~
m M o o
1 1 r1~-Vttj1 I r1 .Li W P-1 1 I ~-I(~ I
~i N r1 -rlp; -r1 1-a ,~'',v-IN -ri
O~ N LfW C~ a1
-1
c7 C7 ~nH ~ C7 c7 o rx x c7 C7C7 H ~ ~7
f~ ~ ~-Icn ~n w ~n U a ~ ~ u-Im
H a ~ w x
~
~
V -
~
m
~r
o
m
o
.
u
O
U
~,
~
z
c~i
0
0
H U1 N
~ N d1
N ,-I
try H
.-I Ln H
.-I
m
.!, U1 In
N N
N L~
M
O ~~ NH
~
,
W
m W o~
o m
O l0 N
M ct'
CO
M N
r1 r1
N
HulH ~trs
N
'O o M
_ ,
U -II
~
M M
N
W
O H H
W
O
N
, U U
h t~
. M
~
U N l
H
u r
H~
O
W
H -i r1 -I
,-O
y ~
89
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~ o
o ~ a
V ~ U
O f~ U~ O
~~ tn U2 I ~'.,WI ~SU1 a Ul S -nl-
,-~ in Ul C!~ U7 ~;
~ H H W U E
'"I
,s; ,'e.,' C C W ~i f.~-~~' U
. '~-y'T-~l7 J~ '-7r'l
~ G-1 f~
.1-I H H r.~ aC H O H Ft,' FG'
rt1 H H O ~ ~ O x H O
~a~a a x x as x ax
x a
r a a a I r a
mw oaw ww a~ x x as w mw oaw as
as
>~
.r.,
tn
o
~r ~ w o ~ w
.. ,-~ x w M zs~ o x a
o w
-I r1 H ~ a o o, M H 1
M a~a I ,~N a~oa'Jn
v~,~ a~a
L~
~o~,
U1 ~1 u1 fx U7 ~-1U1 U7 ~-i ~ Ul
U7 ~-I N H l~ OI a1 H ~-I
I I
~zo ~tnxoas~ x~-I --o,~.I ~I ~,~oor~~ x~
,~ ~I H ~ o ~ I o a H o
I I a o a ~
~, I I o
o (IS N P-t H x-I~ .1-I, W H
.r., l~ l0 W N .1-> - W
~'., N c-I G4 00 (a C.T~
.1..1 I
N
N Fi S~ W ~i W O , ~ ~'. W W
l~ N ,'7-tN ~ ,~i
H L~ Ul
~ b1 ~ U u7 w .. .NN N b1 U W
~-I ~ W .. I N ~ ~ u~ .
N W
-r.,m w z U u7 , U U -~I w U
~' ~ x rx r1 s~ ~-Ia~ di ,-I ~ ~
~ .. ~ w a~.. a~ .. ~ w
u7 w o ~r ~I ~n Ix ,~
~r w ~
~r w
~
. P U~ P -.-iU ~-1 ~I ~ U~ R,'
00 i d~ i FCl~ C7 N M
M
S-IONU f~'HHOI ca01N u-1 I ~i ,'~E-~HaI
~o N
O O P-W~O Ei (~ y-I~I'L5 '~ O ~, q
CO N M 11~ L~ N O [-1 01
IY., N a I
.1~ C,7 E-~ W O N O .h O W
W M (a v-IN N M O CO (~ N
1 c-I ~ a 'CS ',N r1 I ~
(Ja N ,~ a r1 v-S[J~(Y.,l0
I H Pt N M Ea
M W I W
I
.I~ N N W a W I ~ , , N U W
.,~ o~ o ~ o ~ o Gv I a d1
~ I ~o ~ ~-I
c~ U x U w p W c ~ ~ U r.~ p
c~ In o d~ ,-Io -~Io o, w ~n
N d~ o N a
v~~ .~Ixow~zN o~ >~~alasoaN o a~lnaw~z oo.
t37 ~-t r1 f~,' U fIS~ U U ~-1 -l U
Q W O dl ~-I.~,P(a ~'m O O
~-I H H H
H
. . I U W N ~I O ~ O M
W a H U
W
.,-~.I~ "~, H N G' S-~"~ E-~ "~-i
~ O ~ (3tv N N W
.. ~-I -r-1117 H
~-I !.>i'
-r-I Z,
~-t O
01 ~-I
O (fl O H W N tl1N N O O W
~ ~ fx M O ~ ~ ~ Ln H M
N O N N N 0.',
N
.v.~f-~ H W H W ~ ~ ~ .u H N
d~ ~I-~mo ~-Ir7 ~.,.L~ -N d~ W rl
C7 ~ ~-I C7 w
a~
UN OcdWUHO~ Oo ulUc~rIO~dW OcdUN P.iE-~OoOo
I I
c~ 3 ~ O fx ~ f-I~I ~I c~ W p;
o ~ U o I .~I~ ~ o O o
0 I a~ I ~ U
o
4-I O (~ W (~ .1-1~ ~ 4-I U W
O 07 P; O l~ ~ O) ~ O P.~' O
M dl ~ O M ,5-I
~'I O
~ '~ ~ a ~ ~ '~ 'm w A a
O '~. q ~ N ~
O a
a
a t 7P C7 C -sc C7 O 7P C7
,~ n~ a al ~4C7 f. a
C nOI .~ ~C
.7C '~C
n
s~
0
O rl
.ri
U
M o
o
-
a
.
u
r
n
~ W
n
o z
c~
0
w co
0
H W -I
M
U1
U1
.r1
r1
Ul
1~ c--I
N L1~
N
~
-I
E-t
LJ~
W lfl
U7 N
O
O
N
c-I
N
HH~
m
N
U
.'-I
M
(h'
N H
q
U
W
U N
~
H
H
O d'
W
W
H ~-W -I
~
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
U W
U1
~
W 1 W I I q I
~ ~ I zn a u~ u1 y I v1 ~x m ~
''oca ~ u1 H zn u~ HO H x u~
wx WH WH ~x
w W W aW w r
~ H H H H ' H
~ H
J- U7 O O F(, FC H u1 O
(d ~ O
f Pa PI1 W W W Pa ~ U1 Pa
-0 W W PO
P7
~', 5~,
-,-1 . -,
U7 O 4-1 U1
o rI S.~t
~
w a o u
O M -.-1 H I ~ O
~
~ ~ ~
a
H
U1 ?-I!J7 U1 S-I to p' U1 U7 ~-I
U1 o1 ., r1
1
N v ~-1 ~-IW 4-I O P.'f-1 '~ ~-I
4-I a1 -1 N Pa E-~
O
U O O O -I~ ~-1 E-~ O O d~ ~ O
-rl W c-1 ~'
o1
G.~,<'I ~-I-LJ l~ QS O ',~ W E-~.!~LP'1 ~-I.!-1
.!~ N 1 W GO
N f~
d~ O ~ S3~G' ~ I W W ~ ~(', O ,
,'~ l~ ,~i N
Ul
C7 .1.~N Wo bl~ ~ d~ UvlW W N I .I~~N
I U1 I U U -I U7 W I I
d~ o yo
l -
i
, . U U ~- , U
'y -I~,'r N W-I~ W-I ~ ~ N ~,'~',N N
N r L~ W W o1
d~ U7 o o
H ~
d
U1 ~iri U ~-I ~-1CO 1~' CJ P: ~1 -r1U S-1
1=,' C~ C~ FC, GTa M M M ~
01 M
(~ N~oN 01 I ~I U IxHHfxI rtMNU'L
~N N o1
~, ~-1'tS '~ O W O (~ '~ ~.,~-I'~
N L~ N O L~ [-~ 00 N N
N a ,'~, I N
(J~ ON NMx NO .NN s [-i Wv-1N ON Nrl
I h (~ n'.~
uM0 LO
I
i rd N r-I r-I, N W W a r-IN'Z5N r1
~,' N r1 OI -I W a W
1 M d~ I
~
J-1 N I ~.,'~ ~ N N O W W ~ tS7I ~,'~
-r-I ~i O f~ 1 OI a l0 i
w-I L~ t~ N C~
(a '~N (I$,.'~~ U 'x' U ~ ~ (ISN (W ~
(jj N ri O a1 O W In l0 -I ~
~ N 1 E t~
N
-rl~ ~I O O N -r1 W O O ~S~ Wt O
O O di a tn f~ ~ M o ~ p
N ~ ~ ~' N
P;
t57 I~cd ~ U U ~-I r1 fk U U cdN ~ U
N ~ PO ~ W O r-I ~-I~ !~
~ H In H E-~
W ~ U
LJ~ N N'~~' $ 5 '' '~ 'te~ la N ..
q N '' N N E-~ CQ ' l~ '
~ N N l0
F
-.-I., , a , ,. ., r~ ~ ~
~-I -rly -r1 P~ a -rlU .,
01 ~-I~I S-1 ~ H N r1
~ O FC
Ln N r-I ~1
N U1 N N O U1 O W N N . N
~ ~ ~ ~ M ~ H M r1 M ., C~
N N O p'., Ul l~
N N -~
.-I~ ~',~ .I~.I-~~ l~ H H .I->r1~ ~'.,.1~
di ~r .1W .t~di tt1 W ~-I',~ u~ ~y M
-i C7 H W M
~
N m ~d O O U O td U O O cdU1 ai O
a r-Icd td N a E-i o I ,~ r-IN
W I 1 O N
a1
', $.IS-1 ~I rd 'i~ a; fY ~I ~,'~,'~I ~I
t -rlG' .$~',o ~', O o o I -rlo
I L~ I U 0
o1 d~
~S7(O J-1S]a C2~4-I O IJl FLI W ~ ~(LS.1J~
O ~ >,~ ~l O l0 P O r1 L~ O
O M 01 i O
~
r-1
U7H L~ C7 C7 O R; O C7 C7 u11~.~L~ C7
W U1 U7 W u1 C7 f~ H ',~~ W
r.~ W W C7 l~1
H PAa
~1
O
H M
V ~
~
m
~~
o
m
O o
U
U'
C~
0
'H N M
-N
~
-ri
r-I
Tn
h p
N
~ H U7
~
O
i
W N N
ff7 O l0
0 L~ N
01 00
r1 N
N N
Tn v~
tri H
m
C
~ ~ o
'~
~
~
I
_
~ M M
N
q
5r t~ o
~ N
~1
U
H
N
s~ tm n
H t~
~ ,
O
~
H ~-I -I
Z
~
91
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~
" 0 0
~
~ q
~
o y H C~H H O H O w
~ P ~
0. .
, (-
-i
,$~' 'fir f= HCI7 tJ~ u7 U2 ~'
i f~ ~1 U
-I-~H H H H O [--i~ ~(,' r.~r.~ H
cd O O O
~~a ax ax x oa ax a ax as
, ww oaw n~ ~r~ oaw m ww oaw
I
U H
'
z,
~r d~O 01 ,y, M W H
01
00
.-I ~ NO o1 H o [-~
01 O
01
-r-1 00 c-IM N a W M O f~,'
N N ~
Hwaax a .H xw
~ En I '
U7 -I U7 ICIA p Ll~W O
U1 ~ 4-I I ~I ooI ., I I U ~1
!)) I I ~ p; r1
4.-I f~' H o~
tn O
Ln
tt1
d~
U ~ ~-I d~ O OO r-I ~ O C7 O
-.-I r-I En r1 ~
r-I !Y1 N
N
s~ (d N N .!-,-IE-~ W ~i H a
1~ a a w c~
a ,~
N G' >~ ~ ~ ~~ W W W W C7 C~
~ w .. O
..
.. o~w w x
~i N U .. W U1 .. H W U
d~ -i ~o Z U o
~o M ~
-I
U
~, . . ~ . . . ~,-, ~ re w~Ia A
. . ~-I,~ c w~n P-n'MI W ~-I
01000 p'.,h d~01000M wooo,-I~C]N ~O
P'.,MMMM
. eo In U M N In I ~II I ~ H I ~ 0
o0 o N 1.n o1 I I H 0
(U O~c-INNM WNOOv-Ic-INNN'~NOC~111hh00PiHH (~01OI~ '~MM
I "
~1 .1~ h C7 O h H O .NW r1 O d~ W E-~ N
U7 ~ 'J a a x x O ,r-I E-~ N ~i a-I
a GTa o ,y., I rl-I r-I f~ a 'J-~ ,'~.,
I I ~ i I ~ I c-I ~ w w ~-I
I a ~ a w
I
- .1-IN I Lr7 N P; I N ~L NW O ~-I W W ~,' ~
-.-I117 01 N h d~ a' to U W di H I
to h h O ~H
(d U h h ,S,' W h ~ U',~ ~ a ~ U ~1 ~
(d M lO o M Ol O O~-I a ~1 ~ c-l
00 M to to f o~
N LW -I -1 tW -I to W Z O
N N N - h O
l O
-1 O
. h N ~ O W 1
>37 ~I ~ w r U P4N , a1 ~ ~ N
O a ~i ~ U a1 a I-~ U Gu U
H N N M h H O x
H 'J ~, M E-i
a ,'~ ~
~'
-r1 I " IN N O O M
(~ M N W
. .. .. ~ O .. .. ~ ~Z ~ U H ~ ~.,
.. .. .. .. O p_, pa H
.. p, w
p, h
'
'
'
FC Pa -~ ~I Pa -.-I-.-1H P; H Z d -r1
U ~1 U f-a W ~-INW M O W 0. FC
W f~ Ch N M M r-I M . U
O ~7 In U1 ~ h h ~ M O .~.~ O Ca N
Lf7 111 h h h h pC, W h
Lf7 N N h
.!-7 d~ ~ .1-1 M .4~.hH v-I E-~ H H W ~-I~
d~ d~ M M M M .1~ v-I H v-IC7 M
d~ 'd~ M ~-1 W a M
r1 01
U N N O (d N N O OO O W W O U a O
N N N N N N N (d O O O O H N
O O I N
N o 0 ~ ~ 0 0 ~-I~Ip; 0 W E-~ p~ r.~ ~I
0 0 0 0 0 0 0 ~ 0 0 U o W o
o o (a 0
h
4-I O O ~1 O O .i WW O U O W W '"a a
O O O O O O O t37IO O '~-r O l0 O
O ~-~Ixxxxxx I-~I O O I ao~~ O
-Ilxxxxx I ~~~~ wxaa ~ I
as
owwwww mwwwwww om r;~chAaaa xwc7w chAOU c7r~w
a
o
O ~
-
s~
~
~
Cr7 ~
o
.
u
o z
[-a >~
0
M
r~ H
l~
-r~
r-I
U1
N
O h
w-1
~ H
O
Cz,
~M
O
l0
N
~
Tn
N
'~
1~,
~
U
r1
M
O
N H
q
U
H
W
H r1
U
O
~', Ln
H h
H
O
W h
Z c1 ri
92
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~ ~
1 O
I I I
O w w a ~ q N w w H a w
~ H O x
H l rx l cx !k
-I -II
H H H W W H H H W W
H
~ O FC ~' O O E-~
~ arx arxx ~ ~ a O aa a x ~ ~
~oa ax x
r I o
a~w ww w x w raw ~ar~oaw w x x
- H - o
00 U1 '-~~ W
~
1 O M W d~ O I
E~ lO
f~ N '~ ~o E-~ L .-I O '~
O .. l~
W ~-I d~ O M O O~ PW -I' r-IO l0
P; W N
N " ~ N ,~'," P.' r1 N In H .~ ,-I
I_n a W M In ~
Ul ~-1 .1-1Ul N ~-iUl W W ~-1 U7 I ~I ~i
Ul Pa I O dWJ I
di w d~
.. n7 ~ ,l~'~ ~ (1',,I ~-I~ N ~-ICO
N [v U 1 1 N Ln
c-1
U .1J ~',O I o1 O C7 O ~!-~ O CO
.,-IcH L~ 'Ji N o l0 Ln
tn N O
O
~,' tLi t37.I-1'd~~1 E-~a .1~(ti -I-W-l ~1 4-I
.1-JN Ln N G.lto di O 01 N 00
O O
~.," -r1, O O W W ~ S.,' ~ H O -rl
O N f~ C7 c-1f~,' tI~ d~
P=n 01 N 11,'
~ O U1 47 N .4~W '~-~C, N ~ W N .l-~.L~
Cl] 01 I d~ ''>(,f1-i O M
W W
-r1 U ,'~S.~U H U -rS U
(~ d~ N ~ W N ~~
t r1
C11 u~wo.. ~IMW-I~ N~rwo a N. cn......N~C~riU
~,' d' t~ O ~I -riU Ix f~ ~I oo U ~-I-rlo1
~o E-~ C7 M 1 ~D M I ~-I
~
W
~ .. J-1I cLWN 1 P: tf7~-I O (LSN ~-I
N OJ f~ -I M In N 01
d~
O O c-1 , '~ ~.,~I ~1 O '~ O c-I ~ ~, S-IO
C~ I M N L~ LY1 M d~ to CraC7
N M
~, .I-> a~ ~ o w H a~ -~.~ a~ o .u
m ~ a o~ o r1 ~1 ~ x x N .-I1
~ a
~ x U ~-I~ a~ a w ~I s~, ~1 ~ o ~,
I ~r a ~1 .. w I I o ~, ~r
a I
.I->N I N s~,1 >~ W W (~,N ~ ~2,o~ ~
-~I U ~o Ea f~ ~ Ln ~ o o N ~
H
rd U o ~1 ~ N aS ',~U ~ U ~-1 ~ N Id U
of Ln O N r-Ito U7 d' R; O .-I~-IO
S''.,L ~'.,~-1O W O M ~',~I
~, N ~ O I N ~ M N v-I ,~,'I
d~ ~ ~ W M
N ''
'
~ U ~ ~ U f~ U S-I U ctf~
~I M 1~ H ~ , ~
' Ft ~
,
U1 'Jy ~ ~ - O Z ~ .$'',al .. ~i O O ~i
O .. .. O a L~ P-IE-~ M N ~ L~
~ A - ~ ~ I",W ~ ~
S l LIl ~
~ f1' ~ '
La O
-I !~ r ~ ~ .ri~ d 'r-Id ~. ~ri
-r S-I-1 O Ul W Z ~1 Ca ~ S-IN 1l7N
O tS7 N N Ifs M ~p O O In N ~-1
W Ln ~ O L N L11 ~
M ~1 M
W
M
~r r~ o .u ~ ~ H W .u .u ~r .u ~ ~
d~ .u d~ ,- w M Z d~ .u a
c7 a
x
UN ~N ~o O u1a~~-I00 UaH ON UN I O u~ girlO
1 aS I N 1 ~ I
([j r1 ,~-1~''.,~-IPi F(,' ~-i(a O ~-1~,'~.1S.-1
O N O '~,'I r1 O W O LO 'S-.j[~ r1
O M H O 01
Ln
4..1 i,]~ tIj[--iW GG ~ 4-1 ~ Qj .1.~W
O 01 O t~7[~ ~ O ~,7 0 O M ~ v-Ij~ I
O 01 W a ~ O a O ~H ~
O W W ~ W ~
W ~
Z t7 H -1 C7 O C7 O C7 H 4 C9
~ r H ~ A U P W W ~ ~ -1
n 4 5 d. ~ r
n
s~
~I O
~
-
u~
'
o
-
u
N
U
O p
d~
u)
M
N
~O
rd U7
(IS N
d~
-~I H
~-I H
u~
0
N CO
O L~
w-1 L!1
N
N
t1~
M
Ln
W
In
C~
H
~
N
di
~
O N
~
N
N
y -I
M
N
LI7
tn
rn
H
En
N
0
.r1
U
.r-1
M
U
W
O H
q
U
W
U ~-I
O
H
H
O
W
W
H -1 r-i
y
93
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
U U
I I I I I
~
~ I I rn u rr~ I v~a I zn a zWn
z5 ~ rn z ai u~
~
,- E-~E-r w ~ w r~ c~ ~.,H ~ ~ w H w N
~ O x n E-~ x
a, H
' H H H H W W W W H H H
H p
~ FC O O E-tO O
~ ~
q
~ Pa PO Pa Pa L4 0.~ ~W al W Pa
W W L4 Pa W
I
O I -rl
H
'z, oo ttf U1
O
W H '-1 O I I di ~y
H
d~
o~ H ~ .. ~I o u-I m n ~ N .-I
O o
~
01 O W ~ O1 -1 di W O O -rl
P; M
N
.. pi' ~1 N .1-1H .1-IN I 'C'.,M
N W ~ O
H
U1 CJsPa .. ~I PWH cti O r-1 t ~-IU2 U1a0
u1 ~ O ~ fx
..
O P,'I ~-1 ~ l!1 ~.,''. ~,, H~I N '~S-I ~-14-I
4-1 I U M . N d~I N
~-I
U O U' O -t~ a3~~o .-. 1O a ~ O O S-I
-ri to ~ N dW-1 ~ ~-I
N O
~,' E-~a .IJ (d N -ri~H S-1 00.1J ~-I.1-I .!->N H
.N r1 lO O Ln ~-I N CO
O
W W ~ .5~., N ,'~ O O~ O ~t i i I
[-~[7 O O N I ~ N
O1 P-n'
W ~ N LS~ I .l~ ~-Irv .1~N N ~
d~ a O C7 ~ I L4 M
W
U H U r1 R; ~I M ~ E-tU ~ U U U7
L~ c-1 W t .!-~ M 1.c1O
a~ W a a~ rn w o N a~ a~ ~ m a~ a~,--I
z5 p A ~ . ~ M ~ . r-IN
U7 P; I ~I M M .h E-~ U CY.,-rlU ~-I S-Ip'.,
~'.,M W d~ C7o P-',H
~ O
1 P L~ ~I (2~.. O ,C.p-1(CjN l0 I U
i ~ N . M
00
O 'ZS O 00 N ~I O'~ .~.,~1'~ 'LSW l~
W N f.~ O ~'t H L~ d~
N N
S-I W E-r O J-~ U ~, r1 .LJN O N O O M
(fl 'r-I~' c-I l~ ~ I M O N
~ a U7 1
"~' a W r1 ~ ,~C, N .-I O ari '~$N r-I n-IN ~
,C, W W I f~ r1 -r1 O N r1l0
a 00 I
yJ W W i N I S-I(d ~".,Ni ~'-,~, f~N O
-rl lfl~', I U N I N ~ O >_',O f~,.'f,
H 00 d~ L~
(a ~ U ~ U L~ l0 N tTj UW N c6~ ~ ?4
ILj Ln tJ~ 00 t11 .~. N -I riO O
L~ N M I
N
O W O U In cft~ ~I NO ~ ~-iO O r1
M oo d~ O 4-t f~ c~E-l fW-I
N a ~ N H
Y37 U t~,' U ~ I 5:''.,(!S ~ (Y,U dS~ U U r-I
O ~-I~ '~' '~I ,'~'d 1 ~ .~.,fY1 W
tn f= N ''r d I '' O W ~
i o ~ 0 '
t I
~
c n >~ -I 7 ..
U1 ~ 'J~ ~i o .. ~, I 1 ~'G," N f-, G',
Ul E-~ -~-IM .. ~ O -rlN ~ N N ~i
H W ~, ~ FC ~ ~, .-I -r-I .~,~ -.-IN
!3~' P~ ~1 01 O S-I ri ~IM
~, f~ N .~., ~-t w-I
O c-I U1 u-I ~-1
N ~o
W O N O In ~-1N ~ NN N U2N N U1
M ~1 l~ W In N .~, ~ ~ --.~ ~ ~
W M a H M N
N
E-m-IN ~ .L.I O ~ ~ .I-I.u ~ >~.u ~ ~,
W M cr ~r ~n o a ~ .u .L~.mn
c7 d~ ,-I E-~
r~
oo UaH oN UN ..N mo m ,~~ oo u~as~-Io o o ~r~
~ .. ca raw cdI
..
Ix FC n~I c~ o .-I~ ~I ~I~I ~ ~I?~ ~.I~ ~
o P-t o ~ o o c~ o ~ -~I~ ~ I
E-m ~o o~ ~ co I o~
W [i.i O-~ 4-I [J r~ .h WW (LS.V~2I (~O C31
O ,'J O O ~ O W ,~i I~7 C37 b1~
I 01 O 00 ' -I M I N I M
" I ; ~ I I ''
; ~
~ a Ma r1 R Ca I I -riS-1 r-I -rl,i,
, O xN N P, 1W ~-I ocornH r~w01 c~-rl
c~r~oU~ owx r1 P ww -I r~~-~ o u~N
owawu~ H--~ rnc~ N
x rn~~
o
~
-
M ~om ~
w . ~r
~ .
o z z
H
0
-'1 M 01
H
(I~
(<j C/1
r1
~-I
U
.V .
4J l0
O1
Wr-I~p l0
Cl~ C~
Ul
~ N tn
O E-~
,
W . v-1
Ul l0 M
01
l0
O Lr1 M
00 l0
CO
w-I
l
0 N
v-I N
N
M
rn u1
u1 H
zn
H.
0
A
.~ oo rI
,~
r1 -1 N
U
y
~ M M
O
P,'
O
.,
A R
1J M '
~
W (
H N O
U
O
In l0
H I~ t
H
O '~
t~
Z c-1 rI
94
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
~ U ~ ~
fly ~ a W A a
(~d W W
I I I p I
~ ~ .i
' W O W ~ P H W O W ~ W
O ~ ~ ~
c C H H fx .i ~ C- H H fx
d -~ ~
tn U7 H W W ~ f~ ~ tn tl~H W W ~
Ca U Z ~1 U
~ H FC r~ H ~ ~ a w a a x a o ~ ~ a
tti H O a ~ ~
q a
~ mw ~w w ~ x x mm w mw raw r~ ~ x x yaw
~
x - .
o ~ 4 m o, 4-I m
i
H o -~I ..
W M .1.~ O l0 W N .1-1N O
M
W fx O TS O x W ~,.4O d~ ''d
In U I ~ O ' H y I ~ M O
M ',~
N
O W O ,S''., N a ~ N I ,i,''
tf7 N a F(',
a
U7 ~-I (y.,U~ Ul ~I U1 ilkS-I Q', U1 Ul M ~-1U7
(J~ N 01 N 01 H N I
I
N ~ a-I~' ~I -- ~I ~-I~ O G~1 t.Y,~I N ~- S-1
4-I H C4 r-I w d~
N
U .~.~ q O O ,-IO O h H ~
.,~ I M f~ a
Q
o w H .u ~I .u .u c~ w w N .u N ~I .~
r~ o, I Gv o
N
~r a w s~, o s~, ~, ~ w ~ w c~,a o ~,
I N ~ N
~n
tn w W N . .>,N N b~ U u1 W ~ . .L~N
N o~ ~ ~ ~ W ~
-.-I 'n-7U U U1 , U U r-1 W "j~ U U Ul ~ U
a di d1 I d~ c-I to L ' I
'
Ul O W N ~,'N N N W p', W O ~',N N
N O N c-ICia W O M M
to di
~
.' U fx ~I-~IU ~1 ~I ~ C7 !~ ~I -~iU ~I
~ M d' 01 i N M In d~ o
cd ~I I rtiNNC701 1 ~I ~HHa 1 rd~-iN[7O
M 'N
!v O Z, ~1 'ZS~, ~-i~ '~ O P'., (~ ''~.~.,~-1'TS
O1 ~ N l~ M v-I H N ,~ L~
N a t M
,C.1.!-> H W N O N N .t~ O ~l W N O N
~ .-I r1 r-I M O 00 L~ c-1 1 M
'.-'rn I ,1~,
W W a r-I'ZSN r-I r1 ~ H W ,~ r1 rd N r1
~1 N v-I',~,~ v-I N
I Lt) l0 I
,N O H W i I ~.,"~ ~ O U a W ~ M ~''.,a
.,~ I M di O f~ I r1 lO o
M l~ d~
U o ~ ~ U c~ ~ ~ U ~ W Wn ~ N as ~
o~ o ~ N ~ 0 o a r-Is~ o
00 N eo
rv rx~o~ o ~o ~I-~1oaN o morewpZ oM o s~w~1-~IoaN
~
b7 ~I W U U cd ~ U U ~I a O U U cd cd U
O ~-I o In ~-I~ Pa ~' H .-I f~
H H
-~I H t7 d~ ~I ~ .. .' p U ~n ~I
~1 ~ Zt7~ G4 ~ ~ W ' ~
-l
u1 ~ m O ~N' 5~Nd H u~ ~t o NO >~N'
.. C~ H r1~ ~ -rl -rl~ p' ~ ~ ~ l
.' N ' '~ ~I ~1 ~T H l N 'ZSS
O Ln -I N -
O -I
O ~ W N N . N N O i W r N ., r
L!~ W M ~-I00 ., ~ ~ In ., M N ~-1U1 ~-I
N U1 M N ,. ~-1 ~ w
~ c N
O H ~
p; M
N
.t~ H H .1~~ ~ .!-~.I-~.I->H W H .I->~ ~ .rte
d~ r-iH d~ ~r .I-~.I->d~ W ~-iH ~ ~ .u
e0 .~ C7 a~ rl
U H O O m rd O O U W H O O m c~ O
N o I ~ r-Ird c~ N O o 1 I r1 cd
x 0.i I o W
a$ ~(,'P; ~i>-'.,~I ~I ~I rd W O Ix ~I ~',~I ~I
o U o N I -rls~ ~',o U o ~-1d~ -rl~',
I I 01 o I
4-t H W y-IftS.1-~~ Q.t4-I U Ri W y-1(~ .!~~
O v-IO Ol .~.,X31 t77O ',~-~ O O ~l
w-I v-I M O N
O w C7 C7H ~ C7 C7 O ~ C~7 C7 C7 C-~W~ C7
W ~ ~ ~ W 4-~i.tearyaw Ua' q H HT-r
~ ~ w P~~
n
~ ~
- ,-I l~
-I .
O ~rt
V .
~n
.1-I t~
ri
N
~i M
~'I
~
.l~
O
U7
M
O
O M M
''~ M O1
Ln l~
N N
O N
d'
U~ U1
N N
H H
.1-~
~y ~ o
N ,-I H
~ oo oW
~I m o
.u o
N ~H i
o H H
-~I
~
o t u
~ r~ ~
00 O1
N N
w-1
O M M
01 a1
L~ L~
y -I c-1
N l0
N N
>:n u1
~n u~
H H
N
f~ M N
~
r~
--I p -I N
U
.,_.
M M
'
A A
N
~
U U
) M ~
L
. ~i L
. H
~
U ~-1 -I
H
S ~
H L L~
~
O
~ 01 0 .-I
f~
~
H c-I N N
r
-
~
te
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
O O
U
O f= U7 O
~
~ ~ ~
~' w H ' W H W ~ ~
O O ~ H
~
E N P, (x P H f-
-a .s u
C-
~
H W W H H H
H H H
td r~ FC r/1 O O FC H
~a~aax O a w ~ x x
x
a ~ as Ix ar a a o
m a~ w ~nx cn w r~ r~ as
a~ w oa w w
>~
M Ul Ln 4-1
O , c-1ri
L~ W M O M .!->
a~ a ~r . ,~ a~
M ~ ~
H a
U7 ~-1 p_', U1 t1~ ~1 Ul Ul S-I r1 CI7Ul
U] O1 H N N M N
I
N ~ O f~ ~ ~- ~I ~I ~ -~I !~ ~i
4-I ~-i Pa W ~o H r.~ W
M ~
U -t-~ H O r-I d~ O O .I~ I O O
-r1 ~1 ~' I
dl
~ cd W H o~~ ~I -I-~.I~ctf d~ H .I~
.>, I W r-I ~
N fsa
~ W P d1I O R~ ~ ~ 4-I 0.rf~,
o~ ~ i H ~r o
rl~
C57 U W ~,N .i->N U >~ M W N
t~ Cl~ I Ol N
W
.,~ W aJ I rn ~ U U ~I ~I U U
~ z ~ ~r o I_na H ~
.. ~
U7 ~ W ~-IS-',N O N U7 O W N
f~ P; O .-I Ln r-1 O
l W M
cf'
U1 O CJ P-n'~iri U ~-I S-I~ .1-1~' ~I
~' N M W ~(',00 a . M
L~
c~ ~I ,'~ I (d N O I ~I (3~ I
H N O
~ H
N a l0
p O P; (~ ~, ~I '~ 'd O N (~ 'Z1
N H 00 ~ L~ r-1O d~ o
a I E-I M d~
ya .1-1 ~ W O N N .!~ U W N
(J~ ~ (~ r1 In M r-1N M ~-1
I ~ I R,' ~-1
s~ H a 'Ti N .-I ~-I, N a ~I
~ W o, N r-1~1 m
~ ~ M I H
1 ~ CJ P.1N ,'~ ~, ~ ~ N ~-i P.1
~ I a l0 Ln ~i O ',>-~I O ~H
-r1 L~ c-I N I
(~ U FC', ~ '~N (C$~ ~ U O ,'J
(~j c-I W ~.~1 I r1 O l0 117 C~
N a N 01
a~~~cw~z oM -~I~~r,x~.,oaN o a~ ~rxMo~ o
as ~
L71 ~-I a U -4~IIS ~ U U ~i wl U U
O ~' O c-1 t .~.,Pa ~-1 W ~
H W v-I
~I w O In f~,' O U .h ~r
(~ U ~I H
W a
~, ~ H z a~.~ a~'~~ >~ ~ ~I z ~
~ ~ o ~ a~ a~ c~ ~-,
' .
.. ~ H , .. ~ -r-Iri ~-I 0 H -.-I
~7 Z W M U7 ~-I ~-I.. ~ W M
O O M N ~. o0 N .. .. M W
tI~ ~-I L~ N ~ O U -I
N O N ~ ~ ~
H M d1 N
P;
N
J~ H H ~-I~ ~',1~ .h .1.~O H .u
d~ W c-i tn ?i .h .L)d~ .N r1 H
t7 W H r-I oo L
o~
U W O ~ U1 c~ O O U >~ o O
N H o H r1 ~f c~ N ~ o I
I O I W x a
o
~S W fx ~ ~ ~I ~I ~I c6 ai ~ ~I
o O o 1 -~I>~ ~ o s~ o o~
o U ~-I I I I
o
u-I U W tnc~ ~->p, 2, lu r1 w ,
o tx o o ~ b~ ~ o b~ o r1
d~ ~ ~-I 0 0o o
o
r-I w I -rlS-I cd I I -I . I 1
f~' Pa ~,'' d~ -rl rW h,' N ~,'-I
N a N 01 ~O r1
C~ l0
oww xc~c~wc~av~Haa ~~-Icy o ow~ ~ t.~A~~
rnx m mot
o
~
O
O
o
-
a
r
.
U
n
0
H
0
M
H
1~
.~'
Ul
O
pa
W
U7 N
O
In
N
U
.'-I
M
N
H
O q
~
H o
U
O
H L
H
O
W
.. N
H N
t~ N
~
96
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
O
f~ U7
~t zn a u~ tn , ~ ~I
r~ cn ~n
,H fx R; W H Pa G4 E-~ E~
O x H H O
c>3 '
I~ '
~
~ W W ~ G4 ~ ~ U) ~1 u1
,- U 7 7
. H H
~
cti
I
- O O H H r~ O FC
- ~ ~ as x arx H ax a
a~a ax
x raw w atw yaw mw w
>~
U7 N
~!, O
di O ~O M
d, '~ O
i-lO ~ N [~ I
al M
I ,.Ci N ,5Y W 00
N w-I r-I
U
l0 ~1 Ul fly,<I r1 a
N 01 N
I
U N ~ S-I ~I ~ r1 ,.tea 0.',
4.1 H c-I r1 f~ W Z, U7
N v-1
~',ov O O .N ~ H p O
t Q 1 H N
a1
N ~I -h .1-tt~ (d W O E-~
N I O W a1
N
N 0 o ~, , >~ 4-I Ea U w
O f~ ~ o H o
u~
.. .1-tN N t3I N O O W
N I ~ t~ O ..
fly, U U -ri f-I 1~,'
a H d~ ~-I ,5 ~ P,'
o
'y.,'N U N Ul O W H W
<H ~-1(~ W W c-i
l0
U1 W U ~I ~I o ~ W O Ix
~ w U' o~ U W M
~
j td N 01 I ~I i 'Ja I
N ~ H U
N t~
N ~ ~I ~ ~ o N f~ O p
~ ~ N o d~ ~ o~
N a M
~I OrI NMx No .uoo UM~-Iorxa~ wN
u, I
~r~a~ ~tN ~t~-1~,x~ a~~n~nHwOa a
I
I ~ ~2, ~2,N ~I U C7 W
~,'o f=,I o H d~
m ~ I
N c~ ~ ~ U o ~ W yn
o -~Io o~ ~o ~
m N
mn ~, OaN o a~~~ ~txNraw oa,
as
~ U U ~I 'u O H U
O W ~ a' ~ W
H H
~ , M
~C
U7 N ~,' 5~ ~ S-I al W Z
'd O N ~ N to W
~ r-1 O 0.~' H
~ f-ILO ~-1 ~ ~
w-1 w '-~~
~-I di
o~
N u1 N N O U O O W
oo -~ ~ ~ u~ ~ W W M
N N M N
~ .I-~.L~.u 0 H E-W H
~.,.u .u ~ .mo C7 ~-I
~I C7 a
u~ cd O O U ~'.,W W O
H r-I~ ~ N cd Ul o
W t a H I
~,'~-1~I ~I cIf rtS W W (1,'
I -rl.S",~',O ~,' E~ O
1 a1 I to
(~ .U , ~ 4-I r-1 CJ U W
.-I.~,tA CS7O W l0 O
O M -I
Ha ~ ~~m ~~ ow iu w ~a
z~~
~ c w ~ x c
~ .a
' s~
o
~
_
~
~rn
-
wr
M u
o
.
rn
o z
c~
0
-I
H
~
+~
~ U1
N
d
N
~
H
N
O
--rl
~
~
W ~
U1
0 M
l~
>
n
~
tn
~
N
~
~
H
'-I
M
N
N
P,'
N H
N U
~
H
-I
r
O
W
W
H N
-O
r
~
97
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
0
.,
M 01N Lf1 LI)
ri ~
U1 MO M O N 01 00 ~ M N N O N O
O L~l0 01 OW -1 M L~ M O di d~ M dil0
W NN 01 OW -i 01 01 01 w-1 a1 d1 O1 01M
>~
O
.,
11
11~ M
,-I
N M
O ~"I M
Nu-I r1 c-I u-I c-I v-Ir-Ic-I u-Ir1 c-1N w-1
O
U
N N N d~ d~ N d~ N N N N
O O O O O O O O O O O ([S
O O O O O O O O O O O S.-I
V NI I I 1 I I 1 I I I I
~ O l0 ~ l ~
G'
O M d 0 N l 00 O M ~D N N
Uv-I O O u-I M O O N c~ r1 N N
HO O O O O O O O O O O O
O O O d~ O O O O O O O O O
N WO O O O O O O O O O O O O
~
U1
~ CI~O O O O O O O O O O O O O
oI I I I I I I I I I I 1 I
'Z,t t1~L(7 L~ 01 ~O tn L Lf~tW W -ic-i
'-'lD w-Ic-I 01 O1 l0 r1 N lflc-I l0 N N
O1 l0 l0 O d1 c-Il0 LC7 00 l0 00 tf7Lf~
-
cM 01 01 ~ M Gf'01 v-I l0 01 l0 c-Ic-1
-
I
~.,N N N M tn N N N O N O N N
.
~
W
ML!7 M M L~ d~ O M M Op M 00 M M
NL~ l~ L~ M l0 L~ C~ L l0 l~ l0 l~L~
:
~1
C7 C7 U' U' C7 C7 C7 C7 CJ C7 C7 C7C7
I
~ L
M ~ tn O
N M LI~ I
n '
01 ~
-I
y OJ ~ w -1 M O1
1 M N d
1 M
t
~
. n M O u--1 0~ l0 O N v-I O N
- w-I 01 r-1 O O
~ M
C
U c-I 01 a1 O 01 . .
O c-I v-1 [~ M
N l0
N
N
O I 01 01 c--I. N N I d1 d~ O
~ O 01 N I M 01 d1 ~1 01 01 01
I 01
I
I
r1 l0 , t~ I O L~ ~-101 M 00 LC7M
~ N I I di 01 I I N 1 ~ I 1
N d~ 1 M I
01
M
L~ N N O M 00 c-100 M O1 M N
r1 v-1~l 00 I u-Il.nO ~D lO O O1
N L~ 1 O N
01
l0
~ N ' I t~ I I 1 I I I I I
1 In r-I O O N a1 O 01 N 01 L~
l0 I L~ ~ l0 d~
N
d~
-1 N r-I dW ~-I ~-I~-I~-I -I ~-I v-I~-I
r1 ~-1O1 -I N 01 ~-Ir1 M OJ M d~
r1 l ~ LW 01
N
N
N
U
,s.,'
N M M O N 01 00 l0 M N N O N
~
F-i l~ ~ ~ H M L~ M O d~ d~ M cP
~t N 01 01 H O1 d1 O1 H 01 01 01 d1
O
a~
a
a~
r1 c-I w-Ir-I. ~-I ~-1 v-Ir-Ir-I r-Ir-I r-Ir-I
m as r~ as m m m m r~ r~ cn oa
N U C1 U U U U U U U U U U
O
J~ ~ r1 N d~ O l~ O c--1 d~ M L~ M
N
,5y O O tf1 l0 L~ 01 c-IN d~ 01 01 01
r1
q
U N w-Iv-I w-I C-1 c-IN N N N N v-I
U
H
l1~ Ln Ln LC7 LI~ Lc1l1~tn In In N tI~
,
H L I~ t~ L L~ l~ L~ t~ I~ t~ L L
~
'~t' d~ di di d~ d~ d~ d' d' d~ d~ d~
r~ L~ L~ <' <' <' L~ L~ L~ L~ l~ l~ l~
O
W
N
.l-~
O
O
'~-
N
r1 c)' t11l0 L~ 00 01 O ~-I N M dW .c1
(~
H N N N N N N M M M M M M
O<
w
r-i
Cl~
O
W
98
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
0
+.~
M 01 M
r1
Ul N M W -I v-Id~ L~ l0 to C~ 111
O O M di LfW-IM LC7 l0 l~ O~ L~ di
W ~-I o~ 01 01 ~-Io1 0~ 01 01 01 01 01
O
.,
I
1J
Ld
-.-I
O
r-I .-I~-Ir-I~-Il ~-i r-I~-I r-I r-Ir-I
N N d~ d~ N N N d~ N N
O O O O O O O O O O
U 0I 0I oI oI 0I oI oI oI oI oI
-a
~i In Lf7l~ M l0 LI1l~ N W -1
~
-1 M N O O ~-iO ~-1 ~-IO
O O O O O O O O O O
O O O O dl O O O O O O
O O O O O O O O O O O
O
O O O O O O O O O O
I I I I ( I I I I I I
l~ ~ cN In L r-I L~ 00 0~ t~ H
l0 l0 N v-1 L~ 01 d~ d~ O1 L~
<' c-Id~ Ln o~ di d~ H H V~ H
cf' cN M O N d~ 00 In tn 00 O
M N d~ r1 01O ~ LI)O O tl701
c-I O u-Id1 O O 01 l0 L~ L~ l0 lfl
<' ~
t51 ~ ~ ~1 ~1Ln LT i~ ~7
N
C'~ U' U' CJ C7b~ C7 C7 C7. C7 C7 C7
U
N M
1J O
1
I 1 ~ l ~
N M CO w- LW 00 O N L L(1CO
U ~ 1 - Lf7 l L(1 N ~ ~
L ~
N . . d 11 ~ Ol 0 LC7 ~ ~ d
O M r-101 c-1 M ~ ~ ~ l Ol
LW lflO1 a1 c-I Lf7 M L N O
-I 01 O N 01 00 di O1
L~ l0 ~ 01
1 a1 01 CO
-I ~ M o0 I -I I M I i.tl O~ 1
~ I I 1 cW I I I L 1 1
~ I I I
N 0~ M lD N O1 M O1 M c-Id~
v-I M LIlM ~ lO O1 M IlW l0
~D l0 O -I
I 1 I c0 1 L~ I M 1 1 L
o1 0~ ~-i1 c-I .-1 O I W N
O L~ M c-I
v-I c-I-I M c-I N c-Id~ c-I c-IIll
LIl W ~N v-Id~ d~ ~N c-1 ~ ~N
c-I 00 01 d~
N
U
,~',
M 00 ~-1~ l~ lflL(1 l~ LC)N
N N M d~ In 117 l0 L~ CO L~ d~
LT
~
N r-I ~ o~ o~ H Q1 0~ o~ o~ a~ a~
a~
a
.r1 ~-1 ~--1r-1~-Ir-I r1 ~-1r-1 r1 ~-Ir1
.u r~ w r~ m m oo as ~a m m m
~ U U U U U U U U U U U
O
.1~ M N O v-ILf7 M L~ M L~ O1 N
O
~r -1 L O N l0 L~ LW -I ~-I L~ ~-I
r1
W
U N N N ~-I~-I N O ~-I ~-I o r-I
U
H
~''aLO M to U1 Il7 Ln lfllfl l0 l0 1O
~
H L~ L~ t~ G L~ L~ L L~ t~ L~ L~
~
cft d~ ~ dl d~ cH d~ d~ d~ d~ di
r-1 L~ L~ L' I~ L~ L~ L~ <' C~ <' L~
O
W
N
.!-~
O
O
'~,'
N
r1 ~O L~ CO 01 O v-I N M ~ In l0
(~
U M M M M d~ d~ d~ d' d~ d' d~
H
O<
W
r~
Ul
O
W
99
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
a~
_5
N
'u O
~ ,~ W
-r1 Cl~
~a~
x
~c,O
~ .°'
H O L~
L4 cN
N
.1.~ O
O "'~,
N
r-I (~ di
U H N
Ot
W
r-I U7
O
W
100
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
0
0
o
0
m
0
~'
m
U
U
1,
N
q ~
~ O
U
3
a ~
~i
H
0
0
.,
a~
N
.,.
N
(d
r~ N
-r-I U1
' -r1
Ea l~
r-I
O ~
~I U
(d H
..
W
al z
lol
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
II ~ ~ o
W ~ .~ "~ II
o ,9 ~ ~ ~b ~, ~, ~ o
-.~ o ~W'o ~ ~ ~ ~ ~° '~ ap
4j P~ O i-'i 'i' ~, ~ i c~
O '~ C1 w ~ ~ O
.f".r > ~ ~ N c~ ~ ~ U ~ r-i
t~", ~° .'''~, ~, ° c~G 5 ~ N ~ Via., O ~ ~O
E'~ ~ ~' o W w cn.~a '~ °~ " ~ ~ P-'
N b-0 ~ y~., N >Wi ~
° O
U
~'JN ~~°_UW_'J'~ ~ '~'~t,.,
t~ ~ 'c~ ~ ~ ~ ~ ~ ~ ~ ~ ~ O ~O N
p~1 w O ~Y > w ~ ~ ~ 4.a ~Y 4-i f1i ~ ~ ~ ~D
U
~
U
~ o ~ 01 pp '.~ ~ O~ c~ ~ O
r;~ ~' ~M~ zU °' '~-' .3M
° O~ OO Pi l0 H ~ ~ N N UW--~
U U U
' O c~ ~ ~ N .-i ~ .~,a' ~ U ~ W W N O can
U U U ~ °~ ~';~ '~ d- ° ~ o ~ W x i o
~ ~! ~ Q. due' oo ~ x ~d E ~ N P..i
w v»n O V7 M a N ~ ~,' ~ N O ~tj
U o, M W rri ° o . ' h a~ O
w w ~ w
O T7 yj V1 ~ ,~-' y ~ ~ by
c~ ~ y b ~ ~~ ~ ~ ~O ~p ~ W--~ ~ U V 'c7
~n v~ w o ~G ~Y ~ ~-,
a GG Pa ~ Pa ~ '~!' ~ ~ ~ ~ ~ s . 4..~ ~ o ° ''.-' ~ o ~' U
x~ ~o.~o~ ~ o
.ate, ~ ~ .~ ~' ~ ~ ~ ~ ~" ~ 'd
~Nz wz~ ~~ x~~NU ~N~.Az
°
o a., ~ "° ~ ~ v o
-d ~ ~ ~ v_
'b ~ ',~ ~ ''-~ .a 't'' ~-0'L; .~.~.. ~ H .v-~O ~ V c'~G w
w Q' G ~ O' N ~ .:~. U cd A~ W ~ ~ b ~ .fl c~
.~ N ~ ~ "C3 ~ ~ ~ ~ ~ ~ c~C U
U _U
:i~.., b
'~ cUC ~ccf '~ U O O U ~ ccf N ~ .~ '~"' y'~D y
u. ~ '~ H ~ s~ w " H ~s ~ v~ ~ o
,U .~ ...,~ ~~w c~'r~,b ~ ~~ v
a~ ~ U ~ ,.~ ~, ~ .c U ~ p
~ w ~ ~ o ~ o a
~~a_~ w ~ ~_
O al ~ V ~ yn U ~ ~ ~ ~ w
N ~ ~ l.~,p .~' N '~ P. ~ v1 ~ > '~ ~ ~ vwn ° .f.
'" ° w o '~ ~ ~~ o~ E~ ~l ~ a~ o o ~ O ~ .o o ~ o
o ~ ~ ~ "~ o .~ b ,.n ~ ,n o ~ ~ .o~n ~ '~' ~ ,x
~ on
i3~ ~ ~ '.~ U U ~ G ~ .~ U j U U ~ U
~u o~ ,.~ ~ Y o~ .~ ~ '~ .~ '.c'~. ',-,'c~.' ~ w v o ~ O ~ a°0 ~ .~
p. ~' w ~ Pa Pa ~ U ~ ° .~ ~ ~ '~ '~ o ~ an ~ '~
d cd a' a P-~ o" c~ a~ ~ a' O ~.. ~ ~ zf o
~.
W
d
U o
w ~ ~ ~ a'~a w
l02
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
C7 "
U ~
U ~ i
w°
~y7 O ~ N
~'n
O ~ ~ 'O a- .N S..,
~" >, ~, ~ c~ °
N
E~ a' ~ ° ° .c o
~.
N ~ v~
I ..o M N
w z ~.~ ~ ° ~ °
~' s~. C7 v~ ~ v~
N N !~.
'~ ;~ ~ ~n O~
s0 O j ~ ~ Vj pp ,--y0 i"i ~ N
..S"',-'. ~ O ~ '~ ~ ~ ~ N .O O
p N Gv ~ ~ ~G ~ s-, '~ ~., ~ b
N c~
.S~', rv ~ ~.~.' 0~1 ~ GUS". ~ p ~ V1 ~ c~ t~. ,~ > '~
W 0~1 v~ ~ ~ ~ .f~~., N .b0 U ~ ~ U O U ~ U c~'C
N ~wd'~ ~ w ~ ~' Pai~ 0U ~ ~ ~O
i.~N ~U~ '~~ o~ ° ~°?~ °'t'.~a ~'°~x °~~C7
U ~ ~ c~ o ; ~ ~ ~.~-, o ° v~ ~ p a, ~ '~ ~
o a ~ ~ b ~ ~ ~ Pa o ~ ~ ~ ~ ~ ~ o Z
00 00 ~ N ~ ~ ~ o .~ o
°° '~ ono
a, Pa ~ rri Wit- ~ .~ ,-i '~ r, ~ ~' o cn a~ ~ ~ ~ : p U
ai ,-~ ~ ~ ~ a ,open ~ y '~ x v
r; b oo '~ '~ M b
N N ~ ~ c~ ~ ~ O~ ~ .s-. ~ N d' ~ ~ M w ~ ~ y.,~ .~, U N
w ~ cC ~ v ~ ~ N N > N cd N ~ ~ y cG PH U ~ N
p '~ '~ pa ono C7 N '~ ~ ~ ~ A '~' U v~ ~ ~ v~ ~ °' ~ ~ G C7
~ o o ~o
an '~ ~ ~ '" °~ o o ~ ~ o ~ ~ ,.o ° ° ~ "o 0 0~
~, .fl .fl U ~ '~~' ~ 01 .~"~' ~. ,-N' U' 'y b ,~ ,~ Pa ~ ~-' ~ ~"~ ~ ~
a~ '~ ~ ~ ~ ~ '.' ~ ~ fy ~ ~ y ° p p ~ ~ m ~ O O
R,' C7 C7 ,-~ ~ W ~ .~ v~ ~ ~ ~s r~ L7 z ~ U w N P-~ v~ U C7
0
w
~. Zs '~ ~ ~ v ~ ~ 'y ~. ~ a~ o
O'" y 4? ~ ~ ''~' U c~ ° N Y c~ N a-i
a' o.
'L~ U p Oc-~ G '~~" ~ ~ .~ ~~ c~ ~ ~ N .N
c~C O' ~ ~L 'b ."' ,~ Q~, (3y at .~ .N N '~ ~" N
~~" ~ w Z aQ ~ ~ b a. O O
~~ ~ ~ U ~ U U ~ ~ O ~ ~O
N p O O ~ ~ ~ ~ ~ ~ U O
° y ,., p ~", "d s..~ N O ''~ ~ p" ~.' G
v~ N .,.t"-J' .-4' ~ cUn bOD ~ ~ ~ N ,s~~" O b ~ 'L1
U U by "."~ ~ c~ ~ ~ U b0 v~ 'b U F' N
V F~, .fl .~ .d ~'3 . .(-'., ar ° v».,"
~o~ ~~~~ '" ~Q. a 6b° i'°~
ou 3 d ~b ~ cn ° ~ ~ o ~ ~ ~ a~ v
~., p~ ... ~ ,~ .~ ° .
.~ ..'~', ~ ,~ ~ t. U y ~ .C '~ ~ cn ~ ~ U
C.i O ~ ~ U ~ ~ U .C ~~' U U F'.' ~ ~ '~'
~~ .~ ~ ~ ~ ~ ~ ~ ~ ~ ~ '~ ~ o ~ ~~ o ~ .d o
A ~~-d ~°~' ~Uo°~' ~ d°~' ~b.b ~b~
U
'b ~ ~ U 4a
P; Pa P-i p-. U
103
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
a~
+ I I I I I II II
1 I I I I I 1+ II
-.': ~+ + + '+;+ + ++ ++ ..
~+ + + +. + .+ ++ ++
M
O
'
+ + I I I + I+ +I
H
O
~
+ I + I I I -I--I-.++
~
N
~ M+ I I I I I I1 II
M
O
N
U N1 I I + I I I-1-I1
M
~
O
+ + + + I I II +I
+ + + + 1 + I+ ++
+ + + -1-I + II II
r-1
+ ~- + + + + I+ 1+
u~ c>i
~
N ~ -r~ l~
' ~ ~ ~ ~ ~ ~
N ~i -
- O
-
~ v ~~ ~
. a~ r1 ~
~a ~
n i ~ ~ ~ ~
~ ~u
~
r ~ u ~ I~ ai
tn ~ U ~ '~ U~ U~ ~
.~ ~ N
~
~
~ 1 , ~
~
O ,FC.h5r
U
~ .
~
. o ~ H N rn ~C-I~
.L ~ .~
~
H ~ tr-1a ~ f~ O ~O
~ ~ ~
~,
~
N cdr
~n ~-1 'rt.L~-1
O
P~lU ~ 'z5
U
CI' i~ ~O U
'
~'', ~.,-Gr1 W ~~
~ .~ ~ W ' r1
O ,
~ .. (Ii ~ ~
~ U7
C
ctiO ~-i G~a
~I ~I x
104
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<110> INCYTE GENOMICS, INC.
PATTERSON, Chandra
TRIBOULEY, Catherine M.
YAO, Monique G.
GRIFFIN, Jennifer A.
THORNTON, Michael
LU, Yan
KALLICK, Deborah A.
GANDHI, Ameena R.
AU-YOUNG, Janice
<120> G-PROTEIN COUPLED RECEPTORS
<130> SF-0781 PCT
<140> To Be Assigned
<141> Herewith
<150> 60/206,222; 60/207,476; 60/208,834; 60/208,861; 60/209,868
<151> 2000-05-22; 2000-05-25; 2000-06-02; 2000-06-02; 2000-06-07
<160> 46
<170> PERL Program
<210> 1
<211> 855
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Tncyte ID No: 7475208CD1
<400> 1
Met Leu Gly Pro Ala Va1 Leu G1y Leu Ser Leu Trp Ala Leu Leu
1 5 10 . 15
His Pro Gly Thr Gly Ala Pro Leu Cys Leu Ser Gln Gln Leu Arg
20 25 30
Met Lys Gly Asp Tyr Val Leu Gly Gly Leu Phe Pro Leu Gly Glu
35 40 45
Ala Glu Glu Ala Gly Leu Arg Ser Arg Thr Arg Pro Ser Ser Pro
50 55 60
Val Cys Thr Arg Phe Ser Ser Asn G1y Leu Leu Trp Ala Leu Ala
65 70 75
Met Lys Met Ala Val Glu Glu Ile Asn Asn Lys Ser Asp Leu Leu
80 85 90
Pro Gly Leu Arg Leu Gly Tyr Asp Leu Phe Asp Thr Cys Ser Glu
95 100 105
Pro Val Val Ala Met Lys Pro Ser Leu Met Phe Leu Ala Lys Ala
110 115 120
Gly Ser Arg Asp Ile Ala Ala Tyr Cys Asn Tyr Thr Gln Tyr Gln
125 130 135
Pro Arg Val Leu Ala Va1 Ile Gly Pro His Ser Ser Glu Leu Ala
140 145 150
Met Val Thr Gly Lys Phe Phe Ser Phe Phe Leu Met Pro Gln Val
155 160 165
Ala Pro Pro Thr Ile Thr His Pro His Pro Ala Leu Pro Val G1y
170 175 180
Ala Pro Val Ser Gly Asp Ala Ser Trp Pro Leu G1n Val Ser Tyr
185 190 195
G1y A1a Ser Met Glu Leu Leu Ser Ala Arg Glu Thr Phe Pro Ser
200 205 210
1/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Phe Phe Arg Thr Val Pro Ser Asp Arg Val Gln Leu Thr Ala Ala
215 220 225
Ala Glu Leu Leu Gln Glu Phe Gly Trp Asn Trp Val Ala Ala Leu
230 235 240
Gly Ser Asp Asp Glu Tyr Gly Arg Gln Gly Leu Ser Ile Phe Ser
245 250 255
Ala Leu Ala Arg His Ala Ala Ser Ala Ser Arg Thr Arg Ala Trp
260 265 270
Cys Arg Cys Pro Val Gln Asp Val Leu His Gln Val Asn Gln Ser
275 280 285
Ser Val Gln Val Val Leu Leu Phe Ala Ser Val His Ala Ala His
290 295 300
Ala Leu Phe Asn Tyr Ser Ile Ser Ser Arg Leu Ser Pro Lys Val
305 310 315
Trp Val Ala Ser Glu Ala Trp Leu Thr Ser Asp Leu Val Met Gly
320 325 330
Leu Pro Gly Met Ala Gln Met Gly Thr Val Leu Gly Phe Leu Gln
335 340 345
Arg Gly Ala Gln Leu His Glu Phe Pro Gln Tyr Val Lys Thr His
350 355 360
Leu Ala Leu Ala Thr Asp Pro Ala Phe Cys Ser Ala Leu Gly Glu
365 370 375
Arg Glu Gln Gly Leu Glu Glu Asp Val Val Gly Gln Arg Cys Pro
380 385 390
Gln Cys Asp Cys Ile Thr Leu Gln Asn Arg Ala Gln Ala Leu His
395 400 405
Asn Thr Leu Gln Cys Asn A1a Ser Gly Cys Pro Ala Gln Asp Pro
410 415 420
Val Lys Pro Trp Gln Leu Leu Glu Asn Met Tyr Asn Leu Thr Phe
425 430 435
His Val Gly Gly Leu Pro Leu Arg Phe Asp Ser Ser Gly Asn Val
440 445 450
Asp Met Glu Tyr Asp Leu Lys Leu Trp Val Trp Gln Gly Ser Val
455 460 465
Pro Arg Leu His Asp Val Gly Arg Phe Asn Gly Ser Leu Arg Thr
470 475 480
Glu Arg Leu Lys Ile Arg Trp His Thr Ser Asp Asn Gln Pro Ser
485 490 495
Arg Ala Arg Pro Gln Ala Cys Ala Gln Lys Pro Val Ser Arg Cys
500 505 510
Ser Arg Gln Cys Gln Glu Gly Gln Val Arg Arg Val Lys Gly Phe
515 ' 520 525
His Ser Cys Cys Tyr Asp Cys Val Asp Cys Glu Ala Gly Ser Tyr
530 535 540
Arg Gln Asn Pro Asp Asp Tle Ala Cys Thr Phe Cys Gly Gln Asp
545 550 555
Glu Trp Ser Pro Glu Arg Ser Thr Arg Cys Phe Arg Arg Arg Ser
560 565 570
Arg Phe Leu Ala Trp Gly Glu Pro Ala Va1 Leu Leu Leu Leu Leu
575. 580 585
Leu Leu Ser Leu Ala Leu Gly Leu Val Leu Ala Ala Leu Gly Leu
590 595 600
Phe Val His His Arg Asp Ser Pro Leu Val Gln Ala Ser Gly Gly
605 610 615
Pro Leu Ala Cys Phe Gly Leu Val Cys Leu Gly Leu Val Cys Leu
620 625 630
Ser Val Leu Leu Phe Pro Gly Gln Pro Ser Pro Ala Arg Cys Leu
635 640 645
Ala Gln Gln Pro Leu Ser His Leu Pro Leu Thr Gly Cys Leu Ser
650 655 660
Thr Leu Phe Leu Gln Ala Ala Glu Ile Phe Val Glu Ser Glu Leu
665 670 675
Pro Leu Ser Trp Ala Asp Arg Leu Ser Gly Cys Leu Arg Gly Pro
2133
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
680 685 690
Trp Ala Trp Leu Val Val Leu Leu Ala Met Leu Val Glu Val Ala
695 700 ' 705
Leu Cys Thr Trp Tyr Leu Val Ala Phe Pro Pro Glu Val. Val Thr
710 715 720
Gly Leu Ala His Ala Ala His Gly Gly Ala Gly Ala Leu Pro His
725 730 735
Thr Leu Leu Gly Gln Leu Arg Pro Ser Ala Arg His His Ala Thr
740 745 750
Leu Ala Phe Leu Cys Phe Thr Gly His Phe Pro Gly Ala Glu Pro
755 760 765
Ala Gly Pro Leu Gln Pro Cys His Val Ala Ser His Ile Cys His
770 775 780
Ala Gly Leu Leu His His Thr Gly Ser His Phe Val Pro Leu Leu
785 790 795
Ala Gln Cys Ala Gly Gly His Ser Gly Pro Ala Val Gln Met Gly
800 805 810
Ala Leu Leu Leu Cys Val Leu Gly Ile Leu Ala Ala Phe His Leu
815 820 825
Pro Arg Cys Tyr Leu Leu Met Arg Gln Pro Gly Leu Asn Thr Pro
830 835 840
Glu Phe Phe Leu Gly Gly Gly Pro Gly Asp Ala Thr Arg Pro Glu
845 850 855
<210> 2
<211> 330
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475101CD1
<400> 2
Met Glu Gly Phe Tyr Leu Arg Arg Ser His Glu Leu Gln Gly Met
1 5 10 15
Gly Lys Pro Gly Arg Val Asn Gln Thr Thr Val Ser Asp Phe Leu
20 25 30
Leu Leu Gly Leu Ser Glu Trp Pro Glu Glu Gln Pro Leu Leu Phe
35 40 ~ 45
Gly Ile Phe Leu Gly Met Tyr Leu Val Thr Met Val Gly Asn Leu
50 55 60
Leu Ile Ile Leu Ala Ile Ser Ser Asp Pro His Leu His Thr Pro
65 70 75
Met Tyr Phe Phe Leu Ala Asn Leu Ser Leu Thr Asp Ala Cys Phe
80 85 90
Thr Ser Ala Ser Ile Pro Lys Met Leu Ala Asn Ile His Thr Gln
95 100 105
Ser Gln Ile Ile Ser Tyr Ser Gly Cys Leu Ala Gln Leu Tyr Phe
110 115 120
Leu Leu Met Phe Gly Gly Leu Asp Asn Cys Leu Leu Ala Val Met
125 130 135
Ala Tyr Asp Arg Tyr Val Ala Ile Cys Gln Pro Leu His Tyr Ser
140 145 150
Thr Ser Met Ser Pro Gln Leu Cys Ala Leu Met Leu Gly Val Cys
155 160 165
Trp Val Leu Thr Asn Cys Pro Ala Leu Met His Thr Leu Leu Leu
170 175 180
Thr Arg Val Ala Phe Cys Ala Gln Lys Ala Ile Pro His Phe Tyr
185 190 195
Cys Asp Pro Ser Ala Leu Leu Lys Leu Ala Cys Ser Asp Thr His
200 205 210
3/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Val Asn Glu Leu Met Ile Ile Thr Met Gly Leu Leu Phe Leu Thr
215 220 225
Val Pro Leu Leu Leu Ile Val Phe Ser Tyr Val Arg Ile Phe Trp
230 235 240
Ala Val Phe Val Ile Ser Ser Pro Gly Gly Arg Trp Lys Ala Phe
245 250 255
Ser Thr Cys Gly Ser His Leu Thr Val Val Leu Leu Phe Tyr Gly
260 265 270
Ser Leu Met G1y Val Tyr Leu Leu Pro Pro Ser Thr Tyr Ser Thr
275 280 285
Glu Arg Glu Ser Arg Ala Ala Val Leu Tyr Met Val Ile Ile Pro
290 295 300
Thr Leu Asn Pro Phe Ile Tyr Ser Leu Arg Asn Arg Asp Met Lys
305 310 315
Glu Ala Leu Gly Lys Leu Phe Val Ser Gly Lys Thr Phe Phe Leu
320 325 330
<210> 3
<211> 324
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475152CD1
<400> 3
Met Gly Met Ser Asn Leu Thr Arg Leu Ser Glu Phe Ile Leu Leu
1 5 10 15
Gly Leu Ser Ser Arg Ser Glu Asp Gln Arg Pro Leu Phe Ala Leu
20 25 30
Phe Leu Ile Ile Tyr Leu Val Thr Leu Met Gly Asn Leu Leu Ile
35 40 45
Ile Leu Ala Ile His Ser Asp Pro Arg Leu Gln Asn Pro Met Tyr
50 55 60
Phe Phe Leu Ser Ile Leu Ser Phe Ala Asp Ile Cys Tyr Thr Thr
65 70 75
Val Ile Val Pro Lys Met Leu Val Asn Phe Leu Ser Glu Lys Lys
80 85 90
Thr Ile Ser Tyr Ala Glu Cys Leu Ala Gln Met Tyr Phe Phe Leu
95 100 105
Val Phe Gly Asn Ile Asp Ser Tyr Leu Leu Ala Ala Met Ala Ile
110 115 120
Asn Arg Cys Val Ala Ile Cys Asn Pro Phe His Tyr Val Thr Val
125 130 135
Met Asn Arg Arg Cys Cys Val Leu Leu Leu Ala Phe Pro Ile Thr
140 145 150
Phe Ser Tyr Phe His Ser Leu Leu His Val Leu Leu Val Asn Arg
155 160 165
Leu Thr Phe Cys Thr Ser Asn Val Ile His His Phe Phe Cys Asp
170 175 180
Val Asn Pro Val Leu Lys Leu Ser Cys Ser Ser Thr Phe Val Asn
185 190 195
Glu Ile Val Ala Met Thr Glu Gly Leu Ala Ser Val Met Ala Pro
200 205 210
Phe Val Cys Ile Ile Ile Ser Tyr Leu Arg Ile Leu Ile Ala Val
215 220 225
Leu Lys Ile Pro Ser Ala Ala Gly Lys His Lys Ala Phe Ser Thr
230 235 240
Cys Ser Ser His Leu Thr Val Val Ile Leu Phe Tyr Gly Ser Ile
245 250 255
Ser Tyr Val Tyr Leu Gln Pro Leu Ser Ser Tyr Thr Val Lys Asp
4/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
260 265 270
Arg Ile Ala Thr Ile Asn Tyr Thr Val Leu Thr Ser Val Leu Asn
275 280 285
Pro Phe Ile Tyr Ser Leu Arg Asn Lys Asp Met Lys Arg Gly Leu
290 295 300
Gln Lys Leu Ile Asn Lys Ile Lys Ser Gln Met Ser Arg Phe Ser
305 310 315
Thr Lys Thr Asn Lys Ile Cys Gly Pro
320
<210> 4
<211> 374
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475164CD1
<400> 4
Met Ala Ile Cys Asn Pro Leu Leu Tyr Asn Ile Ala Met Ser Pro
1 5 10 15
Lys Val Cys Ser Ser His Met Leu Gly Ser Tyr Phe Trp Pro Phe
20 25 30
Ser Gly Ala Met Ala His Thr Arg Cys Met Leu Lys Leu Thr Ser
35 40 45.
Cys Glu A1a Asn Thr Ile Asn His Tyr Phe Cys Asp Thr Leu His
50 55 60
Leu Leu Gln Leu Ser Cys Thr Ser Thr Tyr Val Arg Ala Glu Phe
65 70 75
Ile Leu Ala Gly Leu Thr Gln Arg Pro Glu Leu Gln Leu Pro Leu
80 85 90
Phe Leu Leu Phe Leu Gly Ile Tyr Val Val Thr Val Val Gly Asn
95 100 105
Leu Gly Met Ile Phe Leu Ile Ala Leu Ser Ser Gln Leu Tyr Pro
110 115 120
Pro Val Tyr Tyr Phe Leu Ser His Leu Ser Phe Ile Asp Leu Cys
125 l30 135
Tyr Ser Ser Val I1e Thr Pro Lys Met Leu Val Asn Phe Val Pro
140 145 150
Glu Glu Asn Ile Ile Ser Phe Leu Glu Cys Ile Thr Gln Leu Tyr
155 160 165
Phe Phe Leu Ile Phe Val Ile Ala Glu Gly Tyr Leu Leu Thr Ala
170 175 180
Met Glu Tyr Asp Arg Tyr Val Ala Ile Cys Arg Pro Leu Leu Tyr
185 190 195
Asn Ile Val Met Ser His Arg Val Cys Ser Ile Met Met Ala Val
200 205 210
Val Tyr Ser Leu Gly Phe Leu Trp Ala Thr Val His Thr Thr Arg
215 220 225
Met Ser Va1 Leu Ser Phe Cys Arg Ser His Thr Val Ser His Tyr
230 235 240
Phe Cys Asp Ile Leu Pro Leu Leu Thr Leu Ser Cys Ser Ser Thr
245 250 255
His Ile Asn Glu Ile Leu Leu Phe Ile Ile Gly Gly Val Asn Thr
260 265 270
Leu Ala Thr Thr Leu Ala Val Leu Ile Ser Tyr Ala Phe Ile Phe
275 280 285
Ser Ser Ile Leu Gly Ile His Ser Thr Glu Gly Gln Ser Lys Ala
290 295 300
Phe Gly Thr Cys Ser Ser His Leu Leu Ala Val Gly Ile Phe Phe
305 310 315
Gly Ser Ile Thr Phe Met Tyr Phe Lys Pro Pro Ser Ser Thr Thr
5133
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
320 325 330
Met Glu Lys Glu Lys Val Ser Ser Val Phe Tyr Ile Thr Ile Ile
335 340 345
Pro Met Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val
350 355 360
Lys Asn Ala Leu Lys Lys Met Thr Arg Gly Arg G1n Ser Ser
365 370
<210> 5
<211> 312
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475170CD1
<400> 5
Met Asp Gln Lys Asn Gly Ser Ser Phe Thr GIy Phe Ile Leu Leu
1 5 10 15
Gly Phe Ser Asp Arg Pro Gln Leu Glu Leu Val Leu Phe Val Val
20 25 30
Leu Leu Ile Phe Tyr Ile Phe Thr Leu Leu Gly Asn Lys Thr Ile
35 40 45
Ile Val Leu Ser His Leu Asp Pro His Leu His Thr Pro Met Tyr
50 55 60
Phe Phe Phe Ser Asn Leu Ser Phe Leu Asp Leu Cys Tyr Thr Thr
65 70 75
Gly Ile Val Pro Gln Leu Leu Val Asn Leu Arg Gly Ala Asp Lys
80 85 90
Ser Ile Ser Tyr Gly Gly Cys Val Val Gln Leu Tyr Ile Ser Leu
95 100 105
Gly Leu Gly Ser Thr Glu Cys Val Leu Leu Gly Val Met Val Phe
110 115 ' 120
Asp Arg Tyr Ala Ala Val Cys Arg Pro Leu His Tyr Thr Val Val
125 130 135
Met His Pro Cys Leu Tyr Val Leu Met Ala Ser Thr Ser Trp Val
140 145 150
Ile Gly Phe Ala Asn Ser Leu Leu Gln Thr Val Leu Ile Leu Leu
155 160 165
Leu Thr Leu Cys Gly Arg Asn Lys Leu Glu His Phe Leu Cys Glu
170 175 180
Val Pro Pro Leu Leu Lys Leu Ala Cys Val Asp Thr Thr Met Asn
185 190 195
Glu Ser Glu Leu Phe Phe Val Ser Val Ile Ile Leu Leu Val Pro
200 205 210
Val Ala Leu Ile Ile Phe Ser Tyr Ser Gln Ile Val Arg Ala Val
215 220 225
Met Arg Ile Lys Leu Ala Thr Gly Gln Arg Lys Val Phe Gly Thr
230 235 240
Cys Gly Ser His Leu Thr Val Val Ser Leu Phe Tyr Gly Thr Ala
245 250 255
Ile Tyr Ala Tyr Leu Gln Pro Gly Asn Asn Tyr Ser Gln Asp Gln
260 265 270
Gly Lys Phe Ile Ser Leu Phe Tyr Thr Ile Ile Thr Pro Met Ile
275 280 285
Asn Pro Leu Ile Tyr Thr Leu Arg Asn Lys Asp Val Lys Gly Ala
290 295 . 300
Leu Lys Lys Val Leu Trp Lys Asn Tyr Asp Ser Arg
305 310
<210> 6
<211> 325
6/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475197CD1
<400> 6
Met Lys Thr Phe Ser Ser Phe Leu Gln Ile Gly Arg Asn Met His
1 5 10 15
Gln Gly Asn Gln Thr Thr Ile Thr Glu Phe Ile Leu Leu Gly Phe
20 25 30
Phe Lys Gln Asp Glu His Gln Asn Leu Leu Phe Val Leu Phe Leu
35 40 45
Gly Met Tyr Leu Val Thr Val Ile Gly Asn Gly Leu Ile Ile Val
50 55 60
Ala Ile Ser Leu Asp Thr Tyr Leu His Thr Pro Met Tyr Leu Phe
65 70 75
Leu Ala Asn Leu Ser Phe Ala Asp Ile Ser Ser Ile Ser Asn Ser
80 85 90
Val Pro Lys Met Leu Val Asn Ile Gln Thr Lys Ser Gln Ser Ile
95 100 105
Ser Tyr Glu Ser Cys Ile Thr Gln Met Tyr Phe Ser Ile Val Phe
110 115 120
Val Val Ile Asp Asn Leu Leu Leu Gly Thr Met Ala Tyr Asp His
125 130 135
Phe Val Ala Ile Cys His Pro Leu Asn Tyr Thr Ile Leu Met Arg
140 145 150
Pro Arg Phe Gly Ile Leu Leu Thr Val Ile Ser Trp Phe Leu Ser
155 160 165
Asn Ile Tle Ala Leu Thr His Thr Leu Leu Leu Ile Gln Leu Leu
170 175 180
Phe Cys Asn His Asn Thr Leu Pro His Phe Phe Cys Asp Leu Ala
185 190 195
Pro Leu Leu Lys Leu Ser Cys Ser Asp Thr Leu Ile Asn Glu Leu
200 205 210
Val Leu Phe Ile Val Gly Leu Ser Val Ile Ile Phe Pro Phe Thr
215 220 225
Leu Ser Phe Phe Ser Tyr Val Cys Ile Ile Arg Ala Val Leu Arg
230 235 240
Val Ser Ser Thr Gln Gly Lys Trp Lys Ala Phe Ser Thr Cys Gly
245 250 255
Ser His Leu Thr Val Val Leu Leu Phe Tyr Gly Thr Ile Val Gly
260 265 270
Val Tyr Phe Phe Pro Ser Ser Thr His Pro Glu Asp Thr Asp Lys
275 280 285
Ile Gly Ala Val Leu Phe Thr Val Val Thr Pro Met Ile Asn Pro
290 295 300
Phe Ile Tyr Ser Leu Arg Asn Lys Asp Met Lys Gly Ala Leu Arg
305 310 315
Lys Leu Ile Asn Arg Lys Ile Ser Ser Leu
320 325
<210> 7
<211> 311
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475210CD1
<400> 7
7/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Met Glu Asn Gln Ser Ser Ile Ser Glu Phe Phe Leu Arg Gly Ile
1 5 10 15
Ser Ala Pro Pro Glu Gln Gln Gln Ser Leu Phe Gly Ile Phe Leu
20 25 30
Cys Met Tyr Leu Val Thr Leu Thr Gly Asn Leu Leu Ile Ile Leu
35 40 45
Ala I1e Gly Ser Asp Leu His Leu His Thr Pro Met Tyr Phe Phe
50 55 60
Leu Ala Asn Leu Ser Phe Val Asp Met Gly Leu Thr Ser Ser Thr
65 70 75
Val Thr Lys Met Leu Val Asn Ile Gln Thr Arg His His Thr Ile
80 85 90
Ser Tyr Thr Gly Cys Leu Thr Gln Met Tyr Phe Phe Leu Met Phe
95 100 105
Gly Asp Leu Asp Ser Phe Phe Leu Ala Ala Met Ala Tyr Asp Arg
110 115 120
Tyr Val Ala Ile Cys His Pro Leu Cys Tyr Ser Thr Val Met Arg
125 130 135
Pro Gln Val Cys Ala Leu Met Leu Ala Leu Cys Trp Val Leu Thr
140 145 150
Asn Ile Val Ala Leu Thr His Thr Phe Leu Met Ala Arg Leu Ser
155 160 165
Phe Cys Val Thr Gly Glu Ile Ala His Phe Phe Cys Asp Ile Thr
170 175 180
Pro Val Leu Lys Leu Ser Cys Ser Asp Thr His Ile Asn Glu Met
185 190 195
Met Val Phe Val Leu Gly Gly Thr Val Leu Ile Val Pro Phe Leu
200 205 210
Cys Ile Val Thr Ser Tyr Ile His Ile Val Pro Ala Ile Leu Arg
215 220 225
Val Arg Thr Arg Gly Gly Val Gly Lys Ala Phe Ser Thr Cys Ser
230 235 240
Ser His Leu Cys Val Val Cys Val Phe Tyr Gly Thr Leu Phe Ser
245 250 255
Ala Tyr Leu Cys Pro Pro Ser Ile Ala Ser Glu Glu Lys Asp Ile
260 265 270
Ala Ala Ala Ala Met Tyr Thr Ile Val Thr Pro Met Leu Asn Pro
275 280 285
Phe Ile Tyr Ser Leu Arg Asn Lys Asp Met Lys Gly Ala Leu Lys
290 295 300
Arg Leu Phe Ser His Arg Ser Ile Val Ser Ser
305 310
<210> 8
<211>.344
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475221CD1
<400> 8
Met Glu Leu Leu Thr Asn Asn Leu Lys Phe Ile Thr Asp Pro Phe
1 5 10 15
Val Cys Arg Leu Arg His Leu Ser Pro Thr Pro Ser Glu Glu His
20 25 30
Met Lys Asn Lys Asn Asn Val Thr Glu Phe Ile Leu Leu Gly Leu
35 40 45
Thr Gln Asn Pro Glu Gly Gln Lys Val Leu Phe Val Thr Phe Leu
50 55 60
Leu Ile Tyr Met Val Thr Ile Met Gly Asn Leu Leu Ile Ile Val
65 70 75
8/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Thr Ile Met Ala Ser Gln Ser Leu Gly Ser Pro Met Tyr Phe Phe
80 85 90
Leu Ala Ser Leu Ser Phe Ile Asp Thr Val Tyr Ser Thr Ala Phe
95 100 105
Ala Pro Lys Met Ile Val Asp Leu Leu Ser Glu Lys Lys Thr Ile
110 115 120
Ser Phe Gln Gly Cys Met Ala Gln Leu Phe Met Asp His Leu Phe
125 . 130 135
Ala Gly Ala Glu Val Ile Leu Leu Val Val Met Ala Tyr Asp Arg
140 145 150
Tyr Met Ala Ile Cys Lys Pro Leu His Glu Leu Ile Thr Met Asn
155 160 165
Arg Arg Val Cys Val Leu Met Leu Leu Ala Ala Trp Ile Gly Gly
170 175 180
Phe Leu His Ser Leu Val Gln Phe Leu Phe Ile Tyr Gln Leu Pro
185 190 195
Phe Cys Gly Pro Asn Val Ile Asp Asn Phe Leu Cys Asp Leu Tyr
200 205 210
Pro Leu Leu Lys Leu Ala Cys Thr Asn Thr Tyr Val Thr Gly Leu
215 220 225
Ser Met Ile Ala Asn Gly Gly Ala Ile Cys Ala Val Thr Phe Phe
230 235 240
Thr Ile Leu Leu Ser Tyr Gly Val Ile Leu His Ser Leu Lys Thr
245 250 255
Gln Ser Leu Glu Gly Lys Arg Lys Ala Phe Tyr Thr Cys Ala Ser
260 265 270
His Val Thr Val Val Ile Leu Phe Phe Val Pro Cys Ile Phe Leu
275 280 285
Tyr Ala Arg Pro Asn Ser Thr Phe Pro Ile Asp Lys Ser Met Thr
290 295 300
Val Val Leu Thr Phe Ile Thr Pro Met Leu Asn Pro Leu Ile Tyr
305 310 315
Thr Leu Lys Asn Ala Glu Met Lys Ser Ala Met Arg Lys Leu Trp
320 325 330
Ser Lys Lys Val Ser Leu Ala Gly Lys Trp Leu Tyr His Ser
335 340
<210> 9
<211> 313
<212> PRT
<213>,Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475244CD1
<400> 9 .
Met Ala Ser Glu Arg Asn Gln Ser Ser Thr Pro Thr Phe Ile Leu
1 5 10 15
Leu Gly Phe Ser G1u Tyr Pro Glu Ile Gln Val Pro Leu Phe Leu
20 25 30
Val Phe Leu Phe Val Tyr Thr Val Thr Val Val Gly Asn Leu Gly
35 40 45
Met Ile Ile Ile Ile Arg Leu Asn Ser Lys Leu His Thr Ile Met
50 55 60
Tyr Phe Phe Leu Ser His Leu Ser Leu Thr Asp Phe Cys Phe Ser
65 70 75
Thr Val Val Thr Pro Lys Leu Leu Glu Asn Leu Val Val Glu Tyr
80 85 90
Arg Thr Ile Ser Phe Ser Gly Cys Ile Met Gln Phe Cys Phe Ala
95 100 105
Cys Ile Phe Gly Val Thr Glu Thr Phe Met Leu Ala Ala Met A1a
110 115 120
9/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Tyr Asp Arg Phe Val Ala Val Cys Lys Pro Leu Leu Tyr Thr Thr
125 130 135
Ile Met Ser Gln Lys Leu Cys Ala Leu Leu Val Ala Gly Ser Tyr
140 145 150
Thr Trp Gly Ile Val Cys Ser Leu Ile Leu Thr Tyr Phe Leu Leu
155 160 165
Asp Leu Ser Phe Cys Glu Ser Thr Phe Ile Asn Asn Phe Ile Cys
170 175 180
Asp His Ser Val Ile Val Ser Ala Ser Tyr Ser Asp Pro Tyr Ile
185 190 195
Ser Gln Arg Leu Cys Phe Ile Ile Ala Ile Phe Asn Glu Val Ser
200 205 210
Ser Leu Ile Ile Ile Leu Thr Ser Tyr Met Leu Ile Phe Thr Thr
215 220 225
Ile Met Lys Met Arg Ser Ala Ser Gly Arg Gln Lys Thr Phe Ser
230 235 240
Thr Cys Ala Ser His Leu Thr Ala Ile Thr I1e Phe His Gly Thr
245 250 255
Ile Leu Phe Leu Tyr Cys Val Pro Asn Pro Lys Thr Ser Ser Leu
260 265 270
Ile Val Thr Val Ala Ser Val Phe Tyr Thr Val Ala Ile Pro Met
275 280 285
Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Ile Asn Asn
290 295 300
Met Phe Glu Lys Leu Val Val Thr Lys Leu Ile Tyr His
305 310
<210> 10
<211> 313
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475293CD1
<400> 10
Met Lys Arg Glu Asn Gln Ser Ser Val Ser Glu Phe Leu Leu Leu
1 5 10 15
Asp Leu Pro Ile Trp Pro Glu Gln Gln Ala Val Phe Phe Thr Leu
20 25 30
Phe Leu Gly Met Tyr Leu Ile Thr Val Leu Gly Asn Leu Leu Ile
35 ' 40 45
Ile Leu Leu Ile Arg Leu Asp Ser His Leu His Thr Pro Met Phe
50 55 60
Phe Phe Leu Ser His Leu Ala Leu Thr Asp Ile Ser Leu Ser Ser
65 70 75
Val Thr Val Pro Lys Met Leu Leu Ser Met Gln Thr Gln Asp Gln
80 85 90
Ser Ile Leu Tyr Ala Gly Cys Val Thr Gln Met Tyr Phe Phe Ile
95 100 105
Phe Phe Thr Asp Leu Asp Asn Phe Leu Leu Thr Ser Met Ala Tyr
110 115 120
Asp Arg Tyr Val Ala Ile Cys His Pro Leu Arg Tyr Thr Thr Ile
125 130 135
Met Lys Glu Gly Leu Cys Asn Leu Leu Val Thr Val Ser Trp Ile
140 145 150
Leu Ser Cys Thr Asn Ala Leu Ser His Thr Leu Leu Leu Ala Gln
155 160 165
Leu Ser Phe Cys Ala Asp Asn Thr Ile Pro His Phe Phe Cys Asp
170 175 180
Leu Val Ala Leu Leu Lys Leu Ser Cys Ser Asp Ile Ser Leu Asn
185 190 195
10/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Glu Leu Val Ile Phe Thr Val Gly Gln Ala Val Ile Thr Leu Pro
200 . 205 ' 210
Leu Ile Cys Ile Leu Ile Ser Tyr Gly His Ile Gly Val Thr Ile
215 220 225
Leu Lys Ala Pro Ser Thr Lys Gly Ile Phe Lys Ala Leu Ser Thr
230 235 240
Cys Gly Ser His Leu Ser Val Val Ser Leu Tyr Tyr Gly Thr Ile
245 250 255
Ile Gly Leu Tyr Phe Leu Pro Ser Ser Ser Ala Ser Ser Asp Lys
260 265 270
Asp Val Ile Ala Ser Val Met Tyr Thr Val Ile Thr Pro Leu Leu
275 280 285
Asn Pro Phe Ile Tyr Ser Leu Arg Asn Arg Asp Ile Lys Gly Ala
290 295 300
Leu Glu Arg Leu Phe Asn Arg Ala Thr Val Leu Ser Gln
305 310
<210> 11
<211> 309
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte TD No: 7475297CD1
<400> 11
Met G1u Asn Gln Asn Asn Val Thr Glu Phe Ile Leu Leu Gly Leu
1 5 10 15
Thr Glu Asn Leu Glu Leu Trp Lys Ile Phe Ser Ala Val Phe Leu
20 25 30
Val Met Tyr Val Ala Thr Val Leu Glu Asn Leu Leu Ile Val Val
35 40 45
Thr Ile Ile Thr Ser Gln Ser Leu Arg Ser Pro Met Tyr Phe Phe
50 55 ~ 60
Leu Thr Phe Leu Ser Leu Leu Asp Val Met Phe Ser Ser Val Val
65 70~ 75
Ala Pro Lys Val Ile Val Asp Thr Leu Ser Lys Ser Thr Thr Ile
80 85 90
Ser Leu Lys Gly Cys Leu Thr Gln Leu Phe Val Glu His Phe Phe
95 100 105
Gly Gly Val Gly Ile Ile Leu Leu Thr Val Met Ala Tyr Asp Arg
110 115 120
Tyr Val Ala Tle Cys Lys Pro Leu His Tyr Thr Ile Ile Met Ser
125 130 135
Pro Arg Val Cys Cys Leu Met Val Gly Gly A1a Trp Val Gly Gly
140 145 150
Phe Met His Ala Met Ile Gln Leu Leu Phe Met Tyr Gln Ile Pro
155 160 165
Phe Cys Gly Pro Asn Ile Ile Asp His Phe Ile Cys Asp Leu Phe
170 175 180
Gln Leu Leu Thr Leu Ala Cys Thr Asp Thr His Ile Leu Gly Leu
185 190 195
Leu Val Thr Leu Asn Ser Gly Met Met Cys Val Ala Ile Phe Leu
200 205 210
Ile Leu Ile Ala Ser Tyr Thr Val Ile Leu Cys Ser Leu Lys Ser
215 220 225
Tyr Ser Ser Lys Gly Arg His Lys Ala Leu Ser Thr Cys Ser Ser
230 235 ' 240
His Leu Thr Val Val Val Leu Phe Phe Val Pro Cys Ile Phe Leu
245 250 255
Tyr Met Arg Pro Val Val Thr His Pro Ile Asp Lys Ala Met Ala
260 265 270
11/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Val Ser Asp Ser Ile Ile Thr Pro Met Leu Asn Pro Leu Ile Tyr
275 280 285
Thr Leu Arg Asn Ala Glu Val Lys Ser Ala Met Lys Lys Leu Trp
290 295 300
Met Lys Trp Glu Ala Leu Ala Gly Lys
305
<210> 12
<211> 313
<212> PRT
<213> Homo sapiens
<220>
<221> misC_feature
<223> Incyte ID No: 7475193CD1
<400> 12
Met Glu Thr Ala Asn Tyr Thr Lys Val Thr Glu Phe Val Leu Thr
1 5 10 15
Gly Leu Ser Gln Thr Pro G1u Val Gln Leu Val Leu Phe Val Ile
20 25 30
Phe Leu Ser Phe Tyr Leu Phe Ile Leu Pro Gly Asn Ile Leu Ile
35 40 45
Ile Cys Thr Ile Ser Leu Asp Pro His Leu Thr Ser Pro Met Tyr
50 55 60
Phe Leu Leu Ala Asn Leu Ala Phe Leu Asp Ile Trp Tyr Ser Ser
65 70 75
Ile Thr Ala Pro Glu Met Leu Ile Asp Phe Phe Val Glu Arg Lys
80 85 90
Ile Ile Ser Phe Asp Gly Cys Ile Ala Gln Leu Phe Phe Leu His
95 100 105
Phe Ala Gly Ala Ser Glu Met Phe Leu Leu Thr Val Met Ala Phe
110 115 120
Asp Leu Tyr Thr Ala Ile Cys Arg Pro Leu His Tyr Ala Thr Ile
125 130 135
Met Asn Gln Arg Leu Cys Cys Ile Leu Val Ala Leu Ser Trp Arg
140 145 150
Gly Gly Phe Ile His Ser Ile Ile Gln Val Ala Leu Ile Val Arg
155 160 165
Leu Pro Phe Cys Gly Pro Asn Glu Leu Asp Ser Tyr Phe Cys Asp
170 175 180
Ile Thr Gln Val Val Arg Ile Ala Cys Ala Asn Thr Phe Pro Glu
185 190 195
Glu Leu Val Met Ile Cys Ser Ser Gly Leu Ile Ser Val Val Cys
200 205 210
Leu Ile Ala Leu Leu Met Ser Tyr Ala Phe Leu Leu Ala Leu Phe
215 220 225
Lys Lys Leu Ser Gly Ser Gly Glu Asn Thr Asn Arg Ala Met Ser
230 235 240
Thr Cys Tyr Ser His Ile Thr Ile Val Val~Leu Met Phe Gly Pro
245 250 255
Ser Ile Tyr Ile Tyr Ala Arg Pro Phe Asp Ser Phe Ser Leu Asp
260 265 270
Lys Val Val Ser Val Phe Asn Thr Leu Ile Phe Pro Leu Arg Asn
275 280 285
Pro Ile Ile Tyr Thr Leu Arg Asn Lys Glu Val Lys Ala Ala Met
290 295 300
Arg Lys Leu Val Thr Lys Tyr Ile Leu Cys Lys Glu Lys
305 310
<210> 13
<211> 342
<212> PRT
12/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475213CD1
<400> 13
Met Lys Arg Lys Asn Phe Thr Glu Val Ser Glu Phe Ile Phe Leu
1 5 10 15
Gly Phe Ser Ser Phe Gly Lys His Gln Ile Thr Leu Phe Val Val
20 25 30
Phe Leu Thr Val Tyr Ile Leu Thr Leu Val Ala Asn Ile Ile Ile
35 40 45
Val Thr Ile Tle Cys Ile Asp His His Leu His Thr Pro Met Tyr
50 55 60
Phe Phe Leu Ser Met Leu Ala Ser Ser Glu Thr Val Tyr Thr Leu
65 70 75
Val Ile Val Pro Arg Met Leu Leu Ser Leu Ile Phe His Asn Gln
80 85 90
Pro Ile Ser Leu Ala Gly Cys Ala Thr Gln Met Phe Phe Phe Val
95 100 105
Ile Leu Ala Thr Asn Asn Cys Phe Leu Leu Thr Ala Met Gly Tyr
110 115 120
Asp Arg Tyr Val Ala Ile Cys Arg Pro Leu Arg Tyr Thr Val Ile
125 130 135
Met Ser Lys Gly Leu Cys Ala Gln Leu Val Cys Gly Ser Phe Gly
140 145 150
Ile Gly Leu Thr Met Ala Val Leu His Val Thr Ala Met Phe Asn
155 160 165
Leu Pro Phe Cys Gly Thr Val Val Asp His Phe Phe Cys Asp Ile
170 175 180
Tyr Pro Val Met Lys Leu Ser Cys Ile Asp Thr Thr Ile Asn Glu
185 190 195
Ile Ile Asn Tyr Gly Val Ser Ser Phe Val Ile Phe Val Pro Ile
200 205 210
Gly Leu Ile Phe Ile Ser Tyr Val Leu Val Ile Ser Ser Ile Leu
215 220 225
Gln Ile Ala Ser Ala Glu Gly Arg Lys Lys Thr Phe Ala Thr Cys
230 235 240
Val Ser His Leu Thr Val Val Ile Val His Cys Gly Cys Ala Ser
245 250 255
Ile Ala Tyr Leu Lys Pro Lys Ser Glu Ser Ser Ile Glu Lys Asp
260 265 270
Leu Val Leu Ser Val Thr Tyr Thr Ile Ile Thr Pro Leu Leu Asn
275 280 285
Pro Val Val Tyr Ser Leu Arg Asn Lys Glu Ile Gln Glu Ser Leu
290 295 300
Gln Ala Gly Leu Arg Leu Leu Val Ser Val Leu Glu Asp Phe Ser
305 310 315
Phe Glu Ser Phe Leu Ala Pro Ile Leu Pro Glu Leu Ser Asp Ser
320 325 330
Gln Ile Phe Glu Leu Val Trp Leu Gly Asp Val Glu
335 340
<210> 14
<211> 310
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475272CD1
13/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<400> 14
Met Ala Glu Met Asn Leu Thr Leu Val Thr Glu Phe Leu Leu Ile
1 5 10 15
Ala Phe Thr Glu Tyr Pro Glu Trp Ala Leu Pro Leu Phe Leu Leu
20 25 30
Leu Leu Phe Met Tyr Leu Ile Thr Val Leu Gly Asn Leu Glu Met
35 40 ~ 45
Ile Ile Leu Ile Leu Met Asp His Gln Leu His Ala Pro Met Tyr
50 55 60
Phe Leu Leu Ser His Leu Ala Phe Met Asp Val Cys Tyr Ser Ser
65 70 75
Ile Thr Val Pro Gln Met Leu Ala Val Leu Leu Glu His Gly Ala
80 85 90
Ala Leu Ser Tyr Thr Arg Cys Ala Ala Gln Phe Phe Leu Phe Thr
95 100 105
Phe Phe Gly Ser Ile Asp Cys Tyr Leu Leu Ala Leu Met Ala Tyr
110 115 120
Asp Arg Tyr Leu Ala Val Cys Gln Pro Leu Leu Tyr Val Thr Ile
125 130 135
Leu Thr Gln Gln Ala Arg Leu Ser Leu Val Ala Gly Ala Tyr Val
140 145 150
Ala Gly Leu Tle Ser Ala Leu Val Arg Thr Val Ser Ala Phe Thr
155 160 165
Leu Ser Phe Cys Gly Thr Ser Glu Ile Asp Phe Ile Phe Cys Asp
170 175 180
Leu Pro Pro Leu Leu Lys Leu Thr Cys Gly Glu Ser Tyr Thr Gln
185 190 195
Glu Val Leu Tle Ile Met Phe Ala Ile Phe Val Ile Pro Ala Ser
200 205 210
Met Val Val Tle Leu Val Ser Tyr Leu Phe Ile Ile Val Ala Ile
215 220 225
Met Gly Ile Pro Ala Gly Ser Gln Ala Lys Thr Phe Ser Thr Cys
230 235 240
Thr Ser His Leu Thr Ala Val Ser Leu Phe Phe Gly Thr Leu Ile
245 250 255
Phe Met Tyr Leu Arg Gly Asn Ser Asp Gln Ser Ser Glu Lys Asn
260 265 270
Arg Val Val Ser Val Leu Tyr Thr Glu Val Ile Pro Met Leu Asn
275 280 285
Pro Leu Ile Tyr Ser Leu Arg Asn Lys Glu Val Lys Glu Ala Leu
290 295 300
Arg Lys Ile Leu Asn Arg Ala Lys Leu Ser
305 310
<210> 15
<211> 302
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475200CD1
<400> 15
Met Asp Ile Pro Gln Asn Ile Thr Glu Phe Phe Met Leu Gly Leu
1 5 10 15
Ser Gln Asn Ser Glu Val Gln Arg Val Leu~Phe Val Val Phe Leu
20 25 30
Leu Ile Tyr Val Val Thr Val Cys Gly Asn Met Leu Ile Val Val
35 40 45
Thr Ile Thr Ser Ser Pro Thr Leu Ala Ser Pro Val Tyr Phe Phe.
50 55 60
Leu Ala Asn Leu Ser Phe I1e Asp Thr Phe Tyr Ser Ser Ser Met
14/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
65 70 75
Ala Pro Lys Leu Ile Ala Asp Ser Leu Tyr Glu Gly Arg Thr Ile
80 85 90
Ser Tyr Glu Cys Cys Met Ala Gln Leu Phe Gly Ala His Phe Leu
95 100 105
Gly Gly Val Glu Ile Ile Leu Leu Thr Val Met Ala Tyr Asp Arg
110 115 120
Tyr Val Ala Ile Cys Lys Pro Leu His Asn Thr Thr Ile Met Thr
125 130 135
Arg His Leu Cys Ala Met Leu Val Gly Val Ala Trp Leu Gly Gly
140 145 150
Phe Leu His Ser Leu Val Gln Leu Leu Leu Val Leu Trp Leu Pro
155 160 165
Phe Cys Gly Pro Asn Val Ile Asn His Phe Ala Cys Asp Leu Tyr
170 175 180
Pro Leu Leu Glu Val Ala Cys Thr Asn Thr Tyr Val Ile Gly Leu
185 190 195
Leu Val Val Ala Asn Ser Gly Leu Ile Cys Leu Leu Asn Phe Leu
200 205 210
Met Leu Ala Ala Ser Tyr Ile Val Ile Leu Tyr Ser Leu Arg Ser
215 220 225
His Ser Ala Asp Gly Arg Cys Lys Ala Leu Ser Thr Cys Gly Ala
230 235 240
His Phe Ile Val Val Ala Leu Phe Phe Val Pro Cys Ile Phe Thr
245 250 255
Tyr Val His Pro Phe Ser Thr Leu Pro Ile Asp Lys Asn Met Ala
260 265 270
Leu Phe Tyr Gly Ile Leu Thr Pro Met Leu Asn Pro Leu Ile Tyr
275 280 285
Thr Leu Arg Asn Glu Glu Val Lys Asn Ala Met Arg Lys Leu Phe
290 295 300
Thr Trp
<210> 16
<211> 316
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475121CD1
<400> 16
Met Pro Ser Gln Asn Tyr Ser Ile Ile Ser Glu Phe Asn Leu Phe
1 5 10 15
Gly Phe Ser Ala Phe Pro Gln His Leu Leu Pro Ile Leu Phe Leu
20 25 30
Leu Tyr Leu Leu Met Phe Leu Phe Thr Leu Leu Gly Asn Leu Leu
35 40 45
Ile Met Ala Thr Ile Trp Ile Glu His Arg Leu His Thr Pro Met
50 55 60
Tyr Leu Phe Leu Cys Thr Leu Ser Val Ser Glu Ile Leu Phe Thr
65 70 75
Val Ala Ile Thr Pro Arg Met Leu Ala Asp Leu Leu Ser Thr His
80 85 90
His Ser Ile Thr Phe Val Ala Cys Ala Asn Gln Met Phe Phe Ser
95 100 105
Phe Met Phe Gly Phe Thr His Ser Phe Leu Leu Leu Val Met Gly
110 115 120
Tyr Asp Arg Tyr Val Ala Ile Cys His Pro Leu Arg Tyr Asn Val
125 130 135
Leu Met Ser Pro Arg Asp Cys Ala His Leu Val Ala Cys Thr Trp
15/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
140 145 150
Ala Gly Gly Ser Val Met Gly Met Met Val Thr Thr Ile Val Phe
155 160 165
His Leu Thr Phe Cys G1y Ser Asn Val Ile His His Phe Phe Cys
170 175 180
His Val Leu Ser Leu Leu Lys Leu Ala Cys Glu Asn Lys Thr Ser
185 190 195
Ser Val Ile Met Gly Val Met Leu Val Cys Val Thr Ala Leu Ile
200 205 210
Gly Cys Leu Phe Leu Ile Ile Leu Ser Tyr Val Phe Ile Val Ala
215 220 225
Ala Ile Leu Arg Ile Pro Ser Ala Glu Gly Arg His Lys Thr Phe
230 235 240
Ser Thr Cys Val Ser His Leu Thr Val Val Val Thr His Tyr Ser
245 250 255
Phe Ala Ser Phe Ile Tyr Leu Lys Pro Lys Gly Leu His Ser Met
260 265 270
Tyr Ser Asp Ala Leu Met Ala Thr Thr Tyr Thr Val Phe Thr Pro
275 280 285
Phe Leu Ser Pro Ile Ile Phe Ser Leu Arg Asn Lys Glu Leu Lys
290 295 300
Asn Ala Ile Asn Lys Asn Phe Tyr Arg Lys Phe Cys Pro Pro Ser
305 310 315
Ser
<210> 17
<211> 370
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475165CD1
<400> 17
Met Leu Val Leu Asn Ser Trp Ala Gln Val Ile His Trp Pro Gln
1 5 10 15
Pro Pro Lys Val Leu Gly Leu Gln Pro Leu Glu Lys Thr Gln Tyr
20 25 30
Gly Phe Leu Gly Thr Asp Arg Val Glu Glu Lys Thr Ser Val Ile
35 40 45
Thr Ile Arg Val Ser Val Thr His Arg His Asn Ser Tyr Met Glu
50 55 60
Ala Glu Asn Leu Thr Glu Leu Ser Lys Phe Leu Leu Leu Gly Leu
65 70 75
Ser Asp Asp Pro Glu Leu Gln Pro Val Leu Phe Gly Leu Phe Leu
80 85 90
Ser Met Tyr Leu Val Thr Val Leu Gly Asn Leu Leu Ile Ile Leu
95 100 105
Ala Val Ser Ser Asp Ser His Leu His Thr Pro Met Tyr Phe Phe
110 115 120
Leu Ser Asn Leu Ser Phe Val Asp Ile Cys Phe Ile Ser Thr Thr
125 130 135
Val Pro Lys Met Leu Val Ser Ile Gln Ala Arg Ser Lys Asp Ile
140 145 150
Ser Tyr Met Gly Cys Leu Thr Gln Val Tyr Phe Leu Met Met Phe
155 160 165
Ala Gly Met Asp Thr Phe Leu Leu Ala Val Met Ala Tyr Asp Arg
170 175 180
Phe Val Ala Ile Cys His Pro Leu His Tyr Thr Val Ile Met Asn
185 190 195
Pro Cys Leu Cys Gly Leu Leu Val Leu Ala Ser Trp Phe Ile Ile
16/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
200 205 210
Phe Trp Phe Ser Leu Val His Ile Leu Leu Met Lys Arg Leu Thr
215 220 225
Phe Ser Thr Gly Thr Glu Ile Pro His Phe Phe Cys Glu Pro Ala
230 235 240
Gln Val Leu Lys Val Ala Cys Ser Asn Thr Leu Leu Asn Asn Ile
245 250 255
Val Leu Tyr Val Ala Thr Ala Leu Leu Gly Val Phe Pro Val Ala
260 265 270
Gly Ile Leu Phe Ser Tyr Ser Gln Ile Val Ser Ser Leu Met Gly
275 280 285
Met Ser Ser Thr Lys Gly Lys Tyr Lys Ala Phe Ser Thr Cys Gly
290 295 300
Ser His Leu Cys Val Val Ser Leu.Phe Tyr Gly Thr Gly Leu Gly
305 310 315
Val Tyr Leu Ser Ser Ala Val Thr His Ser Ser Gln Ser Ser Ser
320 325 330
Thr Ala Ser Val Met Tyr Ala Met Val Thr Pro Met Leu Asn Pro
335 340 345
Phe Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Gly Ala Leu Glu
350 355 360
Arg Leu Leu Ser Arg Ala Asp Ser Cys Pro
365 370
<210> 18
<211> 318
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475273CD1
<400> 18
Met Lys Asn Val Thr Glu Val Thr Leu Phe Val Leu Lys Gly Phe
1 5 10 15
Thr Asp Asn Leu Glu Leu Gln Thr Ile Phe Phe Phe Leu Phe Leu
20 25 30
Ala Ile Tyr Leu Phe Thr Leu Met Gly Asn Leu Gly Leu Ile Leu
35 40 45
Val Val Ile Arg Asp Ser Gln Leu His Lys Pro Met Tyr Tyr Phe
50 55 60
Leu Ser Met Leu Ser Ser Val Asp Ala Cys Tyr Ser Ser Val Ile
65 70 75
Thr Pro Asn Met Leu Val Asp Phe Thr Thr Lys Asn Lys Val Ile
80 85 90
Ser Phe Leu Gly Cys Val Ala Gln Val Phe Leu Ala Cys Ser Phe
95 100 105
Gly Thr Thr Glu Cys Phe Leu Leu Ala Ala Met Ala Tyr Asp Arg
110 115 120
Tyr Val Ala Ile Tyr Asn Pro Leu Leu Tyr Ser Val Ser Met Ser
125 130 135
Pro Arg Val Tyr Met Pro Leu Ile Asn Ala Ser Tyr Val Ala Gly
140 145 150
Ile Leu His Ala Thr Ile His Thr Val Ala Thr Phe Ser Leu Ser
155 160 165
Phe Cys Gly Ala Asn Glu Ile Arg Arg Val Phe Cys Asp Ile Pro
170 175 180
Pro Leu Leu Ala Ile Ser Tyr Ser Asp Thr His Thr Asn Gln Leu
185 190 195
Leu Leu Phe Tyr Phe Val Gly Ser Ile Glu Leu Val Thr Ile Leu
200 205 210
Ile Val Leu TIe Ser Tyr Gly Leu Ile Leu Leu Ala Ile Leu Lys
17!33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
215 220 225
Met Tyr Ser Ala Glu Gly Arg Arg Lys Val Phe Ser Thr Cys Gly
230 235 240
Ala His Leu Thr Gly Val Ser Ile Tyr Tyr Gly Thr Ile Leu Phe
245 250 255
Met Tyr Val Arg Pro Ser Ser Ser Tyr Ala Ser Asp His Asp Met
260 265 270
Ile Val Ser Ile Phe Tyr Thr Ile Val Ile Pro Leu Leu Asn Pro
275 280 285
Val Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Asp Ser Met Lys
290 295 300
Lys Met Phe Gly Lys Asn Gln Val Ile Asn Lys Val Tyr Phe His
305 310 315
Thr Lys Lys
<210> 19
<211> 321
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476077CD1
<400> 19
Met Glu Ser Pro Asn His Thr Asp Val Asp Pro Ser Val Phe Phe
1 5 10 15
Leu Leu Gly Ile Pro Gly Leu Glu G1n Phe His Leu Trp Leu Ser
20 25 30
Leu Pro Val Cys Gly Leu Gly Thr Ala Thr Ile Val Gly Asn Ile
35 40 45
Thr Ile Leu Val Val Val Ala Thr Glu Pro Val Leu His Lys Pro
50 55 60
Val Tyr Leu Phe Leu Cys Met Leu Ser Thr Ile Asp Leu Ala Ala
65 70 75
Ser Val Ser Thr Val Pro Lys Leu Leu Ala Ile Phe Trp Cys Gly
80 85 90
Ala Gly His Ile Ser Ala Ser Ala Cys Leu Ala Gln Met Phe Phe
95 100 105
Ile His Ala Phe Cys Met Met Glu Ser Thr Val Leu Leu Ala Met
110 115 120
Ala Phe Asp Arg Tyr Val Ala Ile Cys His Pro Leu Arg Tyr Ala
125 130 135
Thr Ile Leu Thr Asp Thr Ile Ile Ala His Ile Gly Val Ala Ala
140 145 150
Val Val Arg Gly Ser Leu Leu Met Leu Pro Cys Pro Phe Leu Ile
155 160 165
G1y Arg Leu Asn Phe Cys Gln Ser His Val Ile Leu His Thr Tyr
170 175 180
Cys Glu His Met Ala Val Val Lys Leu Ala Cys Gly Asp Thr Arg
185 190 195
Pro Asn Arg Val Tyr Gly Leu Thr Ala Ala Leu Leu Val I1e Gly
200 205 210
Val Asp Leu Phe Cys Ile Gly Leu Ser Tyr Ala Leu Ser Ala Gln
215 220 225
Ala Val Leu Arg Leu Ser Ser His Glu Ala Arg Ser Lys Ala Leu
230 235 240
Gly Thr Cys Gly Ser His Val Cys Val Ile Leu Ile Ser Tyr Thr
245 250 255
Pro Ala Leu Phe Ser Phe Phe Thr His Arg Phe Gly His His Val
260 265 270
Pro Val His Ile His Ile Leu Leu Ala Asn Val Tyr Leu Leu Leu
1 x/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
275 280 285
Pro Pro Ala Leu Asn Pro Val Val Tyr Gly Val Lys Thr Lys Gln
290 295 300
Ile Arg Lys Arg Val Val Arg Val Phe Gln Ser Gly Gln Gly Met
305 310 315
Gly Ile Lys Ala Ser Glu
320
<210> 20
<211> 313
<212> PRT
<213> Homo Sapiens
<220>
<22l> misc_feature
<223> Incyte ID No: 7476113CD1
<400> 20
Met Leu Leu Thr Asp Arg Asn Thr Ser Gly Thr Thr Phe Thr Leu
1 5 10 15
Leu Gly Phe Ser Asp Tyr Pro Glu Leu Gln Val Pro Leu Phe Leu
20 25 30
Val Phe Leu Ala Ile Tyr Asn Val Thr Val Leu Gly Asn Ile Gly
35 40 45
Leu Ile Val Ile Ile Lys Ile Asn Pro Lys Leu His Thr Pro Met
50 55 60
Tyr Phe Phe Leu Ser Gln Leu Ser Phe Val Asp Phe Cys Tyr Ser
65 70 75
Ser Ile Ile Ala Pro Lys Met Leu Val Asn Leu Val Val Lys Asp
80 85 90
Arg Thr Ile Ser Phe Leu Gly Cys Val Val Gln Phe Phe Phe Phe
95 100 105
Cys Thr Phe Val Val Thr Glu Ser Phe Leu Leu Ala Val Met Ala
110 l15 120
Tyr Asp Arg Phe Val Ala Ile Cys Asn Pro Leu Leu Tyr Thr Val
125 130 135
Asn Met Ser Gln Lys Leu Cys Val Leu Leu Val Val Gly Ser Tyr
140 145 150
A1a Trp Gly Val Ser Cys Ser Leu Glu Leu Thr Cys Ser Ala Leu
155 160 165
Lys Leu Cys Phe His Gly Phe Asn Thr Ile Asn His Phe Phe Cys
170 175 180
Glu Phe Ser Ser Leu Leu Ser Leu Ser Cys Ser Asp Thr Tyr Ile
185 190 195
Asn Gln Trp Leu Leu Phe Phe Leu Ala Thr Phe Asn Glu Ile Ser
200 205 210
Thr Leu Leu Ile Val Leu Thr Ser Tyr Ala Phe Ile Val Val Thr
215 220 225
Ile Leu Lys Met Arg Ser Val Ser Gly Arg Arg Lys Ala Phe Ser
230 235 240
Thr Cys Ala Ser His Leu Thr Ala Ile Thr Ile Phe His Gly Thr
245 250 255
Ile Leu Phe Leu Tyr Cys Val Pro Asn Ser Lys Asn Ser Arg His
260 265 270
Thr Val Lys Val Ala Ser Val Phe Tyr Thr Val Val Ile Pro Met
275 280 285
Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Asp
290 295 300
Thr Val Thr Glu Ile Leu Asp Thr Lys Val Phe Ser Tyr
305 310
<210> 21
<211> 328
19133
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476117CD1
<400> 21
Met Phe Leu Thr Glu Arg Asn Thr Thr Ser Glu Ala Thr Phe Thr
1 5 10 15
Leu Leu Gly Phe Ser Asp Tyr Leu Glu Leu Gln Ile Pro Leu Phe
20 25 30
Phe Val Phe Leu Ala Val Tyr Gly Phe Ser Val Val Gly Asn Leu
35 40 45
Gly Met Ile Val Ile Ile Lys Ile Asn Pro Lys Leu His Thr Pro
50 55 60
Met Tyr Phe Phe Leu Asn His Leu Ser Phe Val Asp Phe Cys Tyr
65 70 75
Ser Ser Tle Ile Ala Pro Met Met Leu Val Asn Leu Val Val G1u
80 85 90
Asp Arg Thr Ile Ser Phe Ser Gly Cys Leu Val Gln Phe Phe Phe
95 100 105
Phe Cys Thr Phe Val Val Thr Glu Leu Ile Leu Phe Ala Val Met
110 115 120
Ala Tyr Asp His Phe Val Ala Ile Cys Asn Pro Leu Leu Tyr Thr
125 130 135
Val Ala Ile Ser Gln Lys Leu Cys Ala Met Leu Val Val Val Leu
140 145 150
Tyr Ala Trp Gly Val Ala Cys Ser Leu Thr Leu Ala Cys Ser Ala
155 160 165
Leu Lys Leu Ser Phe His Gly Phe Asn Thr Ile Asn His Phe Phe
170 175 180
Cys Glu Leu Ser Ser Leu Tle Ser Leu Ser Tyr Pro Asp Ser Tyr
185 190 195
Leu Ser Gln Leu Leu Leu Phe Thr Val Ala Thr Phe Asn Glu Tle
200 205 210
Ser Thr Leu Leu Ile Ile Leu Thr Ser Tyr Ala Phe Ile Ile Val
215 220 225
Thr Thr Leu Lys Met Pro Ser A1a Ser Gly His Arg Lys Val Phe
230 235 240
Ser Thr Cys Ala Ser His Leu Thr Ala Ile Thr Ile Phe His Gly
245 250 255
Thr Ile Leu Phe Leu Tyr Cys Val Pro Asn Ser Lys Asn Ser Arg
260 265 270
His Thr Val Lys Val Ala Ser Val Phe Tyr Thr Val Val Ile Pro
275 280 285
Leu Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys
290 295 300
Asp Ala Ile Arg Lys Ile Ile Asn Thr Lys Tyr Phe His Ile Lys
305 310 315
His Arg His Trp Tyr Pro Phe Asn Phe Val Ile GIu Gln
320 325
<210> 22
<211> 324
<212> PRT
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476079CD1
<400> 22
20/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Met Asn His Met Ser Ala Ser Leu Lys Ile Ser Asn Ser Ser Lys
1 5 10 15
Phe Gln Val Ser Glu Phe Ile Leu Leu Gly Phe Pro G1y Ile His
20 25 30
Ser Trp Gln His Trp Leu Ser Leu Pro Leu Ala Leu Leu Tyr Leu
35 40 45
Ser Ala Leu Ala Ala Asn Thr Leu Ile Leu Ile Ile Ile Trp Gln
50 55 60
Asn Pro Ser Leu Gln Gln Pro Met Tyr Ile Phe Leu Gly Ile Leu
65 70 75
Cys Met Val Asp Met Gly Leu Ala Thr Thr Ile 21e Pro Lys Ile
80 85 90
Leu Ala Ile Phe Trp Phe Asp Ala Lys Val Ile Ser Leu Pro Glu
95 100 105
Cys Phe Ala Gln Ile Tyr Ala Ile His Phe Phe Val Gly Met Glu
110 115 120
Ser Gly Ile Leu Leu Cys Met Ala Phe Asp Arg Tyr Val Ala Ile
125 130 135
Cys His Pro Leu Arg Tyr Pro Ser Ile Val Thr Ser Ser Leu Ile
140 145 150
Leu Lys Ala Thr Leu Phe Met Val Leu Arg Asn Gly Leu Phe Val
155 160 165
Thr Pro Val Pro Val Leu Ala Ala Gln Arg Asp Tyr Cys Ser Lys
170 175 180
Asn Glu Ile Glu His Cys Leu Cys Ser Asn Leu Gly Val Thr Ser
185 190 195
Leu Ala Cys Asp Asp Arg Arg Pro Asn Ser Ile Cys Gln Leu Val
200 205 210
Leu Ala Trp Leu Gly Met Gly Ser Asp Leu Ser Leu Ile 21e Leu
215 220 225
Ser Tyr Ile Leu Ile Leu Tyr Ser Val Leu Arg Leu Asn Ser Ala
230 235 240
Glu Ala Ala A1a Lys Ala Leu Ser Thr Cys Ser Ser His Leu Thr
245 250 255
Leu Ile Leu Phe Phe Tyr Thr Ile Val Val Va1 Ile Ser Val Thr
260 265 270
His Leu Thr Glu Met Lys A1a Thr Leu Ile Pro Val Leu Leu Asn
275 280 285
Val Leu His Asn Ile Ile Pro Pro Ser Leu Asn Pro Thr Val Tyr
290 295 300
Ala Leu Gln Thr Lys Glu Leu Arg Ala Ala Phe Gln Lys Val Leu
305 310 315
Phe Ala Leu Thr Lys Glu Ile Arg Ser
320
<210> 23
<211> 315
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476112CD1
<400> 23
Met Gln Gly Leu Asn His Thr Ser Val Ser Glu Phe Ile Leu Val
1 5 10 15
Gly Phe Ser Ala Phe Pro His Leu Gln Leu Met Leu Phe Leu Leu
20 25 30
Phe Leu Leu Met Tyr Leu Phe Thr Leu Leu Gly Asn Leu Leu Ile
35 40 45
Met Ala Thr Val Trp Ser Glu Arg Ser Leu His Met Pro Met Tyr
50 55 60
21/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
Leu Phe Leu Cys Ala Leu Ser Ile Thr Glu Ile Leu Tyr Thr Val
65 70 75
Ala Ile Ile Pro Arg Met Leu Ala Asp Leu Leu Ser Thr Gln Arg
80 85 90
Ser Ile Ala Phe Leu Ala Cys Ala Ser Gln Met Phe Phe Ser Phe
95 100 105
Ser Phe Gly Phe Thr His Ser Phe Leu Leu Thr Val Met Gly Tyr
110 115 120
Asp Arg Tyr Val Ala Tle Cys His Pro Leu Arg Tyr Asn Val Leu
125 130 135
Met Ser Leu Arg Gly Cys Thr Cys Arg Val Gly Cys Ser Trp Ala
140 145 150
Gly Gly Leu Val Met Gly Met Val Val Thr Ser Ala Ile Phe His
155 160 165
Leu Ala Phe Cys Gly His Lys Glu Ile His His Phe Phe Cys His
170 175 180
Val Pro Pro Leu Leu Lys Leu Ala Cys Gly Asp Asp Val Leu Val
185 190 195
Val Ala Lys Gly Val Gly Leu Val Cys Ile Thr Ala Leu Leu Gly
200 205 210
Cys Phe Leu Leu Ile Leu Leu Ser Tyr Ala Phe Ile Val Ala Ala
215 220 225
Ile Leu Lys Ile Pro Ser Ala Glu Gly Arg Asn Lys Ala Phe Ser
230 235 240
Thr Cys Ala Ser His Leu Thr Val Val Val Val His Tyr Gly Phe
245 250 255
Ala Ser Val Ile Tyr Leu Lys Pro Lys Gly Pro Gln Ser Pro Glu
260 265 ~ 270
Gly Asp Thr Leu Met Gly Ile Thr Tyr Thr Val Leu Thr Pro Phe
275 280 285
Leu Ser Pro Ile Ile Phe Ser Leu Arg Asn Lys Glu Leu Lys Val
290 295 300
Ala Met Lys Lys Thr Cys Phe Thr Lys Leu Phe Pro Gln Asn Cys
305 310 315
<210> 24
<211> 2739
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475208CB1
<400> 24
atgctgggcc ctgctgtcct gggcctcagc ctctgggctc tcctgcaccc tgggacgggg 60
gccccattgt gcctgtcaca gcaacttagg atgaaggggg actacgtgct gggggggctg 120
ttccccctgg gcgaggccga ggaggctggc ctccgcagcc ggacacggcc cagcagccct 180
gtgtgcacca ggttctcctc aaacggcctg ctctgggcac tggccatgaa aatggccgtg 240
gaggagatca acaacaagtc ggatctgctg cccgggctgc gcctgggcta cgacctcttt 300
gatacgtgct cggagcctgt ggtggccatg aagcccagcc tcatgttcct ggccaaggca 360
ggcagccgcg acatcgccgc ctactgcaac tacacgcagt accagccccg tgtgctggct 420
gtcatcgggc cccactcgtc agagctcgcc atggtcaccg gcaagttctt cagcttcttc 480
CtCatgCCCC aggtggCg'CC CCCCaCCatC aCCCdCCCCC aCCCagCCCt gCCCgtggga 540
gcccctgtgt caggagatgc ctcttggccc ttgcaggtca gctacggtgc tagcatggag 600
ctgctgagcg cccgggagac cttcccctcc ttcttccgca ccgtgcccag cgaccgtgtg 660
cagctgacgg ccgccgcgga gctgctgcag gagttcggct ggaactgggt ggccgccctg 720
ggcagcgacg acgagtacgg ccggcagggc ctgagcatct tctcggccct ggctcggcac 780
gcggcatctg catcgcgcac.gagggcctgg tgccgctgcc ccgtgcagga cgtcctgcac 840
caggtgaacc agagcagcgt gcaggtggtg ctgctgttcg CCtCCgtgCa CgCCgCCCaC 900
gccctcttca actacagcat cagcagcagg ctctcgccca aggtgtgggt ggccagcgag 960
gcctggctga cctctgacct ggtcatgggg ctgcccggca tggcccagat gggcacggtg 1020
22/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
cttggcttcc tccagagggg tgcccagctg cacgagttcc cccagtacgt gaagacgcac 1080
ctggccctgg ccaccgaccc ggccttctgc tctgccctgg gcgagaggga gcagggtctg 1140
gaggaggacg tggtgggcca gcgctgcccg cagtgtgact gcatcacgct gcagaaccgt 1200
gcccaggccc tgcacaacac tcttcagtgc aacgcctcag gctgccccgc gcaggacccc 1260
gtgaagccct ggcagctcct ggagaacatg tacaacctga ccttccacgt gggcgggctg 1320
ccgctgcggt tcgacagcag cggaaacgtg gacatggagt acgacctgaa gctgtgggtg 1380
tggcagggct cagtgcccag gctccacgac gtgggcaggt tcaacggcag cctcaggaca 1440
gagcgcctga agatccgctg gcacacgtct gacaaccagc cgagcagagc cagaccccag 1500
gcctgtgcgc agaagcccgt gtcccggtgc tcgcggcagt gccaggaggg ccaggtgcgc 1560
cgggtcaagg ggttccactc ctgctgctac gactgtgtgg actgcgaggc gggcagctac 1620
cggcaaaacc cagacgacat cgcctgcacc ttttgtggcc aggatgagtg gtccccggag 1680
cgaagcacac gctgcttccg ccgcaggtct cggttcctgg catggggcga gccggctgtg 1740
ctgctgctgc tcctgctgct gagcctggcg ctgggccttg tgctggctgc tttggggctg 1800
ttcgttcacc atcgggacag cccactggtt caggcctcgg gggggcccct ggcctgcttt 1860
ggcctggtgt gcctgggcct ggtctgcctc agcgtcctcc tgttccctgg ccagcccagc 1920
cctgcccgat gcctggccca gcagcccttg tcccacctcc cgctcacggg ctgcctgagc 1980
acactcttcc tgcaggcggc cgagatcttc gtggagtcag aactgcctct gagctgggca 2040.
gaccggctga gtggctgcct gcgggggccc tgggcctggc tggtggtgct gctggccatg 2100
ctggtggagg tcgcactgtg cacctggtac ctggtggcct tcccgccgga ggtggtgact 2160
ggactggcac atgctgccca cggaggcgct ggtgcactgc cgcacacgct cctgggtcag 2220
cttcggccta gcgcacgcca ccatgccacg ctggcctttc tctgcttcac tgggcacttt 2280
cctggtgcgg agccagccgg gccgctacaa ccgtgccacg tggcctcaca catttgccat 2340
gctggcctac ttcatcacac tgggtctcac tttgtgcccc tcctggcaca atgtgcaggt 2400
ggtcactcag gcccagccgt gcagatgggc gccctcctgc tctgtgtcct gggcatcctg 2460
gCtgCCttCC aCCtgCCCag gtgttaCCtg ctcatgcggc agccagggct caacaccccc 2520
gagttcttcc tgggaggggg ccctggggat gccacaaggc cagaatgacg ggaacacagg 2580
aaatcagggg aaacatgggt gacccaacca ctgtgatctc agccccggtg aacccagact 2640
tagctgcgat cccccccaag ccagcaatga cccgtgtctc gctacagaga ccctcccgct 2700
ctaggttctg accccaggtt.gtctcctgac ctgaccccc 2739
<210> 25
<211> 993
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475101CB1
<400> 25
atggaaggtt tttatctgcg cagatcacac gaactacaag ggatgggaaa accaggcaga 60
gtgaaccaaa ccactgtttc agacttcctc cttctaggac tctctgagtg gccagaggag 120
cagcctcttc tgtttggcat cttccttggc atgtacctgg tcaccatggt ggggaacctg 180
ctcattatcc tggccatcag ctctgaccca cacctccata ctcccatgta cttctttctg 240
gccaacctgt cattaactga tgcctgtttc acttctgcct ccatccccaa aatgctggcc 300
aacattcata cccagagtca gatcatctcg tattctgggt gtcttgcaca gctatatttc 360
ctccttatgt ttggtggcct tgacaactgc ctgctggctg tgatggcata tgaccgctat 420
gtggccatct gccaaccact ccattacagc acatctatga gtccccagct ctgtgcacta 480
atgctgggtg tgtgctgggt gctaaccaac tgtcctgccc tgatgcacac actgttgctg 540
acccgcgtgg ctttctgtgc ccagaaagcc atccctcatt tctattgtga tcctagtgct 600
ctcctgaagc ttgcctgctc agatacccat gtaaacgagc tgatgatcat caccatgggc 660
ttgctgttcc tcactgttcc cctcctgctg atcgtcttct cctatgtccg cattttctgg 720
gctgtgtttg tcatctcatc tcctggaggg agatggaagg ccttctctac ctgtggttct 780
catctcacgg tggttctgct cttctatggg tctcttatgg gtgtgtattt acttcctcca 840
tcaacttact ctacagagag ggaaagtagg gctgctgttc tctatatggt gattattccc 900
acgctaaacc cattcattta tagcttgagg aacagagaca tgaaggaggc tttgggtaaa 960
ctttttgtca gtggaaaaac attcttttta tga 993
<210> 26
<211> 990
<212> DNA
<213> Homo sapiens
23/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<220>
<221> misc_feature
<223> Incyte ID No: 7475152CB1
<220>
<221> unsure
<222> 1
<223> a, t, c, g, or other
<400> 26
ngtgagtaca agtccatggg aatgtccaac ctgacaagac tctctgaatt tattctcttg 60
ggactctcct ctcggtctga agaccagagg ccactctttg ccctctttct tatcatatac 120
ctggtcactt tgatgggaaa tctgctcatc atcttggcta tccactctga tcctcgactt 180
caaaacccta tgtatttttt cctaagcatc ttgtcctttg ctgatatttg ctacacaaca 240
gtcatagtcc caaagatgct cgtgaacttc ttatcagaga aaaagaccat ttcctatgct 300
gaatgtctgg cacagatgta tttcttcctg gtttttggaa acatagatag ttatctcctg 360
gcggctatgg ccatcaaccg ctgtgtagcc atttgtaacc cattccatta tgtcactgtt 420
atgaaccgca gatgctgtgt gttgctacta gcattcccca tcactttctc ctatttccac 480
tctctcctac atgtcctcct ggtgaatcgg ctcacctttt gtacatcaaa tgttatccat 540
catttttttt gtgatgtcaa ccctgtgctg aaactgtcct gctcctccac ctttgtcaat 600
gaaattgtgg ccatgacaga agggctggcc tctgtgatgg ctccatttgt ctgtatcatc 660
atctcttatc taagaattct catcgctgtt ctcaagattc cctcagcagc tggaaaacac 720
aaagccttct ccacctgcag ctcccatctc actgtggtga ttctgtttta tgggagtatt 780
agctatgtct atttgcagcc tttgtccagc tatactgtca aggaccgaat agcaacaatc 840
aactacactg tgttgacatc agtgttgaac ccatttatct acagtttaag aaacaaagac 900
atgaaacggg gcttacagaa attgataaac aagattaagt ctcaaatgag taggttctct 960
acaaagacca ataaaatctg tggaccctga 990
<210> 27
<211> 1125
<212> DNA
<213> Homo Sapiens
i
<220>
<221> misc_feature
<223> Incyte ID No: 7475164CB1
<400> 27
atggccatct gtaacccgct tctgtataac attgccatgt cccctaaagt gtgttccagc 60
catatgcttg gttcctactt ctggcccttt tctggggcca tggcccatac caggtgcatg 120
ctgaaactga cctcctgtga ggcaaacacc atcaaccact acttctgtga cacccttcat 180
ctgctccagc tctcttgcac cagcacctac gtcagggctg agtttatcct ggcaggcttg 240
acacaacgcc cagaacttca actgccactc ttcctcctgt tccttggaat atatgtggtc 300
acagtggtgg ggaacctggg catgatcttc ttaattgctc tcagttctca actttaccct 360
ccagtgtatt attttctcag tcatttgtct ttcattgatc tctgctactc ctctgtcatt 420
acccctaaga tgctggtgaa ctttgttcca gaggagaaca ttatctcctt tctggaatgc 480
attactcaac tttatttctt ccttattttt gtaattgcag aaggctacct tctgacagcc 540
atggaatatg accgttatgt tgctatctgt cgcccactgc tttacaatat tgtcatgtcc 600
cacagggtct gttccataat gatggctgtg gtatactcac tgggttttct gtgggccaca 660
gtccatacta cccgcatgtc agtgttgtca ttctgtaggt ctcatacggt cagtcattat 720
ttttgtgata ttctcccctt attgactctg tcttgctcca gcacccacat caatgagatt 780
ctgctgttca ttattggagg agttaatacc ttagcaacta cactggcggt ccttatctct 840
tatgctttca ttttctctag tatccttggt attcattcca ctgaggggca atccaaagcc 900
tttggcactt gtagctccca tctcttggct gtgggcatct tttttgggtc tataacattc 960
atgtatttca agcccccttc cagcactact atggaaaaag agaaggtgtc ttctgtgttc 1020
tacatcacaa taatccccat gctgaatcct ctaatctata gcctgaggaa caaggatgtg 1080
aaaaatgcac tgaagaagat gactagggga aggcagtcat cctga 1125
<210> 28
<211> 939
<212> DNA
<213> Homo sapiens
24/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<220>
<221> misc_feature
<223> Incyte ID No: 7475170CB1
<400> 28
atggatcaga aaaatggaag ttctttcact ggatttatcc tactgggttt ctctgacagg 60
cctcagctgg agctagtcct ctttgtggtt cttttgatct tctatatctt cactttgctg 120
gggaacaaaa ccatcattgt attatctcac ttggacccac atcttcacac tcctatgtat 180
tttttcttct ccaacctaag ctttttggat ctgtgttaca caaccggcat tgttccacag 240
ctcctggtta atctcagggg agcagacaaa tcaatctcct atggtggttg tgtagttcag 300
ctgtacatct ctctaggctt gggatctaca gaatgcgttc tcttaggagt gatggtattt 360
gaccgctatg cagctgtttg caggcccctc cactacacag tagtcatgca cccttgtctg 420
tatgtgctga tggcttctac ttcatgggtc attggttttg ccaactccct attgcagacg 480
gtgctcatct tgcttttaac actttgtgga agaaataaat tagaacactt tctttgtgag 540
gttcctccat tgctcaagct tgcctgtgtt gacactacta tgaatgaatc tgaactcttc 600
tttgtcagtg tcattattct tcttgtacct gttgcattaa tcatattctc ctatagtcag 660
attgtcaggg cagtcatgag gataaagtta gcaacagggc agagaaaagt gtttgggaca 720
tgtggctccc acctcacagt ggtttccctg ttctacggca cagctatcta tgcttacctc 780
cagcccggca acaactactc tcaggatcag ggcaagttca tctctctctt ctacaccatc 840
attacaccca tgatcaaccc cctcatatat acactgagga acaaggatgt gaaaggagca 900
cttaagaagg tgctctggaa gaactacgac tccagatga 939
<210> 29
<211> 978
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475197CB1
<400> 29 ,
atgaagactt ttagttcctt tcttcagatc ggcagaaata tgcatcaagg aaaccaaacc 60
accatcactg aattcattct cctgggattt ttcaagcagg atgagcatca aaacctcctc 120
tttgtgcttt tcttgggtat gtacctggtc actgtgattg ggaacgggct catcattgtg 180
gctatcagct tggatacgta ccttcatacc cccatgtatc tcttccttgc caatctatcc 240
tttgctgata tttcctccat ttccaactca gtccccaaaa tgctggtgaa tattcaaacc 300
aagagtcaat ccatctctta tgagagctgc atcacacaga tgtacttttc tattgtgttt 360
gtcgtcattg acaatttgct cttggggacc atggcctatg accactttgt ggcgatctgc 420
caccctctga attatacaat tctcatgcgg cccaggttcg gcattttgct cacagtcatc 480
tcatggttcc tcagtaatat tattgctctg acacacaccc ttctgctcat tcaattgctc 540
ttctgtaacc acaacactct cccacacttc ttctgtgact tggcccctct gctcaaactg 600
tcctgttcag atacattgat caatgagctt gtgttgttta ttgtgggttt atcagttatc 660
atcttcccct ttacactcag Cttcttttcc tatgtctgca tcatcagagc tgtcctgaga 720
gtatcttcca cacagggaaa gtggaaagcc ttctccactt gtggctctca cctgacagtt 780
gtattactgt tctacggaac cattgtaggc gtgtaCtttt tCCCCtCCtC CaCtCaCCCt H4O
gaggacactg ataagattgg tgctgtccta ttcactgtgg tgacacccat gataaacccc 900
ttcatctaca gcttgaggaa taaggatatg aaaggtgccc tgagaaagct catcaataga 960
aaaatttctt ccctttga 978
<210> 30
<211> 936
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475210CB1
<400> 30
atggaaaacc aatccagcat ttctgaattt ttcctccgag gaatatcagc'gcctccagag 60
caacagcagt ccctcttcgg aattttcctg tgtatgtatc ttgtcacctt gactgggaac 120
ctgctcatca tcctggccat tggctctgac ctgcacctcc acacccccat gtactttttc 180
25/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
ttggccaacc tgtcttttgt tgacatgggt ttaacgtcct ccacagttac caagatgctg 240
gtgaatatac agactcggca tcacaccatc tcctatacgg gttgcctcac gcaaatgtat 300
ttctttctga tgtttggtga tctagacagc ttcttcctgg ctgccatggc gtatgaccgc 360
tatgtggcca tttgccaccc cctctgctac tccacagtca tgaggcccca agtctgtgcc 420
ctaatgcttg cattgtgctg ggtcctcacc aatatcgttg ccctgactca cacgttcctc 480
atggctcggt tgtccttctg tgtgactggg gaaattgctc actttttctg tgacatcact 540
cctgtcctga agctgtcatg ttctgacacc cacatcaacg agatgatggt ttttgtcttg 600
ggaggcaccg tactcatcgt ccccttttta tgcattgtca cctcctacat ccacattgtg 660
ccagctatcc tgagggtccg aacccgtggt ggggtgggca aggccttttc cacctgcagt 720
tcccacctct gcgttgtttg tgtgttctat gggaccctct tcagtgccta cctgtgtcct 780
ccctccattg cctctgaaga gaaggacatt gcagcagctg caatgtacac catagtgact 840
cccatgttga acccctttat ctatagccta aggaacaagg acatgaaggg ggccctaaag 900
aggctcttca gtcacaggag tattgtttcc tcttag 936
<210> 31
<211> 1035
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475221CB1
<400> 31
atggagcttc tgacaaataa tctcaaattt atcactgacc cttttgtttg taggctccga 60
cacctgagtc caacaccttc agaagaacac atgaaaaata agaacaatgt gactgaattt 120
atcctcttag ggctcacaca gaaccctgag gggcaaaagg ttttatttgt cacattctta 180
ctaatctaca tggtgacgat aatgggcaac ctgcttatca tagtgaccat catggccagc 240
cagtccctgg gttcccccat gtactttttt ctggcttctt tatcattcat agataccgtc 300
tattctactg catttgctcc caaaatgatt gttgacttgc tctctgagaa aaagaccatt 360
tcctttcagg gttgtatggc tcaacttttt atggatcatt tatttgctgg tgctgaagtc 420
attcttctgg tggtaatggc ctatgatcga tacatggcca tctgtaagcc tcttcatgaa 480
ttgatcacca tgaatcgtcg agtctgtgtt cttatgctgt tggcggcctg gattggaggc 540
tttcttcact cattggttca atttctcttt atttatcagc tccctttctg tggacccaat 600
gtcattgaca acttcctgtg tgatttgtat cccttattga aacttgcttg caccaatacc 660
tatgtcactg ggctttctat gatagctaat ggaggagcga tttgtgctgt caccttcttc 720
actatcctgc tttcctatgg ggtcatatta cactctctta agactcagag tttggaaggg 780
aaacgaaaag ctttctacac ctgtgcatcc cacgtcactg tggtcatttt attctttgtc 840
ccctgtatct tcttgtatgc aaggcccaat tctacttttc ccattgataa atccatgact 900
gtagttctaa cttttataac tcccatgctg aacccactaa tctataccct gaagaatgca 960
gaaatgaaaa gtgccatgag gaaactttgg agtaaaaaag taagcttagc tgggaaatgg 1020
ctgtatcact catga 1035
<210> 32
<211> 942
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475244CB1
<400> 32
atggcatctg aaagaaatca aagcagcaca cccactttta ttctcttggg tttttcagaa 60
tacccagaaa tccaggttcc actctttctg gttttcttgt tcgtctacac agtcactgta 120
gtggggaact tgggcatgat aataatcatc agactcaatt caaaactcca tacaatcatg 180
tactttttcc ttagtcactt gtccttgaca gacttctgtt tttccactgt agttacacct 240
aaactgttgg agaacttggt tgtggaatac agaaccatct ctttctctgg ttgcatcatg 300
caattttgtt ttgcttgcat ttttggagtg acagaaactt tcatgttagc agcgatggct 360
tatgaccgtt ttgtggcagt ttgtaaaccc ttgctgtata ccactattat gtctcagaag 420
ctctgtgctc ttctggtggc tgggtcctat acatggggga tagtgtgctc cctgatactc 480
acatattttc ttcttgactt atcgttttgt gaatctacct tcataaataa ttttatctgt 540
gaccactctg taattgtttc tgcctcctac tcagacccct atatcagcca gaggctatgc 600
26/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
tttattattg ccatattcaa tgaggtgagc agcctaatta tcattctgac atcatatatg 660
cttattttca ctaccattat gaagatgcga tctgcaagtg ggcgccagaa aactttctcc 720
acctgtgcct cccacctgac agccatcact atcttccatg gaactatcct tttcctttac 780
tgtgttccta atcctaaaac ttctagcctc atagttacag tggcttctgt gttttacaca 840
gtggcgattc caatgctgaa cccattgatc tacagcctta ggaacaaaga tatcaataac 900
atgtttgaaa aattagttgt caccaaattg atttaccact ga 942
<210> 33
<211> 942
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475293CB1
<400> 33
atgaagaggg agaatcagag cagtgtgtct gagttcctcc tcctggacct ccccatctgg 60
ccagagcagc aggctgtgtt cttcaccctg ttcttgggca tgtacctgat cacggtgctg 120
gggaacctgc tcatcatcct gctcatccgg ctggactctc accttcacac ccccatgttc 180
ttcttcctca gccacttggc tctcactgac atctcccttt catctgtcac tgtcccaaag 240
atgttattaa gcatgcaaac tcaggatcaa tccattcttt atgcagggtg tgtaactcag 300
atgtattttt tcatattttt cactgatcta gacaatttcc ttctcacttc aatggcatac 360
gatcggtatg tggccatctg tcaccccctc cgctacacca ctatcatgaa agagggactg 420
tgtaacttac tagtcactgt gtcctggatc ctctcctgta ccaatgccct gtctcacact 480
ctcctcctgg cccagctgtc cttttgtgct gacaacacca tcccccattt cttctgtgat 540
cttgttgccc tactcaagct ctcatgctca gacatctccc tcaatgagct ggtcattttc 600
acagtgggac aggcagtcat tactctacca ctaatatgca tcttgatctc ttatggccac 660
attggggtca ccatcctcaa ggctccatct actaagggca tcttcaaagc tttgtccacc 720
tgtggctctc acctctctgt ggtgtctctg tattatggca caattattgg actgtatttt 780
ctcccctcat ccagtgcctc cagtgacaag gacgtaattg cctctgtgat gtacacggtg 840
atcaccccat tgctgaatcc cttcatttat agcctaagga acagggacat aaagggagcc 900
ctggagagac tcttcaacag ggcaacagtc ttatctcaat ga 942
<210> 34
<211> 930
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475297CB1
<400> 34
atggaaaatc aaaacaatgt gactgaattc attcttctgg gtctcacaga gaacctggag 60
ctgtggaaaa tattttctgc tgtgtttctt gtcatgtatg tagccacagt gctggaaaat 120
ctacttattg tggtaactat tatcacaagt cagagtctga ggtcacctat gtattttttt 180
cttaccttct tgtccctttt ggatgtcatg ttctcatctg tcgttgcccc caaggtgatt 240
gtagacaccc tctccaagag cactaccatc tctctcaaag gctgcctcac ccagctgttt 300
gtggagcatt tctttggtgg tgtggggatc atcctcctca ctgtgatggc ctatgaccgc 360
tacgtggcca tctgtaagcc cctgcactac acgatcatca tgagtccacg ggtgtgctgc 420
ctaatggtag gaggggcttg ggtgggggga tttatgcacg caatgataca acttctcttc 480
atgtatcaaa tacccttctg tggtcctaat atcatagatc actttatatg tgatttgttt 540
cagttgttga cacttgcctg cacggacacc cacatcctgg gcctcttagt taccctcaac 600
agtgggatga tgtgtgtggc catctttctt atcttaattg cgtcctacac ggtcatccta 660
tgctccctga agtcttacag ctctaaaggg cggcacaaag ccctctctac ctgcagctcc 720
cacctcacgg tggttgtatt gttctttgtc ccctgtattt tcttgtacat gaggcctgtg 780
gtcactcacc ccatagacaa ggcaatggct gtgtcagact caatcatcac acccatgtta 840
aatcccttga tctatacact gaggaatgca gaggtgaaaa gtgccatgaa gaaactctgg 900
atgaaatggg aggctttggc tgggaaataa 930
<210> 35
<211> 942
27/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte 2D No: 7475193CB1
<400> 35
atggaaactg caaattacac caaggtgaca gaatttgttc tcactggcct atcccagact 60
ccagaggtcc aactagtcct atttgttata tttctatcct tctatttgtt catcctacca 120
ggaaatatcc ttatcatttg caccatcagt ctagaccctc atctgacctc tcctatgtat 180
ttcctgttgg ctaatctggc cttccttgat atttggtact cttccattac agcccctgaa 240
atgctcatag acttctttgt ggagaggaag ataatttctt ttgatggatg cattgcacag 300
ctcttcttct tacactttgc tggggcttcg gagatgttct tgctcacagt gatggccttt 360
gacctctaca ctgctatctg ccgacccctc cactatgcta ccatcatgaa tcaacgtctc 420
tgctgtatcc tggtggctct ctcctggagg gggggcttca ttcattctat catacaggtg 480
gctctcattg ttcgacttcc tttctgtggg cccaatgagt tagacagtta cttctgtgac 540
atcacacagg ttgtccggat tgcctgtgcc aacaccttcc cagaggagtt agtgatgatc 600
tgtagtagtg gtctgatctc tgtggtgtgt ttgattgctc tgttaatgtc ctatgccttc 660
cttctggcct tgttcaagaa actttcaggc tcaggtgaga ataccaacag ggccatgtcc 720
acctgctatt cccacattac cattgtggtg ctaatgtttg ggccatccat ctacatttat 780
gctcgcccat ttgactcgtt ttccctagat aaagtggtgt ctgtgttcaa tactttaata 840
ttccctttac gtaatcccat tatttacaca ttgagaaaca aggaagtaaa ggcagccatg 900
aggaagttgg tcaccaaata tattttgtgt aaagagaagt ga 942
<210> 36
<211> 1029
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475213CB1
<400> 36
atgaagagaa agaacttcac agaagtgtca gaattcattt tcttgggatt ttctagcttt 60
ggaaagcatc agataaccct ctttgtggtt ttcctaactg tctacatttt aactctggtt 120
gctaacatca tcattgtgac tatcatctgc attgaccatc atctccacac tcccatgtat 180
ttcttcctaa gcatgctggc tagttcagag acggtgtaca cactggtcat tgtgccacga 240
atgcttttga gcctcatttt tcataaccaa cctatctcct tggcaggctg tgctacacaa 300
atgttctttt ttgttatctt ggccactaat aattgcttcc tgcttactgc aatggggtat 360
gaccgctatg tggccatctg cagacccctg agatacactg tcatcatgag caagggacta 420
tgtgcccagc tggtgtgtgg gtcctttggc attggtctga ctatggcagt tctccatgtg 480
acagccatgt tcaatttgcc gttctgtggc acagtggtag accacttctt ttgtgacatt 540
tacccagtca tgaaactttc ttgcattgat accactatca atgagataat aaattatggt 600
gtaagttcat ttgtgatttt tgtgcccata ggcctgatat ttatctccta tgtccttgtc 660
atctcttcca tccttcaaat tgcctcagct gagggccgga agaagacctt tgccacctgt 720
gtctcccacc tcactgtggt tattgtccac tgtggctgtg cctccattgc ctacctcaag 780
ccgaagtcag aaagttcaat agaaaaagac cttgttctct cagtgacgta caccatcatc 840
actcccttgc tgaaccctgt tgtttacagt ctgagaaaca aggagataca agaatcactc 900
caagctggat taagactact tgtttctgtg cttgaagatt tcagttttga aagctttttg 960
gctcccattt tacctgaact ctctgacagt caaatctttg agcttgtctg gttaggggat 1020
gtggagtag 1029
<210> 37
<211> 933
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475272CB1
28/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<400> 37
atggcagaga tgaacctcac cttggtgacc gagttcctcc ttattgcatt cactgaatat 60
cctgaatggg cactccctct cttcctcttg ttattattta tgtatctcat caccgtattg 120
gggaacttag agatgattat tctgatcctc atggatcacc agctccacgc tccaatgtat 180
ttccttctga gtcacctcgc tttcatggaC gtctgctact catctatcac tgtcccccag 240
atgctggcag tgctgctgga gcatggggca gctttatctt acacacgctg tgctgctcag 300
ttctttctgt tcaccttctt tggttccatc gactgctacc tcttggccct catggcctat 360
gaccgctact tggctgtgtg ccagcccctg ctttatgtca ccatcctgac acagcaggcc 420
cgcttgagtc ttgtggctgg ggcttacgtt gctggtctca tcagtgcctt ggtgcggaca 480
gtctcagcct tcactctctc cttctgtgga accagtgaga ttgactttat tttctgtgac 540
ctccctcctc tgttaaagtt gacctgtggg gagagctaca ctcaagaagt gctgattatt 600
atgtttgcca tttttgtcat ccctgcttcc atggtggtga tcttggtgtc ctacctgttt 660
atcatcgtgg ccatcatggg gatccctgct ggaagccagg ccaagacctt ctccacctgc 720
acctcccacc tcactgctgt gtcactcttc tttggtaccc tcatcttcat gtacttgaga 780
ggtaactcag atcagtcttc ggagaagaat cgggtagtgt ctgtgcttta cacagaggtc 840
atccccatgt tgaatcccct catctacagc ctgaggaaca aggaagtgaa ggaggccctg 900
agaaaaattc tcaatagagc caagttgtcc taa 933
<210> 38
<211> 948
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475200CB1
<220>
<221> unsure
<222> 1
<223> a, t, c, g, or other
<400> 38
ngcaatactg cacctgcatt ctcagtgacc ttggaatcta tggacatacc acaaaatatc 60
acagaatttt tcatgctggg gctctcacag aactcagagg tacagagagt tctctttgtg 120
gtctttttgc tgatctatgt ggtcacggtt tgtggcaaca tgctcattgt ggtcactatc 180
acctccagcc ccacgctggc ttcccctgtg tattttttcc tggccaacct atcctttatt 240
gacacctttt attcttcttc tatggctcct aaactcattg ctgactcatt gtatgagggg 300
agaaccatct cttatgagtg ctgcatggct cagctctttg gagctcattt tttgggaggt 360
gttgagatca ttctgctcac agtgatggct tatgaccgct atgtggccat ctgtaagccc 420
ctgcacaata ctaccatcat gaccaggcat ctctgtgcca tgcttgtagg ggtggcttgg 480
cttgggggct tcctgcattc attggttcag ctcctcctgg tcctttggtt gcccttctgt 540
gggcccaatg tgatcaatca ctttgcctgt gacttgtacc ctttgctgga agttgcctgc 600
accaatacgt atgtcattgg tctgctggtg gttgccaaca gtggtttaat ctgcctgttg 660
aacttcctca tgctggctgc ctcctacatt gtcatcctgt actccttgag gtcccacagt 720
gcagatggga gatgcaaagc cctctccacc tgtggagccc acttcattgt tgttgccttg 780
ttctttgtgc cctgtatatt tacttatgtg catccatttt ctactttacc tatagacaaa 840
aatatggcat tattttatgg tattctgaca cctatgttga atccactcat ttataccctg 900
agaaatgaag aggtaaaaaa tgccatgaga aagctcttta catggtaa 948
<210> 39
<211> 951
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475121CB1
<400> 39
atgcctagtc agaactatag catcatatct gaatttaacc tctttggctt ctcagccttc 60
ccccagcacc tcctgcccat cttgttcctg ctgtacctcc tgatgttcct gttcacattg 120
ctgggcaacc ttctcatcat ggccacaatc tggattgaac acagactcca cacacccatg 180
29/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
taCCtCttCt tgtgcaCCCt CtCCgtCtCt gagattctgt tcactgttgc Catcacccct 240
cgcatgctgg ctgatctgct ttccacccat cattccatca cctttgtggc ttgtgccaac 300
cagatgttct tctccttcat gtttggcttc actcactcct tccttctcct ggtcatgggc 360
tatgatcgct atgtggccat ctgccaccca ctgcgttaca atgtgctcat gagcccccgt 420
gactgtgccc atcttgtggc ctgtacctgg gctggtggct cagtcatggg gatgatggtg 480
acaacgatag ttttccacct cactttctgt gggtctaatg tgatccacca ttttttctgt 540
catgtgcttt ccctcttgaa gttggcctgt gaaaacaaga catcatctgt catcatgggt 600
gtgatgctgg tgtgtgtcac agccctgata ggctgtttat tcctcatcat cctctcctat 660
gtcttcattg tggctgccat cttgaggatt ccctctgccg aaggccggca caagacattt 720
tctacgtgtg tatcccacct cactgtggtg gtcacgcact atagttttgc ctcctttatc 780
tacctcaagc ccaagggcct ccattctatg tacagtgacg ccttgatggc caccacctat 840
actgtcttca cccccttcct tagcccaatc attttcagcc taaggaacaa ggagctgaag 900
aatgccataa ataaaaactt ttacagaaaa ttctgtcctc caagttcctg a 951
<210> 40
<211> 1113
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475165CB1
<400> 40
atgctggtct tgaactcctg ggctcaagtg atccactggc ctcagcctcc caaagtgctg 60
ggattacagc ctttggaaaa aacccagtac ggcttcctag gaacagatcg tgtagaagag 120
aaaacttcag tgataaccat cagagttagt gtgacccaca gacacaacag ctacatggaa 180
gcagaaaacc ttacagaatt atcaaaattt ctcctcctgg gactctcaga tgatcctgaa 240
ctgcagcccg tcctctttgg gctgttcctg tccatgtacc tggtcacggt gctggggaac 300
ctgctcatca ttctggccgt cagctctgac tcccacctcc acacccccat gtacttcttc 360
ctctccaacc tgtcctttgt tgacatctgt ttcatctcca ccacagtccc caagatgcta 420
gtgagcatcc aggcacggag caaagacatc tcctacatgg ggtgcctcac tcaggtgtat 480
tttttaatga tgtttgctgg aatggatact ttcctactgg ccgtgatggc ctatgaccgg 540
tttgtggcca tctgccaccc actgcactac aoggtcatca tgaacccctg cctctgtggc 600
ctcctggttc tggcatcttg gttcatcatt ttctggttct ccctggttca tattctactg 660
atgaagaggt tgaccttctc cacaggcact gagattccgc atttcttctg tgaaccggct 720
caggtcctca aggtggcctg ctctaacacc ctcctcaata acattgtctt gtatgtggcc 780
acggcactgc tgggtgtgtt tcctgtagct gggatcctct tctcctactc tcagattgtc 840
tcctccttaa tgggaatgtc ctccaccaag ggcaagtaca aagccttttc cacctgtgga 900
tctcacctct gtgtggtctc cttgttctat ggaacaggac ttggggtcta tctgagttct 960
gctgtgaccc attcttccca gagcagctcc accgcctcag tgatgtacgc catggtcacc 1020
cccatgctga accccttcat ctacagcctg aggaacaagg atgtgaaggg ggccctggaa 1080
agactcctca gcagggccga ctcttgtcca tga 1113
<210> 41
<211> 957
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7475273CB1
<400> 41
atgaagaatg tcactgaagt taccttattt gtactgaagg gctteacaga caatcttgaa 60
ctgcagacta tcttcttctt cctgtttcta gcaatctacc tcttcactct catgggaaat 120
ttaggactga ttttagtggt cattagggat tcccagctcc acaaacccat gtactatttt 180
ctgagtatgt tgtcttctgt ggatgcctgc tattcctcag ttattacccc aaatatgtta 240
gtagatttta cgacaaagaa taaagtcatt tcattccttg gatgtgtagc acaggtgttt 300
cttgcttgta gttttggaac cacagaatgc tttctcttgg ctgcaatggc ttatgatcgc 360
tatgtagcca tctacaaccc tctcctgtat tcagtgagca tgtcacccag agtctacatg 420
ccactcatca atgcttccta tgttgctggc attttacatg ctactataca tacagtggct 480
acatttagcc tatccttctg tggagccaat gaaattaggc gtgtcttttg tgatatccct 540
30/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
cctctccttg ctatttctta ttctgacact cacacaaacc agcttctact cttctacttt 600
gtgggctcta tcgagctggt cactatcctg attgttctga tctcctatgg tttgattctg 660
ttggccattc tgaagatgta ttctgctgaa gggaggagaa aagtcttctc cacatgtgga 720
gctcacctaa ctggagtgtc aatttattat gggacaatcc tcttcatgta tgtgagacca 780
agttccagct atgcttcgga ccatgacatg atagtgtcaa tattttacac cattgtgatt 840
cccttgctga atcccgtcat ctacagtttg aggaacaaag atgtaaaaga ctcaatgaaa 900
aaaatgtttg ggaaaaatca ggttatcaat aaagtatatt ttcatactaa aaaataa 957
<210> 42
<211> 966
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476077CB1
<400> 42
atggaatctc ctaatcacac tgatgttgac ccttctgtct tcttcctcct gggcatccca 60
ggtctggaac aatttcattt gtggctctca ctccctgtgt gtggcttagg cacagccaca l20
attgtgggca atataactat tctggttgtt gttgccactg aaccagtctt gcacaagcct l80
gtgtaccttt ttctgtgcat gctctcaa,cc atcgacttgg ctgcctctgt ctccacagtt 240
cccaagctac tggctatctt ctggtgtgga gccggacata tatctgcctc tgcctgcctg 300
gcacagatgt tcttcattca tgccttctgc atgatggagt ccactgtgct actggccatg 360
gcctttgatc gctacgtggc catctgccac ccactccgct atgccacaat cctcactgac 420
accatcattg cccacatagg ggtggcagct gtagtgcgag gctccctgct catgctccca 480
tgtcccttcc ttattgggcg tttgaacttc tgccaaagcc atgtgatcct acacacgtac 540
tgtgagcaca tggctgtggt gaagctggcc tgtggagaca ccaggcctaa ccgtgtgtat 600
gggctgacag ctgcactgtt ggtcattggg gttgacttgt tttgcattgg tctctcctat 660
gccctaagtg cacaagctgt ccttcgcctc tcatcccatg aagctcggtc caaggcccta 720
gggacctgtg gttcccatgt ctgtgtcatc ctcatctctt atacaccagc cctcttctcc 780
ttttttacac accgctttgg ccatcacgtt ccagtccata ttcacattct tttggccaat 840
gtttatctgc ttttgccacc tgctcttaat cctgtggtat atggagttaa .gaccaaacag 900
atccgtaaaa gagttgtcag ggtgtttcaa agtgggcagg gaatgggcat caaggcatct 960
gagtga . 966
<210> 43
<211> 975
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476113CB1
<220>
<221> unsure
<222> 1
<223> a, t, c, g, or other
<400> 43
naactaactt tcagattcga agaaacagaa gcgatgctgc tgactgatag aaatacaagt 60
gggaccacgt tcaccctctt gggcttctca gattacccag aactgcaagt cccactcttc 120
ctggtttttc tggccatcta caatgtcact gtgctaggga atattgggtt gattgtgatc 180
atcaaaatca accccaaact gcataccccc atgtactttt tcctcagcca actctccttt 240
gtggatttct gctattcctc catcattgct cccaagatgt tggtgaacct tgttgtcaaa 300
gacagaacca tttcattttt aggatgcgta gtacaattct ttttcttctg tacctttgtg 360
gtcactgaat cctttttatt agctgtgatg gcctatgacc gcttcgtggc catttgcaac 420
cctctgctct acacagttaa catgtcccag aaactctgcg tgctgctggt tgtgggatcc 480
tatgcctggg gagtctcatg ttccttggaa ctgacgtgct ctgctttaaa gttatgtttt 540
catggtttca acacaatcaa tcacttcttc tgtgagttct cctcactact ctccctttct 600
tgctctgata cttacatcaa ccagtggctg ctattctttc ttgccacctt taatgaaatc 660
agcacactac tcatcgttct cacatcttat gcgttcattg ttgtaaccat cctcaagatg 720
31/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
cgttcagtca gtgggcgccg caaagccttc tccacctgtg cctcccacct gactgccatc 780
accatcttcc atggcaccat cctcttcctt tactgtgtgc ccaactccaa aaactccagg 840
cacacagtca aagtggcctc tgtgttttac accgtggtga tccccatgtt gaatcccctg 900
atctacagtc tgagaaataa agatgtcaag gatacagtca ccgagatact ggacaccaaa 960
gtcttctctt actga 975
<210> 44
<211> 987
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476117CB1
<400> 44
atgtttctga cagagagaaa tacgacatct gaggccacat tcactctctt gggcttctca 60
gattacctgg aactgcaaat tcccctcttc tttgtatttc tggcagtcta cggcttcagt 120
gtggtaggga atcttgggat gatagtgatc atcaaaatta acccaaaatt gcataccccc 180
atgtattttt tcctcaacca cctctccttt gtggatttct gctattcctc catcattgct 240
cccatgatgc tggtgaacct ggttgtagaa gatagaacca tttcattctc aggatgtttg 300
gtgcaattct ttttcttttg cacctttgta gtgactgaat taattctatt tgcggtgatg 360
gcctatgacc actttgtggc catttgcaat cctctgctct acacagttgc catctcccag 420
aaactctgtg ccatgctggt ggttgtattg tatgcatggg gagtcgcatg ttccctgaca 480
ctcgcgtgct ctgctttaaa gttatctttt catggtttca acacaatcaa tcatttcttc 540
tgtgagttat cctccctgat atcactctct taccctgact cttatctcag ccagttgctt 600
cttttcactg ttgccacttt taatgagata agcacactac tcatcattct gacatcttat 660
gcattcatca ttgtcaccac cttgaagatg ccttcagcca gtgggcaccg caaagtcttc 720
tccacctgtg cctcccacct gactgccatc accatcttcc atggcaccat cctcttcctc 780
tactgtgtac ccaactccaa aaactccagg cacacagtca aagtggcctc tgtgttttac 840
accgtggtga tccccttgtt gaatcccctg atctacagtc tgagaaataa agatgttaag 900
gatgcaatcc gaaaaataat caatacaaaa tattttcata ttaaacatag gcattggtat 960
ccatttaatt ttgttattga acaataa 987
<210> 45
<211> 975
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476079CB1
<400> 45
atgaatcata tgtctgcatc tctcaaaatc tccaatagct ccaaattcca ggtctctgag 60
ttcatcctgc tgggattccc gggcattcac agctggcaac actggctatc tctgcccctg 120
gcactactgt atctctcagc acttgctgca aacaccctca tcctcatcat catctggcag 180
aacccttctt tacagcagcc catgtatatt ttccttggca tcctctgtat ggtagacatg 240
ggtctggcca ctactatcat ccctaagatc ctggccatct tctggtttga tgccaaggtt 300
attagcctcc ctgagtgctt tgctcagatt tatgccattc acttctttgt gggcatggag 360
tctggtatcc tactctgcat ggcttttgat agatatgtgg ctatttgtca ccctcttcgc 420
tatccatcaa ttgtcaccag ttccttaatc ttaaaagcta ccctgttcat ggtgctgaga 480
aatggcttat ttgtcactcc agtgcctgtg cttgcagcac agcgtgatta ttgctccaag 540
aatgaaattg aacactgcct gtgctctaac cttggggtca caagcctggc ttgtgatgac 600
aggaggccaa acagcatttg ccagttggtt ctggcatggc ttggaatggg gagtgatcta 660
agtcttatta tactgtcata tattttgatt ctgtactctg tacttagact gaactcagct 720
gaagctgcag ccaaggccct gagcacttgt agttcacatc tcaccctcat ccttttcttt 780
tacactattg ttgtagtgat ttcagtgact catctgacag agatgaaggc tactttgatt 840
ccagttctac ttaatgtgtt gcacaacatc atcccccctt ccctcaaccc tacagtttat 900
gcacttcaga ccaaagaact tagggcagcc ttccaaaagg tgctgtttgc ccttacaaaa 960
gaaataagat cttag
975
<210> 46
32/33
CA 02408140 2002-11-05
WO 01/90359 PCT/USO1/16833
<211> 948
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 7476112CB1
<400> 46
atgcaggggc taaaccacac ctccgtgtct gaattcatcc tcgttggctt ctctgccttc 60
ccccacctcc agctgatgct cttcctgctg ttcctgctga tgtacctgtt cacgctgctg 120
ggcaacctgc tcatcatggc cactgtctgg agcgagcgca gcctccacat gcccatgtac 180
ctcttcctgt gtgccctctc catcaccgag atcctctaca ccgtggccat catcccgcgc 240
atgctggccg acctgctgtc cacccagcgc tccatcgcct tcctggcctg tgccagtcag 300
atgttcttct ccttcagctt cggcttcacc cactccttcc tgctcactgt catgggctac 360
gaccgctacg tggccatctg ccaccccctg cgttacaacg tgctcatgag cctgcggggc 420
tgcacctgcc gggtgggctg ctcctgggct ggtggcttgg tcatggggat ggtggtgacc 480
tcggccattt tccacctcgc cttctgtgga cacaaggaga tccaccattt cttctgccac 540
gtgccacctc tgttgaagtt ggcctgtgga gatgatgtgc tggtggtggc caaaggcgtg 600
ggcttggtgt gtatcacggc cctgctgggc tgttttctcc tcatcctcct ctcctatgcc 660
ttcatcgtgg ccgccatctt gaagatccct tctgctgaag gtcggaacaa ggccttctcc 720
acctgtgcct ctcacctcac tgtggtggtc gtgcactatg gctttgcctc cgtcatttac 780
ctgaagccca aaggtcccca gtctccggaa ggagacacct tgatgggcat cacctacacg 840
gtcctcacac ccttcctcag ccccatcatc ttcagcctca ggaacaagga gctgaaggtc 900
gccatgaaga agacttgctt caccaaactc tttccacaga actgctga 948
33/33
